[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f5LRYmwrCgEoiR3Y63jZBiHVNNF4nsoDrEEC5X1wJqsw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":36,"phaseBuckets":47,"rows":54},"Shire",[4,6],"Shire Regenerative Medicine, Inc.",353,false,4,149,81712,2,37,[15,18,21,24,26,29,32,34],{"name":16,"count":17},"Hereditary Angioedema (HAE)",26,{"name":19,"count":20},"Healthy",20,{"name":22,"count":23},"Short Bowel Syndrome",15,{"name":25,"count":23},"Attention Deficit Hyperactivity Disorder (ADHD)",{"name":27,"count":28},"Ulcerative Colitis",13,{"name":30,"count":31},"Healthy Volunteers",12,{"name":33,"count":31},"Fabry Disease",{"name":35,"count":31},"Hunter Syndrome",[37,42],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03771898","A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy","2023-03-08","SHP611",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05067868","A Study of Replagal in Children and Adults With Fabry Disease in India","2026-10-31","Replagal",[48,49,50,51,52,53],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[55,118,141,295,427,487,553,613,650,694,739,772,806,824,848,866,890,914,939,957,975,1000,1151,1255,1346,1422,1494,1566,1620,1677,1730,1780,1825,1874,1919,1959,2003,2049,2090,2124,2157,2184,2206,2228,2262,2284,2317,2352,2386,2408,2440,2472,2504,2529,2547,2571,2595,2619,2637,2663,2681,2699,2723,2748,2766,2784,2802,2820,2844,2868,2893,2911,2929,2953,2971,2989,3007,3025,3050,3074,3098,3122,3145,3170,3188,3206,3232,3250,3268,3290,3315,3333,3351,3369,3394,3412,3436,3454,3478,3496,3520,3542,3560,3578,3602,3620,3644,3662,3686,3710,3734,3752,3776,3794,3812,3836,3854,3879,3897,3920,3938,3995,4031,4053,4085,4116,4150,4181,4211,4244,4262,4280,4303,4327,4349,4367,4385,4403,4421,4447,4465,4483,4507,4525,4549,4571,4594,4620,4638,4656,4680,4705,4728,4751,4775,4799,4824,4849,4867,4892,4919,4944,4968,4986,5010,5038,5056,5074,5092,5110,5134,5152,5180,5198,5216,5234,5259,5285,5309,5327,5345,5369,5413,5448,5479,5497,5521,5539,5557,5581,5599,5617,5635,5653,5677,5695,5719,5737,5755,5780,5798,5816,5838,5862,5880,5903,5926,5951,5975,5998,6023,6041,6063,6081,6099,6117,6142,6160,6178,6196,6214,6232,6250,6268,6286,6304,6328,6351,6369,6393,6411,6435,6453,6471,6494,6519,6537,6555,6579,6608,6715,6773,6820,6866,6906,6948,6991,7013,7031],{"intervention":46,"totalTrials":56,"cells":57},5,{"EARLY_PHASE1":58,"PHASE1":61,"PHASE2":63,"PHASE3":74,"PHASE4":106,"NA":116},{"trials":59,"activeCount":60},[],0,{"trials":62,"activeCount":60},[],{"trials":64,"activeCount":60},[65],{"nctId":66,"briefTitle":67,"status":68,"phases":69,"primaryCompletion":70,"completion":70,"start":71,"enrollment":23,"conditions":72,"interventions":73},"NCT01363492","Safety Study of Replagal® Therapy in Children With Fabry Disease","COMPLETED",[50],"2013-04-17","2011-05-12",[33],[46],{"trials":75,"activeCount":60},[76,87,97],{"nctId":77,"briefTitle":78,"status":79,"phases":80,"primaryCompletion":81,"completion":81,"start":82,"enrollment":83,"conditions":84,"interventions":85},"NCT04840667","A Study of Replagal in Treatment-naïve Adults With Fabry Disease","TERMINATED",[51],"2022-12-16","2021-12-28",17,[33],[86],"REPLAGAL",{"nctId":88,"briefTitle":89,"status":68,"phases":90,"primaryCompletion":91,"completion":92,"start":93,"enrollment":94,"conditions":95,"interventions":96},"NCT00864851","Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease",[51],"2012-06-01","2012-07-05","2008-12-29",44,[33],[46],{"nctId":98,"briefTitle":99,"status":68,"phases":100,"primaryCompletion":101,"completion":101,"start":102,"enrollment":103,"conditions":104,"interventions":105},"NCT01124643","Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease",[51],"2013-07-08","2010-04-13",35,[33],[46],{"trials":107,"activeCount":115,"soonestReadout":45},[108],{"nctId":43,"briefTitle":44,"status":109,"phases":110,"primaryCompletion":45,"completion":111,"start":112,"enrollment":56,"conditions":113,"interventions":114},"RECRUITING",[52],"2026-11-30","2022-11-01",[33],[46],1,{"trials":117,"activeCount":60},[],{"intervention":41,"totalTrials":115,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":135,"PHASE4":137,"NA":139},{"trials":121,"activeCount":60},[],{"trials":123,"activeCount":60},[],{"trials":125,"activeCount":115,"soonestReadout":40},[126],{"nctId":38,"briefTitle":39,"status":127,"phases":128,"primaryCompletion":40,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},"ACTIVE_NOT_RECRUITING",[50],"2026-05-01","2019-05-13",36,[133],"Metachromatic Leukodystrophy (MLD)",[41],{"trials":136,"activeCount":60},[],{"trials":138,"activeCount":60},[],{"trials":140,"activeCount":60},[],{"intervention":142,"totalTrials":143,"cells":144},"Lisdexamfetamine Dimesylate",14,{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":190,"PHASE3":203,"PHASE4":264,"NA":293},{"trials":146,"activeCount":60},[],{"trials":148,"activeCount":60},[149,159,168,178],{"nctId":150,"briefTitle":151,"status":68,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":157},"NCT00746733","Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC",[49],"2008-10-26","2008-09-08",24,[30],[142,158],"Adderall XR",{"nctId":160,"briefTitle":161,"status":68,"phases":162,"primaryCompletion":163,"completion":163,"start":164,"enrollment":165,"conditions":166,"interventions":167},"NCT01890785","Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers",[49],"2013-08-22","2013-07-15",30,[30],[142],{"nctId":169,"briefTitle":170,"status":79,"phases":171,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":176},"NCT00776555","Compare Subjective Drug Liking & Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as an Oral Solution",[49],"2009-03-31","2008-11-21",3,[19],[142,177],"Racemic mixture of dextroamphetamine and lisdexamfetamine",{"nctId":179,"briefTitle":180,"status":68,"phases":181,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":187},"NCT01010750","Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)",[49],"2010-03-28","2010-01-05",18,[186],"Attention-Deficit Hyperactivity Disorder",[142,188,189],"Immediate Release Mixed Amphetamine Salts","LDX Placebo + MAS-IR Placebo",{"trials":191,"activeCount":60},[192],{"nctId":193,"briefTitle":194,"status":68,"phases":195,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},"NCT01291173","Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder",[50],"2012-01-30","2011-05-10",271,[200],"Binge Eating Disorder",[202,202,202],"lisdexamfetamine dimesylate",{"trials":204,"activeCount":60},[205,216,225,235,244,255],{"nctId":206,"briefTitle":207,"status":68,"phases":208,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT00763971","Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17",[51],"2011-03-16","2008-11-17",336,[213],"ADHD",[142,215],"Methylphenidate Hydrochloride",{"nctId":217,"briefTitle":218,"status":68,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":224},"NCT00764868","Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study",[51],"2010-04-22","2008-11-13",269,[213],[142],{"nctId":226,"briefTitle":227,"status":68,"phases":228,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":233},"NCT01657019","Open Label Extension in Adults With Binge Eating Disorder (BED)",[51],"2014-10-21","2012-08-21",604,[200],[234],"Lisdexamfetamine dimesylate",{"nctId":236,"briefTitle":237,"status":68,"phases":238,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":243},"NCT00784654","Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17",[51],"2011-10-26","2009-01-27",276,[213],[234],{"nctId":245,"briefTitle":246,"status":68,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":253},"NCT01106430","Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit\u002FHyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate",[51],"2012-07-19","2010-06-28",267,[252],"Attention-Deficit\u002FHyperactivity Disorder",[142,254],"Atomoxetine Hydrochloride",{"nctId":256,"briefTitle":257,"status":68,"phases":258,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":263},"NCT02009163","Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder",[51],"2015-04-08","2014-01-27",418,[200],[234],{"trials":265,"activeCount":60},[266,276,284],{"nctId":267,"briefTitle":268,"status":68,"phases":269,"primaryCompletion":270,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":275},"NCT01552902","Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit\u002FHyperactivity Disorder",[52],"2014-05-22","2012-04-03",549,[274],"Attention-deficit\u002FHyperactivity Disorder",[234,215],{"nctId":277,"briefTitle":268,"status":68,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":283},"NCT01552915",[52],"2014-01-22","2012-04-17",464,[274],[234,215],{"nctId":285,"briefTitle":286,"status":68,"phases":287,"primaryCompletion":288,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":292},"NCT01328756","Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[52],"2014-09-30","2011-07-07",314,[25],[234],{"trials":294,"activeCount":60},[],{"intervention":296,"totalTrials":28,"cells":297},"SPD489",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":312,"PHASE3":342,"PHASE4":404,"NA":425},{"trials":299,"activeCount":60},[],{"trials":301,"activeCount":60},[302],{"nctId":303,"briefTitle":304,"status":68,"phases":305,"primaryCompletion":306,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":311},"NCT01457339","Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia",[49],"2012-01-20","2011-10-21",31,[310],"Schizophrenia",[296],{"trials":313,"activeCount":60},[314,324,334],{"nctId":315,"briefTitle":316,"status":68,"phases":317,"primaryCompletion":318,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":323},"NCT00922272","Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms",[50],"2011-01-20","2009-09-14",92,[322],"Schizophrenia and Predominant Negative Symptoms",[296],{"nctId":325,"briefTitle":326,"status":68,"phases":327,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":333},"NCT00985725","SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder",[50],"2011-04-18","2009-10-29",143,[332],"Major Depressive Disorder",[296],{"nctId":335,"briefTitle":336,"status":68,"phases":337,"primaryCompletion":338,"completion":338,"start":339,"enrollment":155,"conditions":340,"interventions":341},"NCT02402166","Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit\u002FHyperactivity Disorder",[50],"2016-06-30","2015-04-15",[25],[296],{"trials":343,"activeCount":60},[344,353,362,370,379,388,397],{"nctId":345,"briefTitle":346,"status":68,"phases":347,"primaryCompletion":348,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":352},"NCT01436149","Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder",[51],"2013-12-23","2011-10-27",1262,[332],[296],{"nctId":354,"briefTitle":355,"status":68,"phases":356,"primaryCompletion":357,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":361},"NCT01718509","SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder",[51],"2013-09-20","2012-11-26",390,[200],[296],{"nctId":363,"briefTitle":364,"status":79,"phases":365,"primaryCompletion":366,"completion":366,"start":367,"enrollment":12,"conditions":368,"interventions":369},"NCT01760993","Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia",[51],"2013-04-01","2013-02-01",[310],[296],{"nctId":371,"briefTitle":372,"status":68,"phases":373,"primaryCompletion":374,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":378},"NCT02466386","Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit\u002FHyperactivity Disorder",[51],"2020-01-03","2015-08-21",113,[25],[296],{"nctId":380,"briefTitle":381,"status":68,"phases":382,"primaryCompletion":383,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":387},"NCT03260205","Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit\u002FHyperactivity Disorder (ADHD)",[51],"2018-10-23","2017-09-06",199,[25],[296,296],{"nctId":389,"briefTitle":390,"status":391,"phases":392,"primaryCompletion":393,"completion":393,"start":394,"enrollment":60,"conditions":395,"interventions":396},"NCT01274221","Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit\u002FHyperactivity Disorder (ADHD)","WITHDRAWN",[51],"2011-05-04","2011-03-06",[213],[296],{"nctId":398,"briefTitle":355,"status":68,"phases":399,"primaryCompletion":400,"completion":400,"start":358,"enrollment":401,"conditions":402,"interventions":403},"NCT01718483",[51],"2013-09-25",383,[200],[296],{"trials":405,"activeCount":60},[406,416],{"nctId":407,"briefTitle":408,"status":68,"phases":409,"primaryCompletion":410,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":415},"NCT01101022","Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[52],"2010-11-29","2010-05-19",161,[414],"ADHD Specifically With Executive Function Impairment",[296],{"nctId":417,"briefTitle":418,"status":68,"phases":419,"primaryCompletion":420,"completion":420,"start":421,"enrollment":422,"conditions":423,"interventions":424},"NCT00877487","Safety and Efficacy of Vyvanse in Adults With Attention-Deficit\u002FHyperactivity Disorder",[52],"2010-07-08","2009-04-30",123,[252],[296],{"trials":426,"activeCount":60},[],{"intervention":428,"totalTrials":56,"cells":429},"Atomoxetine hydrochloride",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":463,"NA":485},{"trials":431,"activeCount":60},[],{"trials":433,"activeCount":60},[],{"trials":435,"activeCount":60},[],{"trials":437,"activeCount":60},[438,448,459],{"nctId":439,"briefTitle":440,"status":68,"phases":441,"primaryCompletion":442,"completion":442,"start":443,"enrollment":131,"conditions":444,"interventions":446},"NCT00557960","ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD",[51],"2004-10-25","2004-02-25",[445],"Attention Deficit Disorder With Hyperactivity",[447,428],"Mixed salts of a single-entity amphetamine",{"nctId":449,"briefTitle":450,"status":68,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":457},"NCT01244490","Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[51],"2013-05-01","2011-01-17",338,[456],"Attention Deficit Hyperactivity Disorder",[458,254],"Extended-release Guanfacine Hydrochloride",{"nctId":245,"briefTitle":246,"status":68,"phases":460,"primaryCompletion":248,"completion":248,"start":249,"enrollment":250,"conditions":461,"interventions":462},[51],[252],[142,254],{"trials":464,"activeCount":60},[465,475],{"nctId":466,"briefTitle":467,"status":68,"phases":468,"primaryCompletion":469,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":473},"NCT04085172","A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)",[52],"2025-09-02","2019-09-18",396,[456],[474,428],"Guanfacine hydrochloride",{"nctId":476,"briefTitle":477,"status":68,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":483},"NCT00506727","Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD",[52],"2004-07-02","2003-08-05",215,[213],[484,428],"Mixed amphetamine salts",{"trials":486,"activeCount":60},[],{"intervention":488,"totalTrials":56,"cells":489},"prucalopride",{"EARLY_PHASE1":490,"PHASE1":492,"PHASE2":494,"PHASE3":496,"PHASE4":529,"NA":551},{"trials":491,"activeCount":60},[],{"trials":493,"activeCount":60},[],{"trials":495,"activeCount":60},[],{"trials":497,"activeCount":60},[498,509,519],{"nctId":499,"briefTitle":500,"status":68,"phases":501,"primaryCompletion":502,"completion":502,"start":503,"enrollment":504,"conditions":505,"interventions":507},"NCT01147926","Evaluation of Prucalopride in Male Subjects With Chronic Constipation.",[51],"2013-10-25","2010-09-23",374,[506],"Male Subjects With Chronic Constipation",[508],"Prucalopride",{"nctId":510,"briefTitle":511,"status":79,"phases":512,"primaryCompletion":513,"completion":513,"start":411,"enrollment":514,"conditions":515,"interventions":518},"NCT01117051","Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation",[51],"2012-08-13",174,[516,517],"Non-cancer Pain","Opioid Induced Constipation",[488],{"nctId":520,"briefTitle":521,"status":68,"phases":522,"primaryCompletion":523,"completion":523,"start":524,"enrollment":481,"conditions":525,"interventions":527},"NCT01330381","Prucalopride in Pediatric Subjects With Functional Constipation",[51],"2013-03-01","2011-04-28",[526],"Functional Constipation",[488,528],"PEG 4000",{"trials":530,"activeCount":60},[531,541],{"nctId":532,"briefTitle":533,"status":68,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":28,"conditions":537,"interventions":539},"NCT01707667","Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity",[52],"2013-11-27","2013-02-27",[538],"Chronic Constipation",[488,540],"PEG 3350",{"nctId":542,"briefTitle":543,"status":68,"phases":544,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":550},"NCT01424228","Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years",[52],"2012-12-19","2011-04-06",364,[549],"Constipation",[488],{"trials":552,"activeCount":60},[],{"intervention":554,"totalTrials":56,"cells":555},"rhPTH",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":569,"PHASE3":571,"PHASE4":591,"NA":611},{"trials":557,"activeCount":60},[],{"trials":559,"activeCount":60},[560],{"nctId":561,"briefTitle":562,"status":68,"phases":563,"primaryCompletion":564,"completion":564,"start":565,"enrollment":155,"conditions":566,"interventions":568},"NCT03150108","Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects",[49],"2017-06-26","2017-05-16",[567],"Hypoparathyroidism",[554,554,554],{"trials":570,"activeCount":60},[],{"trials":572,"activeCount":60},[573,582],{"nctId":574,"briefTitle":575,"status":79,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT03364738","Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism",[51],"2020-04-14","2018-09-26",22,[567],[554],{"nctId":583,"briefTitle":584,"status":391,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":60,"conditions":588,"interventions":590},"NCT03878953","A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism",[51],"2023-05-31","2022-08-31",[589],"Chronic Hypoparathyroidism",[554],{"trials":592,"activeCount":60},[593,602],{"nctId":594,"briefTitle":595,"status":68,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":601},"NCT03324880","A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)",[52],"2022-05-19","2018-01-24",93,[567],[554],{"nctId":603,"briefTitle":604,"status":68,"phases":605,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":609,"interventions":610},"NCT02910466","A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism",[52],"2019-12-20","2016-10-27",39,[589,567],[554],{"trials":612,"activeCount":60},[],{"intervention":215,"totalTrials":9,"cells":614},{"EARLY_PHASE1":615,"PHASE1":617,"PHASE2":630,"PHASE3":632,"PHASE4":638,"NA":648},{"trials":616,"activeCount":60},[],{"trials":618,"activeCount":60},[619],{"nctId":620,"briefTitle":621,"status":68,"phases":622,"primaryCompletion":623,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":627},"NCT01183234","SPD544 High Strength Bioequivalence Study",[49],"2010-10-22","2010-08-27",28,[213],[628,629],"SPD544","Methylphenidate hydrochloride",{"trials":631,"activeCount":60},[],{"trials":633,"activeCount":60},[634],{"nctId":206,"briefTitle":207,"status":68,"phases":635,"primaryCompletion":209,"completion":209,"start":210,"enrollment":211,"conditions":636,"interventions":637},[51],[213],[142,215],{"trials":639,"activeCount":60},[640,644],{"nctId":267,"briefTitle":268,"status":68,"phases":641,"primaryCompletion":270,"completion":270,"start":271,"enrollment":272,"conditions":642,"interventions":643},[52],[274],[234,215],{"nctId":277,"briefTitle":268,"status":68,"phases":645,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":646,"interventions":647},[52],[274],[234,215],{"trials":649,"activeCount":60},[],{"intervention":651,"totalTrials":174,"cells":652},"Midodrine Hydrochloride",{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":659,"PHASE4":661,"NA":692},{"trials":654,"activeCount":60},[],{"trials":656,"activeCount":60},[],{"trials":658,"activeCount":60},[],{"trials":660,"activeCount":60},[],{"trials":662,"activeCount":60},[663,673,682],{"nctId":664,"briefTitle":665,"status":68,"phases":666,"primaryCompletion":667,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":672},"NCT00046475","A Study for Patients With Neurogenic Orthostatic Hypotension",[52],"1999-11-24","1997-12-01",140,[671],"Hypotension, Orthostatic",[651],{"nctId":674,"briefTitle":675,"status":68,"phases":676,"primaryCompletion":677,"completion":677,"start":678,"enrollment":155,"conditions":679,"interventions":680},"NCT00555880","Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension",[52],"2005-03-21","2004-09-08",[671],[681],"Midodrine hydrochloride",{"nctId":683,"briefTitle":684,"status":79,"phases":685,"primaryCompletion":686,"completion":686,"start":687,"enrollment":688,"conditions":689,"interventions":690},"NCT00046163","A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension",[52],"2003-08-06","2002-09-05",150,[671],[691],"midodrine hydrochloride",{"trials":693,"activeCount":60},[],{"intervention":695,"totalTrials":174,"cells":696},"Vyvanse",{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":713,"PHASE3":715,"PHASE4":726,"NA":737},{"trials":698,"activeCount":60},[],{"trials":700,"activeCount":60},[701],{"nctId":702,"briefTitle":703,"status":68,"phases":704,"primaryCompletion":705,"completion":705,"start":706,"enrollment":707,"conditions":708,"interventions":709},"NCT00919867","A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers",[49],"2009-07-30","2009-06-24",42,[19],[710,711,712],"SPD503","VYVANSE","SPD503 and VYVANSE",{"trials":714,"activeCount":60},[],{"trials":716,"activeCount":60},[717],{"nctId":718,"briefTitle":719,"status":68,"phases":720,"primaryCompletion":721,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":725},"NCT00500149","A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit\u002FHyperactivity Disorder (ADHD)",[51],"2007-12-05","2007-06-13",129,[213],[695],{"trials":727,"activeCount":60},[728],{"nctId":729,"briefTitle":730,"status":68,"phases":731,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":735,"interventions":736},"NCT00500071","Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD",[52],"2008-01-02","2007-06-28",318,[25],[695],{"trials":738,"activeCount":60},[],{"intervention":740,"totalTrials":12,"cells":741},"MMX Mesalamine",{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":770},{"trials":743,"activeCount":60},[],{"trials":745,"activeCount":60},[746],{"nctId":747,"briefTitle":748,"status":68,"phases":749,"primaryCompletion":750,"completion":750,"start":751,"enrollment":752,"conditions":753,"interventions":754},"NCT01130844","Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis",[49],"2013-06-27","2010-10-08",52,[27],[740,740,740],{"trials":756,"activeCount":60},[],{"trials":758,"activeCount":60},[],{"trials":760,"activeCount":60},[761],{"nctId":762,"briefTitle":763,"status":68,"phases":764,"primaryCompletion":765,"completion":765,"start":766,"enrollment":767,"conditions":768,"interventions":769},"NCT00446849","Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)",[52],"2009-08-17","2007-05-01",290,[27],[740],{"trials":771,"activeCount":60},[],{"intervention":773,"totalTrials":12,"cells":774},"Midodrine HCl",{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":783,"NA":804},{"trials":776,"activeCount":60},[],{"trials":778,"activeCount":60},[],{"trials":780,"activeCount":60},[],{"trials":782,"activeCount":60},[],{"trials":784,"activeCount":60},[785,795],{"nctId":786,"briefTitle":787,"status":68,"phases":788,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":792,"interventions":794},"NCT01515865","Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension",[52],"2013-11-11","2012-05-23",98,[793],"Symptomatic Orthostatic Hypotension",[773],{"nctId":796,"briefTitle":797,"status":68,"phases":798,"primaryCompletion":799,"completion":799,"start":800,"enrollment":155,"conditions":801,"interventions":803},"NCT01518946","Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension",[52],"2013-06-22","2012-05-14",[802],"Orthostatic Hypotension",[773],{"trials":805,"activeCount":60},[],{"intervention":540,"totalTrials":115,"cells":807},{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":814,"PHASE4":816,"NA":822},{"trials":809,"activeCount":60},[],{"trials":811,"activeCount":60},[],{"trials":813,"activeCount":60},[],{"trials":815,"activeCount":60},[],{"trials":817,"activeCount":60},[818],{"nctId":532,"briefTitle":533,"status":68,"phases":819,"primaryCompletion":535,"completion":535,"start":536,"enrollment":28,"conditions":820,"interventions":821},[52],[538],[488,540],{"trials":823,"activeCount":60},[],{"intervention":825,"totalTrials":115,"cells":826},"MMX mesalamine\u002F mesalazine",{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":833,"PHASE4":835,"NA":846},{"trials":828,"activeCount":60},[],{"trials":830,"activeCount":60},[],{"trials":832,"activeCount":60},[],{"trials":834,"activeCount":60},[],{"trials":836,"activeCount":60},[837],{"nctId":838,"briefTitle":839,"status":68,"phases":840,"primaryCompletion":841,"completion":841,"start":842,"enrollment":843,"conditions":844,"interventions":845},"NCT01124149","Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis",[52],"2012-12-07","2010-06-29",759,[27],[825],{"trials":847,"activeCount":60},[],{"intervention":474,"totalTrials":115,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":858,"NA":864},{"trials":851,"activeCount":60},[],{"trials":853,"activeCount":60},[],{"trials":855,"activeCount":60},[],{"trials":857,"activeCount":60},[],{"trials":859,"activeCount":60},[860],{"nctId":466,"briefTitle":467,"status":68,"phases":861,"primaryCompletion":469,"completion":469,"start":470,"enrollment":471,"conditions":862,"interventions":863},[52],[456],[474,428],{"trials":865,"activeCount":60},[],{"intervention":867,"totalTrials":115,"cells":868},"C1 inhibitor (human) [C1 INH]",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":877,"NA":888},{"trials":870,"activeCount":60},[],{"trials":872,"activeCount":60},[],{"trials":874,"activeCount":60},[],{"trials":876,"activeCount":60},[],{"trials":878,"activeCount":60},[879],{"nctId":880,"briefTitle":881,"status":68,"phases":882,"primaryCompletion":883,"completion":883,"start":884,"enrollment":20,"conditions":885,"interventions":887},"NCT00914966","A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE",[52],"2012-05-24","2009-08-31",[886],"Hereditary Angioedema",[867],{"trials":889,"activeCount":60},[],{"intervention":891,"totalTrials":115,"cells":892},"Elaprase for intravenous (IV)",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":901,"NA":912},{"trials":894,"activeCount":60},[],{"trials":896,"activeCount":60},[],{"trials":898,"activeCount":60},[],{"trials":900,"activeCount":60},[],{"trials":902,"activeCount":60},[903],{"nctId":904,"briefTitle":905,"status":68,"phases":906,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":911},"NCT02455622","Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at \u003C 6 Years of Age",[52],"2025-07-29","2015-10-28",21,[35],[891],{"trials":913,"activeCount":60},[],{"intervention":915,"totalTrials":115,"cells":916},"Anagrelide",{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":923,"PHASE4":925,"NA":937},{"trials":918,"activeCount":60},[],{"trials":920,"activeCount":60},[],{"trials":922,"activeCount":60},[],{"trials":924,"activeCount":60},[],{"trials":926,"activeCount":60},[927],{"nctId":928,"briefTitle":929,"status":68,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":688,"conditions":933,"interventions":935},"NCT00202644","A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients",[52],"2015-12-15","2006-01-13",[934],"Thrombocythemia, Hemorrhagic",[915,936],"Hydroxyurea",{"trials":938,"activeCount":60},[],{"intervention":936,"totalTrials":115,"cells":940},{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":947,"PHASE4":949,"NA":955},{"trials":942,"activeCount":60},[],{"trials":944,"activeCount":60},[],{"trials":946,"activeCount":60},[],{"trials":948,"activeCount":60},[],{"trials":950,"activeCount":60},[951],{"nctId":928,"briefTitle":929,"status":68,"phases":952,"primaryCompletion":931,"completion":931,"start":932,"enrollment":688,"conditions":953,"interventions":954},[52],[934],[915,936],{"trials":956,"activeCount":60},[],{"intervention":484,"totalTrials":115,"cells":958},{"EARLY_PHASE1":959,"PHASE1":961,"PHASE2":963,"PHASE3":965,"PHASE4":967,"NA":973},{"trials":960,"activeCount":60},[],{"trials":962,"activeCount":60},[],{"trials":964,"activeCount":60},[],{"trials":966,"activeCount":60},[],{"trials":968,"activeCount":60},[969],{"nctId":476,"briefTitle":477,"status":68,"phases":970,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":971,"interventions":972},[52],[213],[484,428],{"trials":974,"activeCount":60},[],{"intervention":976,"totalTrials":115,"cells":977},"ARALAST NP",{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":998},{"trials":979,"activeCount":60},[],{"trials":981,"activeCount":60},[],{"trials":983,"activeCount":60},[],{"trials":985,"activeCount":60},[],{"trials":987,"activeCount":60},[988],{"nctId":989,"briefTitle":990,"status":391,"phases":991,"primaryCompletion":992,"completion":992,"start":993,"enrollment":60,"conditions":994,"interventions":997},"NCT04440488","ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study",[52],"2025-09-12","2021-03-08",[995,996],"Chronic Obstructive Pulmonary Disease","Alpha1-antitrypsin Deficiency",[976],{"trials":999,"activeCount":60},[],{"intervention":1001,"totalTrials":23,"cells":1002},"Teduglutide",{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1045,"PHASE3":1058,"PHASE4":1147,"NA":1149},{"trials":1004,"activeCount":60},[],{"trials":1006,"activeCount":60},[1007,1016,1025,1036],{"nctId":1008,"briefTitle":1009,"status":68,"phases":1010,"primaryCompletion":1011,"completion":1011,"start":1012,"enrollment":131,"conditions":1013,"interventions":1014},"NCT01209351","Effect of Teduglutide on Gastric Emptying in Healthy Subjects",[49],"2010-11-08","2010-09-28",[30],[1015],"teduglutide",{"nctId":1017,"briefTitle":1018,"status":68,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":1022,"conditions":1023,"interventions":1024},"NCT04465396","A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants",[49],"2021-08-20","2021-01-13",64,[30],[1001],{"nctId":1026,"briefTitle":1027,"status":68,"phases":1028,"primaryCompletion":1029,"completion":1029,"start":1030,"enrollment":1031,"conditions":1032,"interventions":1034},"NCT00820885","A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide",[49],"2007-04-23","2006-09-06",95,[1033],"Pharmacokinetics and Safety of Elevated Doses",[1015,1015,1035],"tedguglutide",{"nctId":1037,"briefTitle":1038,"status":68,"phases":1039,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":155,"conditions":1042,"interventions":1044},"NCT00819468","Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants",[49],"2007-08-23","2007-07-26",[1043],"Hepatic Impairment",[1001],{"trials":1046,"activeCount":60},[1047],{"nctId":1048,"briefTitle":1049,"status":68,"phases":1050,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1057},"NCT00308438","Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008",[50],"2005-11-01","2006-06-01","2004-03-01",67,[1056],"Crohn's Disease",[1001],{"trials":1059,"activeCount":60},[1060,1069,1078,1087,1096,1104,1113,1121,1130,1138],{"nctId":1061,"briefTitle":1062,"status":68,"phases":1063,"primaryCompletion":1064,"completion":1064,"start":1065,"enrollment":1066,"conditions":1067,"interventions":1068},"NCT03268811","A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302",[51],"2021-11-02","2017-08-23",9,[22],[1001],{"nctId":1070,"briefTitle":1071,"status":68,"phases":1072,"primaryCompletion":1073,"completion":1073,"start":1074,"enrollment":1075,"conditions":1076,"interventions":1077},"NCT00930644","Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)",[51],"2013-01-24","2009-09-21",88,[22],[1015],{"nctId":1079,"briefTitle":1080,"status":68,"phases":1081,"primaryCompletion":1082,"completion":1082,"start":1083,"enrollment":1084,"conditions":1085,"interventions":1086},"NCT03571516","Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome",[51],"2020-09-24","2018-08-31",10,[22],[1001],{"nctId":1088,"briefTitle":1089,"status":68,"phases":1090,"primaryCompletion":1091,"completion":1091,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1095},"NCT02340819","Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)",[51],"2018-11-05","2014-12-18",11,[22],[1001],{"nctId":1097,"briefTitle":1098,"status":68,"phases":1099,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":143,"conditions":1102,"interventions":1103},"NCT01560403","A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021",[51],"2013-07-23","2012-05-21",[22],[1001],{"nctId":1105,"briefTitle":1106,"status":68,"phases":1107,"primaryCompletion":1108,"completion":1108,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1112},"NCT02949362","Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study",[51],"2020-07-14","2016-12-09",29,[22],[1001],{"nctId":1114,"briefTitle":1115,"status":68,"phases":1116,"primaryCompletion":1117,"completion":1117,"start":1118,"enrollment":707,"conditions":1119,"interventions":1120},"NCT01952080","A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome",[51],"2015-01-09","2013-11-14",[22],[1015],{"nctId":1122,"briefTitle":1123,"status":68,"phases":1124,"primaryCompletion":1125,"completion":1125,"start":1126,"enrollment":1127,"conditions":1128,"interventions":1129},"NCT00798967","Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects",[51],"2011-01-25","2008-11-25",86,[22],[1015],{"nctId":1131,"briefTitle":1132,"status":68,"phases":1133,"primaryCompletion":1134,"completion":1134,"start":1135,"enrollment":1084,"conditions":1136,"interventions":1137},"NCT02980666","Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support",[51],"2020-01-21","2017-01-13",[22],[1001],{"nctId":1139,"briefTitle":1140,"status":68,"phases":1141,"primaryCompletion":1142,"completion":1142,"start":1143,"enrollment":1144,"conditions":1145,"interventions":1146},"NCT03663582","Study of Teduglutide in Japanese Participants With Short Bowel Syndrome",[51],"2019-08-06","2018-07-06",7,[22],[1001],{"trials":1148,"activeCount":60},[],{"trials":1150,"activeCount":60},[],{"intervention":1152,"totalTrials":1066,"cells":1153},"Maribavir",{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1185,"PHASE3":1206,"PHASE4":1251,"NA":1253},{"trials":1155,"activeCount":60},[],{"trials":1157,"activeCount":60},[1158,1166,1177],{"nctId":1159,"briefTitle":1160,"status":68,"phases":1161,"primaryCompletion":1162,"completion":1162,"start":1163,"enrollment":155,"conditions":1164,"interventions":1165},"NCT04497883","A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants",[49],"2020-11-12","2020-08-07",[30],[1152,1152,1152],{"nctId":1167,"briefTitle":1168,"status":68,"phases":1169,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":184,"conditions":1172,"interventions":1174},"NCT02775240","Study of SHP620 (Maribavir) in Healthy Adults",[49],"2016-09-12","2016-07-21",[1173],"Cytomegalovirus (CMV)",[1175,1152,1176],"Digoxin","Dextromethorphan",{"nctId":1178,"briefTitle":1179,"status":79,"phases":1180,"primaryCompletion":1181,"completion":1181,"start":1182,"enrollment":20,"conditions":1183,"interventions":1184},"NCT04131556","A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants",[49],"2020-01-06","2019-10-25",[30],[1152],{"trials":1186,"activeCount":60},[1187,1196],{"nctId":1188,"briefTitle":1189,"status":68,"phases":1190,"primaryCompletion":1191,"completion":1191,"start":1192,"enrollment":1193,"conditions":1194,"interventions":1195},"NCT01611974","Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients",[50],"2014-12-05","2012-07-17",120,[1173],[1152],{"nctId":1197,"briefTitle":1198,"status":68,"phases":1199,"primaryCompletion":1200,"completion":1200,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1205},"NCT00223925","Maribavir for Prevention of CMV After Stem Cell Transplants",[50],"2006-04-05","2004-10-28",111,[1204],"Cytomegalovirus Infection",[1152],{"trials":1207,"activeCount":60},[1208,1220,1229,1242],{"nctId":1209,"briefTitle":1210,"status":68,"phases":1211,"primaryCompletion":1212,"completion":1213,"start":1214,"enrollment":1215,"conditions":1216,"interventions":1218},"NCT00411645","Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients",[51],"2008-11-10","2009-05-23","2006-12-13",681,[1217],"Cytomegalovirus Infections",[1219],"maribavir",{"nctId":1221,"briefTitle":1222,"status":68,"phases":1223,"primaryCompletion":319,"completion":319,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1227},"NCT00497796","Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients",[51],"2007-07-23",307,[1217],[1219,1228],"ganciclovir",{"nctId":1230,"briefTitle":1231,"status":68,"phases":1232,"primaryCompletion":1233,"completion":1233,"start":1234,"enrollment":1235,"conditions":1236,"interventions":1237},"NCT02931539","Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir",[51],"2020-08-17","2016-12-22",352,[1173],[1152,1238,1239,1240,1241],"Ganciclovir","Valganciclovir","Foscarnet","Cidofovir",{"nctId":1243,"briefTitle":1244,"status":68,"phases":1245,"primaryCompletion":1246,"completion":1246,"start":1247,"enrollment":1248,"conditions":1249,"interventions":1250},"NCT02927067","A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants",[51],"2022-07-01","2017-04-14",553,[1173],[1152,1239],{"trials":1252,"activeCount":60},[],{"trials":1254,"activeCount":60},[],{"intervention":1256,"totalTrials":1257,"cells":1258},"Icatibant",8,{"EARLY_PHASE1":1259,"PHASE1":1261,"PHASE2":1271,"PHASE3":1273,"PHASE4":1342,"NA":1344},{"trials":1260,"activeCount":60},[],{"trials":1262,"activeCount":60},[1263],{"nctId":1264,"briefTitle":1265,"status":68,"phases":1266,"primaryCompletion":1267,"completion":1267,"start":1268,"enrollment":31,"conditions":1269,"interventions":1270},"NCT02045264","Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers",[49],"2014-02-27","2014-02-21",[16],[1256],{"trials":1272,"activeCount":60},[],{"trials":1274,"activeCount":60},[1275,1287,1297,1305,1313,1323,1333],{"nctId":1276,"briefTitle":1277,"status":68,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1283},"NCT00500656","Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)",[51],"2006-07-25","2005-03-01",85,[886],[1256,1284,1285,1286],"Tranexamic Acid","Oral Placebo","S.C. Placebo",{"nctId":1288,"briefTitle":1289,"status":68,"phases":1290,"primaryCompletion":1291,"completion":1291,"start":1292,"enrollment":1293,"conditions":1294,"interventions":1296},"NCT01919801","Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema",[51],"2015-08-22","2013-12-02",118,[1295],"Angiotensin Converting Enzyme Inhibitor Induced Angioedema",[1256],{"nctId":1298,"briefTitle":1299,"status":68,"phases":1300,"primaryCompletion":1301,"completion":1301,"start":1302,"enrollment":791,"conditions":1303,"interventions":1304},"NCT00912093","A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)",[51],"2010-10-01","2009-07-16",[886],[1256],{"nctId":1306,"briefTitle":1307,"status":68,"phases":1308,"primaryCompletion":1309,"completion":1309,"start":1310,"enrollment":1257,"conditions":1311,"interventions":1312},"NCT03888755","A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants",[51],"2016-02-12","2015-03-18",[16],[1256],{"nctId":1314,"briefTitle":1315,"status":68,"phases":1316,"primaryCompletion":1317,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1322},"NCT00097695","Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema",[51],"2006-07-17","2004-12-28",84,[1321],"Angioedema",[1256],{"nctId":1324,"briefTitle":1325,"status":68,"phases":1326,"primaryCompletion":1327,"completion":1327,"start":1328,"enrollment":1329,"conditions":1330,"interventions":1331},"NCT01386658","A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema",[51],"2018-03-12","2012-01-27",32,[16],[1332],"icatibant",{"nctId":1334,"briefTitle":1335,"status":68,"phases":1336,"primaryCompletion":1337,"completion":1337,"start":1338,"enrollment":1339,"conditions":1340,"interventions":1341},"NCT00997204","EASSI - Evaluation of the Safety of Self-Administration With Icatibant",[51],"2011-06-22","2009-09-25",151,[886],[1256],{"trials":1343,"activeCount":60},[],{"trials":1345,"activeCount":60},[],{"intervention":710,"totalTrials":1144,"cells":1347},{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1367,"PHASE3":1389,"PHASE4":1418,"NA":1420},{"trials":1349,"activeCount":60},[],{"trials":1351,"activeCount":60},[1352,1363],{"nctId":1353,"briefTitle":1354,"status":68,"phases":1355,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":1358,"conditions":1359,"interventions":1360},"NCT00901576","A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers",[49],"2009-07-06","2009-05-18",38,[19],[710,1361,1362],"Concerta","SPD503 + Concerta",{"nctId":702,"briefTitle":703,"status":68,"phases":1364,"primaryCompletion":705,"completion":705,"start":706,"enrollment":707,"conditions":1365,"interventions":1366},[49],[19],[710,711,712],{"trials":1368,"activeCount":60},[1369,1380],{"nctId":1370,"briefTitle":1371,"status":68,"phases":1372,"primaryCompletion":164,"completion":164,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1379},"NCT01470469","SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)",[50],"2012-01-04",83,[1376,1377,1378],"Generalized Anxiety Disorder (GAD)","Anxiety, Separation","Phobia, Social",[710],{"nctId":1381,"briefTitle":1382,"status":68,"phases":1383,"primaryCompletion":1384,"completion":1384,"start":1385,"enrollment":1386,"conditions":1387,"interventions":1388},"NCT00150592","Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17",[50],"2005-10-05","2005-05-12",182,[445],[710],{"trials":1390,"activeCount":60},[1391,1400,1409],{"nctId":1392,"briefTitle":1393,"status":68,"phases":1394,"primaryCompletion":1395,"completion":1395,"start":1396,"enrollment":1397,"conditions":1398,"interventions":1399},"NCT00150618","Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17",[51],"2004-10-07","2004-03-30",324,[445],[710,710,710,710],{"nctId":1401,"briefTitle":1402,"status":68,"phases":1403,"primaryCompletion":1404,"completion":1404,"start":1405,"enrollment":1406,"conditions":1407,"interventions":1408},"NCT00152009","Safety and Efficacy of SPD503 in Treating Attention-Deficit\u002FHyperactivity Disorder (ADHD) in Children Aged 6-17",[51],"2003-08-23","2003-01-29",345,[445],[710,710,710],{"nctId":1410,"briefTitle":1411,"status":68,"phases":1412,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":1416,"interventions":1417},"NCT00367835","SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms",[51],"2008-01-04","2006-12-04",217,[213],[710],{"trials":1419,"activeCount":60},[],{"trials":1421,"activeCount":60},[],{"intervention":1423,"totalTrials":1424,"cells":1425},"Ontamalimab",6,{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1432,"PHASE4":1490,"NA":1492},{"trials":1427,"activeCount":60},[],{"trials":1429,"activeCount":60},[],{"trials":1431,"activeCount":60},[],{"trials":1433,"activeCount":60},[1434,1444,1454,1463,1472,1481],{"nctId":1435,"briefTitle":1436,"status":79,"phases":1437,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":1441,"conditions":1442,"interventions":1443},"NCT03259334","Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis",[51],"2020-07-22","2020-10-23","2018-02-09",380,[27],[1423],{"nctId":1445,"briefTitle":1446,"status":79,"phases":1447,"primaryCompletion":1448,"completion":1449,"start":1450,"enrollment":1451,"conditions":1452,"interventions":1453},"NCT03627091","Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)",[51],"2021-06-21","2021-09-13","2019-02-06",40,[1056],[1423],{"nctId":1455,"briefTitle":1456,"status":79,"phases":1457,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":165,"conditions":1461,"interventions":1462},"NCT03559517","Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)",[51],"2020-07-07","2020-10-08","2018-08-29",[1056],[1423],{"nctId":1464,"briefTitle":1465,"status":79,"phases":1466,"primaryCompletion":1467,"completion":1467,"start":1468,"enrollment":1469,"conditions":1470,"interventions":1471},"NCT03566823","Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)",[51],"2020-08-18","2018-07-17",34,[1056],[1423],{"nctId":1473,"briefTitle":1436,"status":79,"phases":1474,"primaryCompletion":1475,"completion":1476,"start":1477,"enrollment":1478,"conditions":1479,"interventions":1480},"NCT03259308",[51],"2020-07-15","2020-10-06","2017-12-05",279,[27],[1423],{"nctId":1482,"briefTitle":1483,"status":68,"phases":1484,"primaryCompletion":1485,"completion":1485,"start":1486,"enrollment":1487,"conditions":1488,"interventions":1489},"NCT03290781","An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis",[51],"2021-07-01","2018-04-04",366,[27],[1423],{"trials":1491,"activeCount":60},[],{"trials":1493,"activeCount":60},[],{"intervention":1495,"totalTrials":1424,"cells":1496},"Lifitegrast",{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1523,"PHASE4":1562,"NA":1564},{"trials":1498,"activeCount":60},[],{"trials":1500,"activeCount":60},[],{"trials":1502,"activeCount":60},[1503,1513],{"nctId":1504,"briefTitle":1505,"status":68,"phases":1506,"primaryCompletion":1507,"completion":1507,"start":1508,"enrollment":1509,"conditions":1510,"interventions":1512},"NCT00926185","A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)",[50],"2010-02-18","2009-08-03",230,[1511],"Dry Eye",[1495],{"nctId":1514,"briefTitle":1515,"status":68,"phases":1516,"primaryCompletion":1517,"completion":1517,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1522},"NCT00882687","Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis",[50],"2009-05-10","2009-04-24",60,[1521],"Allergic Conjunctivitis",[1495],{"trials":1524,"activeCount":60},[1525,1534,1543,1552],{"nctId":1526,"briefTitle":1527,"status":68,"phases":1528,"primaryCompletion":1529,"completion":1529,"start":841,"enrollment":1530,"conditions":1531,"interventions":1533},"NCT01743729","A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye",[51],"2013-10-01",720,[1532],"Dry Eye Disease",[1495],{"nctId":1535,"briefTitle":1536,"status":68,"phases":1537,"primaryCompletion":1538,"completion":1538,"start":1539,"enrollment":1540,"conditions":1541,"interventions":1542},"NCT01636206","Safety Study of Lifitegrast to Treat Dry Eye",[51],"2014-03-03","2012-10-16",332,[1532],[1495],{"nctId":1544,"briefTitle":1545,"status":68,"phases":1546,"primaryCompletion":1547,"completion":1547,"start":1548,"enrollment":1549,"conditions":1550,"interventions":1551},"NCT02284516","A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)",[51],"2015-10-05","2014-11-06",711,[1532],[1495],{"nctId":1553,"briefTitle":1554,"status":68,"phases":1555,"primaryCompletion":1556,"completion":1556,"start":1557,"enrollment":1558,"conditions":1559,"interventions":1561},"NCT01421498","Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)",[51],"2012-04-28","2011-08-29",588,[1560,1532],"Keratoconjunctivitis Sicca",[1495],{"trials":1563,"activeCount":60},[],{"trials":1565,"activeCount":60},[],{"intervention":1567,"totalTrials":56,"cells":1568},"C1 esterase inhibitor [human]",{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1582,"PHASE3":1584,"PHASE4":1616,"NA":1618},{"trials":1570,"activeCount":60},[],{"trials":1572,"activeCount":60},[1573],{"nctId":1574,"briefTitle":1575,"status":68,"phases":1576,"primaryCompletion":1577,"completion":1577,"start":1578,"enrollment":1579,"conditions":1580,"interventions":1581},"NCT00432510","Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects",[49],"2007-02-28","2006-10-09",27,[886],[1567],{"trials":1583,"activeCount":60},[],{"trials":1585,"activeCount":60},[1586,1594,1602,1609],{"nctId":1587,"briefTitle":1588,"status":68,"phases":1589,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":1374,"conditions":1592,"interventions":1593},"NCT00289211","C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks",[51],"2007-04-13","2005-03-14",[886],[1567],{"nctId":1595,"briefTitle":1596,"status":68,"phases":1597,"primaryCompletion":172,"completion":172,"start":1598,"enrollment":1599,"conditions":1600,"interventions":1601},"NCT00462709","Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks",[51],"2006-06-27",146,[886],[1567],{"nctId":1603,"briefTitle":1604,"status":68,"phases":1605,"primaryCompletion":1606,"completion":1606,"start":1591,"enrollment":17,"conditions":1607,"interventions":1608},"NCT01005888","C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks",[51],"2007-08-22",[886],[1567],{"nctId":1610,"briefTitle":1611,"status":68,"phases":1612,"primaryCompletion":172,"completion":172,"start":1613,"enrollment":376,"conditions":1614,"interventions":1615},"NCT00438815","Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks",[51],"2006-09-21",[886],[1567],{"trials":1617,"activeCount":60},[],{"trials":1619,"activeCount":60},[],{"intervention":1621,"totalTrials":56,"cells":1622},"Lanadelumab",{"EARLY_PHASE1":1623,"PHASE1":1625,"PHASE2":1644,"PHASE3":1646,"PHASE4":1673,"NA":1675},{"trials":1624,"activeCount":60},[],{"trials":1626,"activeCount":60},[1627,1635],{"nctId":1628,"briefTitle":1629,"status":68,"phases":1630,"primaryCompletion":1631,"completion":1631,"start":1632,"enrollment":1329,"conditions":1633,"interventions":1634},"NCT03401671","Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects",[49],"2018-05-30","2018-01-15",[30],[1621],{"nctId":1636,"briefTitle":1637,"status":391,"phases":1638,"primaryCompletion":1639,"completion":1639,"start":1640,"enrollment":60,"conditions":1641,"interventions":1643},"NCT04460105","Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia",[49],"2021-01-27","2020-10-31",[1642],"COVID-19 Pneumonia",[1621],{"trials":1645,"activeCount":60},[],{"trials":1647,"activeCount":60},[1648,1656,1665],{"nctId":1649,"briefTitle":1650,"status":68,"phases":1651,"primaryCompletion":1652,"completion":1652,"start":1653,"enrollment":31,"conditions":1654,"interventions":1655},"NCT04180163","Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)",[51],"2021-08-26","2019-12-12",[16],[1621],{"nctId":1657,"briefTitle":1658,"status":68,"phases":1659,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":1662,"conditions":1663,"interventions":1664},"NCT04444895","A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor",[51],"2023-05-05","2021-02-05",73,[1321],[1621],{"nctId":1666,"briefTitle":1667,"status":68,"phases":1668,"primaryCompletion":1669,"completion":1669,"start":1670,"enrollment":909,"conditions":1671,"interventions":1672},"NCT04070326","A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children",[51],"2021-10-30","2019-08-19",[886],[1621],{"trials":1674,"activeCount":60},[],{"trials":1676,"activeCount":60},[],{"intervention":1678,"totalTrials":9,"cells":1679},"ALX1-11",{"EARLY_PHASE1":1680,"PHASE1":1682,"PHASE2":1684,"PHASE3":1697,"PHASE4":1726,"NA":1728},{"trials":1681,"activeCount":60},[],{"trials":1683,"activeCount":60},[],{"trials":1685,"activeCount":60},[1686],{"nctId":1687,"briefTitle":1688,"status":68,"phases":1689,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1415,"conditions":1692,"interventions":1694},"NCT00172107","A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis",[50],"1997-03-24","1995-05-18",[1693],"Osteoporosis",[1695,1696,1678],"ALX1-11 50 mcg","ALX1-11 75mcg",{"trials":1698,"activeCount":60},[1699,1708,1717],{"nctId":1700,"briefTitle":1701,"status":68,"phases":1702,"primaryCompletion":1703,"completion":1703,"start":1704,"enrollment":1705,"conditions":1706,"interventions":1707},"NCT00172133","Open Label Extension Study of PREOS",[51],"2005-04-13","2001-10-16",1683,[1693],[1678],{"nctId":1709,"briefTitle":1710,"status":68,"phases":1711,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":1714,"conditions":1715,"interventions":1716},"NCT00172081","TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis",[51],"2003-11-07","2000-04-27",2532,[1693],[1678],{"nctId":1718,"briefTitle":1719,"status":68,"phases":1720,"primaryCompletion":1721,"completion":1721,"start":1722,"enrollment":1723,"conditions":1724,"interventions":1725},"NCT00172120","Open Label Extension",[51],"2006-10-27","2005-01-10",91,[1693],[1678],{"trials":1727,"activeCount":60},[],{"trials":1729,"activeCount":60},[],{"intervention":1731,"totalTrials":9,"cells":1732},"SHP465",{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1745,"PHASE3":1747,"PHASE4":1776,"NA":1778},{"trials":1734,"activeCount":60},[],{"trials":1736,"activeCount":60},[1737],{"nctId":1738,"briefTitle":1739,"status":68,"phases":1740,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":155,"conditions":1743,"interventions":1744},"NCT03327402","Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[49],"2018-10-05","2018-03-13",[25],[1731],{"trials":1746,"activeCount":60},[],{"trials":1748,"activeCount":60},[1749,1758,1767],{"nctId":1750,"briefTitle":1751,"status":79,"phases":1752,"primaryCompletion":1753,"completion":1753,"start":1754,"enrollment":1755,"conditions":1756,"interventions":1757},"NCT03325894","Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit\u002FHyperactivity Disorder (ADHD)",[51],"2019-01-19","2018-01-02",141,[25],[1731],{"nctId":1759,"briefTitle":1760,"status":68,"phases":1761,"primaryCompletion":1762,"completion":1762,"start":1763,"enrollment":1764,"conditions":1765,"interventions":1766},"NCT03325881","Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit\u002FHyperactivity Disorder (ADHD) in Children Aged 6-12 Years",[51],"2018-06-07","2017-12-09",89,[25],[1731],{"nctId":1768,"briefTitle":1769,"status":68,"phases":1770,"primaryCompletion":1771,"completion":1771,"start":1772,"enrollment":1773,"conditions":1774,"interventions":1775},"NCT02466425","Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)",[51],"2016-02-16","2015-06-18",264,[25],[1731],{"trials":1777,"activeCount":60},[],{"trials":1779,"activeCount":60},[],{"intervention":458,"totalTrials":9,"cells":1781},{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1786,"PHASE3":1788,"PHASE4":1821,"NA":1823},{"trials":1783,"activeCount":60},[],{"trials":1785,"activeCount":60},[],{"trials":1787,"activeCount":60},[],{"trials":1789,"activeCount":60},[1790,1798,1802,1811],{"nctId":1791,"briefTitle":1792,"status":68,"phases":1793,"primaryCompletion":1794,"completion":1794,"start":1795,"enrollment":290,"conditions":1796,"interventions":1797},"NCT01081132","Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit\u002FHyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl",[51],"2013-05-16","2011-09-19",[252],[458],{"nctId":449,"briefTitle":450,"status":68,"phases":1799,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":1800,"interventions":1801},[51],[456],[458,254],{"nctId":1803,"briefTitle":1804,"status":68,"phases":1805,"primaryCompletion":1806,"completion":1806,"start":1807,"enrollment":1808,"conditions":1809,"interventions":1810},"NCT01081145","Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit\u002FHyperactivity Disorder (ADHD)",[51],"2013-06-03","2010-05-11",528,[274],[458],{"nctId":1812,"briefTitle":1813,"status":68,"phases":1814,"primaryCompletion":1815,"completion":1815,"start":1816,"enrollment":1817,"conditions":1818,"interventions":1819},"NCT00997984","Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit\u002FHyperactivity Disorder (ADHD) (The ADHD Tempo Study)",[51],"2010-10-09","2009-11-17",340,[252],[1820,1820],"extended-release guanfacine hydrochloride",{"trials":1822,"activeCount":60},[],{"trials":1824,"activeCount":60},[],{"intervention":1826,"totalTrials":9,"cells":1827},"NPSP558",{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1832,"PHASE3":1834,"PHASE4":1870,"NA":1872},{"trials":1829,"activeCount":60},[],{"trials":1831,"activeCount":60},[],{"trials":1833,"activeCount":60},[],{"trials":1835,"activeCount":60},[1836,1845,1853,1862],{"nctId":1837,"briefTitle":1838,"status":68,"phases":1839,"primaryCompletion":1840,"completion":1841,"start":1842,"enrollment":707,"conditions":1843,"interventions":1844},"NCT01268098","Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)",[51],"2011-09-23","2011-11-11","2011-02-09",[567],[1826],{"nctId":1846,"briefTitle":1847,"status":68,"phases":1848,"primaryCompletion":1849,"completion":1849,"start":546,"enrollment":1850,"conditions":1851,"interventions":1852},"NCT01297309","A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)",[51],"2018-06-08",51,[567],[1826],{"nctId":1854,"briefTitle":1855,"status":68,"phases":1856,"primaryCompletion":1857,"completion":1857,"start":1858,"enrollment":1859,"conditions":1860,"interventions":1861},"NCT00732615","Use of NPSP558 in the Treatment of Hypoparathyroidism",[51],"2011-09-28","2008-12-18",124,[567],[1826],{"nctId":1863,"briefTitle":1864,"status":68,"phases":1865,"primaryCompletion":1866,"completion":1866,"start":1867,"enrollment":155,"conditions":1868,"interventions":1869},"NCT01455181","A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary",[51],"2012-04-26","2011-08-19",[567],[1826],{"trials":1871,"activeCount":60},[],{"trials":1873,"activeCount":60},[],{"intervention":1875,"totalTrials":174,"cells":1876},"SPD476",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1883,"PHASE4":1915,"NA":1917},{"trials":1878,"activeCount":60},[],{"trials":1880,"activeCount":60},[],{"trials":1882,"activeCount":60},[],{"trials":1884,"activeCount":60},[1885,1895,1905],{"nctId":1886,"briefTitle":1887,"status":68,"phases":1888,"primaryCompletion":1889,"completion":1889,"start":1890,"enrollment":1891,"conditions":1892,"interventions":1893},"NCT00151892","Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis",[51],"2009-09-07","2005-04-08",829,[27],[1875,1894],"Asacol",{"nctId":1896,"briefTitle":1897,"status":68,"phases":1898,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":1901,"conditions":1902,"interventions":1904},"NCT00151944","Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.",[51],"2006-03-13","2003-11-26",400,[1903],"Colitis, Ulcerative",[1875],{"nctId":1906,"briefTitle":1907,"status":68,"phases":1908,"primaryCompletion":1909,"completion":1909,"start":1910,"enrollment":1911,"conditions":1912,"interventions":1914},"NCT00545740","Prevention of Recurrence of Diverticulitis",[51],"2012-03-05","2007-11-28",590,[1913],"Diverticulitis",[1875,1875,1875],{"trials":1916,"activeCount":60},[],{"trials":1918,"activeCount":60},[],{"intervention":1920,"totalTrials":174,"cells":1921},"DX-2930",{"EARLY_PHASE1":1922,"PHASE1":1924,"PHASE2":1942,"PHASE3":1944,"PHASE4":1955,"NA":1957},{"trials":1923,"activeCount":60},[],{"trials":1925,"activeCount":60},[1926,1934],{"nctId":1927,"briefTitle":1928,"status":68,"phases":1929,"primaryCompletion":1930,"completion":1930,"start":1931,"enrollment":1329,"conditions":1932,"interventions":1933},"NCT01923207","A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects",[49],"2014-01-07","2013-08-12",[16],[1920],{"nctId":1935,"briefTitle":1936,"status":68,"phases":1937,"primaryCompletion":1938,"completion":1938,"start":1939,"enrollment":1358,"conditions":1940,"interventions":1941},"NCT02093923","A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants",[49],"2015-05-18","2014-05-14",[16],[1920],{"trials":1943,"activeCount":60},[],{"trials":1945,"activeCount":60},[1946],{"nctId":1947,"briefTitle":1948,"status":68,"phases":1949,"primaryCompletion":1950,"completion":1950,"start":1951,"enrollment":1952,"conditions":1953,"interventions":1954},"NCT02741596","Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE",[51],"2019-10-31","2016-05-26",212,[16],[1920,1920],{"trials":1956,"activeCount":60},[],{"trials":1958,"activeCount":60},[],{"intervention":1960,"totalTrials":174,"cells":1961},"SHP640",{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1966,"PHASE3":1968,"PHASE4":1999,"NA":2001},{"trials":1963,"activeCount":60},[],{"trials":1965,"activeCount":60},[],{"trials":1967,"activeCount":60},[],{"trials":1969,"activeCount":60},[1970,1980,1989],{"nctId":1971,"briefTitle":1972,"status":79,"phases":1973,"primaryCompletion":130,"completion":130,"start":1974,"enrollment":1975,"conditions":1976,"interventions":1978},"NCT02998541","Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo",[51],"2017-03-27",219,[1977],"Adenoviral Conjunctivitis",[1960,1979],"PVP-I 0.6%",{"nctId":1981,"briefTitle":1982,"status":79,"phases":1983,"primaryCompletion":1984,"completion":1984,"start":1985,"enrollment":1986,"conditions":1987,"interventions":1988},"NCT02998554","Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo",[51],"2019-05-16","2017-03-28",156,[1977],[1960],{"nctId":1990,"briefTitle":1991,"status":68,"phases":1992,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":1995,"conditions":1996,"interventions":1998},"NCT03004924","Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo",[51],"2018-10-01","2017-03-29",753,[1997],"Bacterial Conjunctivitis",[1960,1979],{"trials":2000,"activeCount":60},[],{"trials":2002,"activeCount":60},[],{"intervention":2004,"totalTrials":174,"cells":2005},"Antidepressant + Placebo",{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2010,"PHASE3":2035,"PHASE4":2045,"NA":2047},{"trials":2007,"activeCount":60},[],{"trials":2009,"activeCount":60},[],{"trials":2011,"activeCount":60},[2012,2025],{"nctId":2013,"briefTitle":2014,"status":68,"phases":2015,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":2019,"interventions":2020},"NCT01435759","SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder",[50],"2014-01-17","2011-05-31",1197,[332],[2021,2022,2023,2024,2004],"Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg","Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg","Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg","Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg",{"nctId":2026,"briefTitle":2027,"status":68,"phases":2028,"primaryCompletion":2029,"completion":2029,"start":705,"enrollment":2030,"conditions":2031,"interventions":2032},"NCT00905424","Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant",[50],"2010-08-04",246,[332],[2033,2034],"Antidepressant + SPD489","Antidepressant + placebo",{"trials":2036,"activeCount":60},[2037],{"nctId":2038,"briefTitle":346,"status":68,"phases":2039,"primaryCompletion":2040,"completion":2040,"start":2041,"enrollment":2042,"conditions":2043,"interventions":2044},"NCT01436162",[51],"2013-12-10","2011-10-19",1105,[332],[2033,2004],{"trials":2046,"activeCount":60},[],{"trials":2048,"activeCount":60},[],{"intervention":2050,"totalTrials":174,"cells":2051},"Oral Budesonide Suspension",{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2067,"PHASE4":2086,"NA":2088},{"trials":2053,"activeCount":60},[],{"trials":2055,"activeCount":60},[],{"trials":2057,"activeCount":60},[2058],{"nctId":2059,"briefTitle":2060,"status":68,"phases":2061,"primaryCompletion":2062,"completion":2062,"start":2063,"enrollment":599,"conditions":2064,"interventions":2066},"NCT01642212","OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension",[50],"2014-10-30","2012-07-23",[2065],"Eosinophilic Esophagitis (EoE)",[2050],{"trials":2068,"activeCount":60},[2069,2078],{"nctId":2070,"briefTitle":2071,"status":68,"phases":2072,"primaryCompletion":2073,"completion":2074,"start":2075,"enrollment":734,"conditions":2076,"interventions":2077},"NCT02605837","A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved",[51],"2019-01-24","2019-02-15","2015-12-07",[2065],[2050],{"nctId":2079,"briefTitle":2080,"status":68,"phases":2081,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":1975,"conditions":2084,"interventions":2085},"NCT02736409","An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)",[51],"2019-11-12","2016-04-01",[2065],[2050],{"trials":2087,"activeCount":60},[],{"trials":2089,"activeCount":60},[],{"intervention":2091,"totalTrials":12,"cells":2092},"SPD422",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2106,"PHASE3":2108,"PHASE4":2120,"NA":2122},{"trials":2094,"activeCount":60},[],{"trials":2096,"activeCount":60},[2097],{"nctId":2098,"briefTitle":2099,"status":68,"phases":2100,"primaryCompletion":2101,"completion":2101,"start":2102,"enrollment":20,"conditions":2103,"interventions":2104},"NCT03866434","Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SPD422 (Anagrelide Hydrochloride) in Healthy Adult Participants",[49],"2019-04-10","2019-02-26",[30],[2091,2105],"Omeprazole",{"trials":2107,"activeCount":60},[],{"trials":2109,"activeCount":60},[2110],{"nctId":2111,"briefTitle":2112,"status":68,"phases":2113,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":2116,"conditions":2117,"interventions":2119},"NCT01467661","Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia",[51],"2015-05-01","2010-10-27",41,[2118],"Essential Thrombocythemia (ET)",[2091],{"trials":2121,"activeCount":60},[],{"trials":2123,"activeCount":60},[],{"intervention":2125,"totalTrials":12,"cells":2126},"SHP615",{"EARLY_PHASE1":2127,"PHASE1":2129,"PHASE2":2131,"PHASE3":2133,"PHASE4":2153,"NA":2155},{"trials":2128,"activeCount":60},[],{"trials":2130,"activeCount":60},[],{"trials":2132,"activeCount":60},[],{"trials":2134,"activeCount":60},[2135,2144],{"nctId":2136,"briefTitle":2137,"status":68,"phases":2138,"primaryCompletion":1670,"completion":1670,"start":2139,"enrollment":2140,"conditions":2141,"interventions":2143},"NCT03336645","Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS\u002FSHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan",[51],"2017-10-23",25,[2142],"Nervous System Diseases",[2125],{"nctId":2145,"briefTitle":2146,"status":68,"phases":2147,"primaryCompletion":2148,"completion":2148,"start":2149,"enrollment":174,"conditions":2150,"interventions":2151},"NCT03336450","Study of Midazolam Hydrochloride Oromucosal Solution (MHOS\u002FSHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting",[51],"2020-10-13","2018-04-23",[2142],[2125,2152],"MHOS\u002FSHP615",{"trials":2154,"activeCount":60},[],{"trials":2156,"activeCount":60},[],{"intervention":447,"totalTrials":12,"cells":2158},{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2165,"PHASE4":2180,"NA":2182},{"trials":2160,"activeCount":60},[],{"trials":2162,"activeCount":60},[],{"trials":2164,"activeCount":60},[],{"trials":2166,"activeCount":60},[2167,2171],{"nctId":439,"briefTitle":440,"status":68,"phases":2168,"primaryCompletion":442,"completion":442,"start":443,"enrollment":131,"conditions":2169,"interventions":2170},[51],[445],[447,428],{"nctId":2172,"briefTitle":2173,"status":68,"phases":2174,"primaryCompletion":2175,"completion":2175,"start":2176,"enrollment":2177,"conditions":2178,"interventions":2179},"NCT00507065","Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)",[51],"2004-03-24","2003-05-28",329,[213],[447],{"trials":2181,"activeCount":60},[],{"trials":2183,"activeCount":60},[],{"intervention":1979,"totalTrials":12,"cells":2185},{"EARLY_PHASE1":2186,"PHASE1":2188,"PHASE2":2190,"PHASE3":2192,"PHASE4":2202,"NA":2204},{"trials":2187,"activeCount":60},[],{"trials":2189,"activeCount":60},[],{"trials":2191,"activeCount":60},[],{"trials":2193,"activeCount":60},[2194,2198],{"nctId":1971,"briefTitle":1972,"status":79,"phases":2195,"primaryCompletion":130,"completion":130,"start":1974,"enrollment":1975,"conditions":2196,"interventions":2197},[51],[1977],[1960,1979],{"nctId":1990,"briefTitle":1991,"status":68,"phases":2199,"primaryCompletion":1993,"completion":1993,"start":1994,"enrollment":1995,"conditions":2200,"interventions":2201},[51],[1997],[1960,1979],{"trials":2203,"activeCount":60},[],{"trials":2205,"activeCount":60},[],{"intervention":1228,"totalTrials":12,"cells":2207},{"EARLY_PHASE1":2208,"PHASE1":2210,"PHASE2":2212,"PHASE3":2214,"PHASE4":2224,"NA":2226},{"trials":2209,"activeCount":60},[],{"trials":2211,"activeCount":60},[],{"trials":2213,"activeCount":60},[],{"trials":2215,"activeCount":60},[2216,2220],{"nctId":1221,"briefTitle":1222,"status":68,"phases":2217,"primaryCompletion":319,"completion":319,"start":1224,"enrollment":1225,"conditions":2218,"interventions":2219},[51],[1217],[1219,1228],{"nctId":1230,"briefTitle":1231,"status":68,"phases":2221,"primaryCompletion":1233,"completion":1233,"start":1234,"enrollment":1235,"conditions":2222,"interventions":2223},[51],[1173],[1152,1238,1239,1240,1241],{"trials":2225,"activeCount":60},[],{"trials":2227,"activeCount":60},[],{"intervention":2229,"totalTrials":12,"cells":2230},"SHP465 12.5mg",{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2244,"PHASE3":2246,"PHASE4":2258,"NA":2260},{"trials":2232,"activeCount":60},[],{"trials":2234,"activeCount":60},[2235],{"nctId":2236,"briefTitle":2237,"status":68,"phases":2238,"primaryCompletion":2239,"completion":2239,"start":2240,"enrollment":1579,"conditions":2241,"interventions":2242},"NCT02578030","Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD",[49],"2015-11-10","2015-10-24",[25],[2229,2243],"SHP465 25mg",{"trials":2245,"activeCount":60},[],{"trials":2247,"activeCount":60},[2248],{"nctId":2249,"briefTitle":2250,"status":68,"phases":2251,"primaryCompletion":2252,"completion":2252,"start":2253,"enrollment":2254,"conditions":2255,"interventions":2256},"NCT02604407","Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit\u002F Hyperactivity Disorder (ADHD)",[51],"2016-03-24","2015-11-19",275,[25],[2229,2257],"SHP465 12.5mg, 25mg, or 37.5mg",{"trials":2259,"activeCount":60},[],{"trials":2261,"activeCount":60},[],{"intervention":1239,"totalTrials":12,"cells":2263},{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2268,"PHASE3":2270,"PHASE4":2280,"NA":2282},{"trials":2265,"activeCount":60},[],{"trials":2267,"activeCount":60},[],{"trials":2269,"activeCount":60},[],{"trials":2271,"activeCount":60},[2272,2276],{"nctId":1230,"briefTitle":1231,"status":68,"phases":2273,"primaryCompletion":1233,"completion":1233,"start":1234,"enrollment":1235,"conditions":2274,"interventions":2275},[51],[1173],[1152,1238,1239,1240,1241],{"nctId":1243,"briefTitle":1244,"status":68,"phases":2277,"primaryCompletion":1246,"completion":1246,"start":1247,"enrollment":1248,"conditions":2278,"interventions":2279},[51],[1173],[1152,1239],{"trials":2281,"activeCount":60},[],{"trials":2283,"activeCount":60},[],{"intervention":2285,"totalTrials":12,"cells":2286},"FST-201 (dexamethasone 0.1%) Otic Suspension",{"EARLY_PHASE1":2287,"PHASE1":2289,"PHASE2":2291,"PHASE3":2293,"PHASE4":2313,"NA":2315},{"trials":2288,"activeCount":60},[],{"trials":2290,"activeCount":60},[],{"trials":2292,"activeCount":60},[],{"trials":2294,"activeCount":60},[2295,2305],{"nctId":2296,"briefTitle":2297,"status":79,"phases":2298,"primaryCompletion":2299,"completion":2299,"start":2300,"enrollment":1424,"conditions":2301,"interventions":2303},"NCT00945646","FST-201 In The Treatment of Acute Fungal Otitis Externa",[51],"2010-07-31","2009-07-31",[2302],"Acute Fungal Otitis Externa",[2285,2304],"Vehicle",{"nctId":2306,"briefTitle":2307,"status":79,"phases":2308,"primaryCompletion":2299,"completion":2299,"start":2300,"enrollment":56,"conditions":2309,"interventions":2311},"NCT00945802","FST-201 In The Treatment of Acute Otitis Externa",[51],[2310],"Acute Otitis Externa",[2285,2312],"ciprofloxacin 0.3%, dexamethasone 0.1%",{"trials":2314,"activeCount":60},[],{"trials":2316,"activeCount":60},[],{"intervention":2318,"totalTrials":12,"cells":2319},"idursulfase-IT",{"EARLY_PHASE1":2320,"PHASE1":2322,"PHASE2":2324,"PHASE3":2326,"PHASE4":2348,"NA":2350},{"trials":2321,"activeCount":60},[],{"trials":2323,"activeCount":60},[],{"trials":2325,"activeCount":60},[],{"trials":2327,"activeCount":60},[2328,2337],{"nctId":2329,"briefTitle":2330,"status":68,"phases":2331,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":2335,"interventions":2336},"NCT02055118","Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment",[50,51],"2017-09-28","2014-03-24",58,[35],[2318],{"nctId":2338,"briefTitle":2339,"status":68,"phases":2340,"primaryCompletion":2341,"completion":2341,"start":2342,"enrollment":2343,"conditions":2344,"interventions":2345},"NCT02412787","Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094",[50,51],"2024-04-18","2015-04-14",56,[35],[2346,2347],"Idursulfase-IT","Elaprase",{"trials":2349,"activeCount":60},[],{"trials":2351,"activeCount":60},[],{"intervention":2353,"totalTrials":12,"cells":2354},"Teduglutide 0.05 mg\u002Fkg\u002Fd",{"EARLY_PHASE1":2355,"PHASE1":2357,"PHASE2":2359,"PHASE3":2361,"PHASE4":2382,"NA":2384},{"trials":2356,"activeCount":60},[],{"trials":2358,"activeCount":60},[],{"trials":2360,"activeCount":60},[],{"trials":2362,"activeCount":60},[2363,2372],{"nctId":2364,"briefTitle":2365,"status":68,"phases":2366,"primaryCompletion":2367,"completion":2367,"start":2368,"enrollment":1319,"conditions":2369,"interventions":2370},"NCT00081458","Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome",[51],"2007-07-06","2004-05-25",[22],[2353,2371],"Teduglutide 0.1 mg\u002Fkg\u002Fd",{"nctId":2373,"briefTitle":2374,"status":68,"phases":2375,"primaryCompletion":2376,"completion":2376,"start":1722,"enrollment":2377,"conditions":2378,"interventions":2379},"NCT00172185","Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)",[51],"2008-01-24",65,[22],[2380,2381],"teduglutide 0.05 mg\u002Fkg\u002Fd","teduglutide 0.10 mg\u002Fkg\u002Fd",{"trials":2383,"activeCount":60},[],{"trials":2385,"activeCount":60},[],{"intervention":2033,"totalTrials":12,"cells":2387},{"EARLY_PHASE1":2388,"PHASE1":2390,"PHASE2":2392,"PHASE3":2398,"PHASE4":2404,"NA":2406},{"trials":2389,"activeCount":60},[],{"trials":2391,"activeCount":60},[],{"trials":2393,"activeCount":60},[2394],{"nctId":2026,"briefTitle":2027,"status":68,"phases":2395,"primaryCompletion":2029,"completion":2029,"start":705,"enrollment":2030,"conditions":2396,"interventions":2397},[50],[332],[2033,2034],{"trials":2399,"activeCount":60},[2400],{"nctId":2038,"briefTitle":346,"status":68,"phases":2401,"primaryCompletion":2040,"completion":2040,"start":2041,"enrollment":2042,"conditions":2402,"interventions":2403},[51],[332],[2033,2004],{"trials":2405,"activeCount":60},[],{"trials":2407,"activeCount":60},[],{"intervention":2409,"totalTrials":12,"cells":2410},"SPD465",{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2426,"PHASE4":2436,"NA":2438},{"trials":2412,"activeCount":60},[],{"trials":2414,"activeCount":60},[],{"trials":2416,"activeCount":60},[2417],{"nctId":2418,"briefTitle":2419,"status":68,"phases":2420,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":1127,"conditions":2423,"interventions":2424},"NCT00928148","The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)",[50],"2004-11-20","2004-06-14",[252],[2409,2425],"Immediate Release Amphetamine Salt",{"trials":2427,"activeCount":60},[2428],{"nctId":2429,"briefTitle":2430,"status":391,"phases":2431,"primaryCompletion":2432,"completion":2432,"start":2433,"enrollment":60,"conditions":2434,"interventions":2435},"NCT00458445","A Study of SPD465 in Young Adult Drivers With Attention-Deficit Hyperactivity Disorder (ADHD) Using Driving Simulators",[51],"2007-06-15","2007-04-30",[456],[2409],{"trials":2437,"activeCount":60},[],{"trials":2439,"activeCount":60},[],{"intervention":2441,"totalTrials":12,"cells":2442},"GA-GCB",{"EARLY_PHASE1":2443,"PHASE1":2445,"PHASE2":2447,"PHASE3":2458,"PHASE4":2468,"NA":2470},{"trials":2444,"activeCount":60},[],{"trials":2446,"activeCount":60},[],{"trials":2448,"activeCount":60},[2449],{"nctId":2450,"briefTitle":2451,"status":68,"phases":2452,"primaryCompletion":2453,"completion":2453,"start":2454,"enrollment":1084,"conditions":2455,"interventions":2457},"NCT00391625","Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)",[49,50],"2008-01-31","2004-09-13",[2456],"Gaucher Disease",[2441],{"trials":2459,"activeCount":60},[2460],{"nctId":2461,"briefTitle":2462,"status":68,"phases":2463,"primaryCompletion":2464,"completion":2464,"start":2465,"enrollment":1451,"conditions":2466,"interventions":2467},"NCT00478647","Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase",[50,51],"2009-06-26","2007-07-25",[2456],[2441],{"trials":2469,"activeCount":60},[],{"trials":2471,"activeCount":60},[],{"intervention":2473,"totalTrials":12,"cells":2474},"SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine",{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2489,"PHASE4":2500,"NA":2502},{"trials":2476,"activeCount":60},[],{"trials":2478,"activeCount":60},[],{"trials":2480,"activeCount":60},[2481],{"nctId":2482,"briefTitle":2483,"status":68,"phases":2484,"primaryCompletion":2485,"completion":2485,"start":2486,"enrollment":1358,"conditions":2487,"interventions":2488},"NCT00545389","Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476",[50],"2004-10-20","2003-02-10",[1903],[2473],{"trials":2490,"activeCount":60},[2491],{"nctId":2492,"briefTitle":2493,"status":68,"phases":2494,"primaryCompletion":2485,"completion":2485,"start":2495,"enrollment":2496,"conditions":2497,"interventions":2498},"NCT00548574","Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis",[51],"2003-12-04",343,[27],[2473,2499],"Mesalazine",{"trials":2501,"activeCount":60},[],{"trials":2503,"activeCount":60},[],{"intervention":2505,"totalTrials":115,"cells":2506},"Phosphate Buffer Saline (PBS), pH 7.0",{"EARLY_PHASE1":2507,"PHASE1":2509,"PHASE2":2511,"PHASE3":2513,"PHASE4":2525,"NA":2527},{"trials":2508,"activeCount":60},[],{"trials":2510,"activeCount":60},[],{"trials":2512,"activeCount":60},[],{"trials":2514,"activeCount":60},[2515],{"nctId":2516,"briefTitle":2517,"status":68,"phases":2518,"primaryCompletion":2519,"completion":2519,"start":2520,"enrollment":2521,"conditions":2522,"interventions":2523},"NCT00457015","Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)",[51],"2008-06-01","2007-04-01",96,[16],[2524,2505],"ecallantide",{"trials":2526,"activeCount":60},[],{"trials":2528,"activeCount":60},[],{"intervention":1894,"totalTrials":115,"cells":2530},{"EARLY_PHASE1":2531,"PHASE1":2533,"PHASE2":2535,"PHASE3":2537,"PHASE4":2543,"NA":2545},{"trials":2532,"activeCount":60},[],{"trials":2534,"activeCount":60},[],{"trials":2536,"activeCount":60},[],{"trials":2538,"activeCount":60},[2539],{"nctId":1886,"briefTitle":1887,"status":68,"phases":2540,"primaryCompletion":1889,"completion":1889,"start":1890,"enrollment":1891,"conditions":2541,"interventions":2542},[51],[27],[1875,1894],{"trials":2544,"activeCount":60},[],{"trials":2546,"activeCount":60},[],{"intervention":2548,"totalTrials":115,"cells":2549},"VPRIV ®,",{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2554,"PHASE3":2556,"PHASE4":2567,"NA":2569},{"trials":2551,"activeCount":60},[],{"trials":2553,"activeCount":60},[],{"trials":2555,"activeCount":60},[],{"trials":2557,"activeCount":60},[2558],{"nctId":2559,"briefTitle":2560,"status":68,"phases":2561,"primaryCompletion":2562,"completion":2562,"start":2563,"enrollment":2140,"conditions":2564,"interventions":2566},"NCT00430625","A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease",[51],"2009-04-01","2007-02-15",[2565],"Gaucher Disease, Type 1",[2548],{"trials":2568,"activeCount":60},[],{"trials":2570,"activeCount":60},[],{"intervention":2572,"totalTrials":115,"cells":2573},"Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate",{"EARLY_PHASE1":2574,"PHASE1":2576,"PHASE2":2578,"PHASE3":2580,"PHASE4":2591,"NA":2593},{"trials":2575,"activeCount":60},[],{"trials":2577,"activeCount":60},[],{"trials":2579,"activeCount":60},[],{"trials":2581,"activeCount":60},[2582],{"nctId":2583,"briefTitle":2584,"status":68,"phases":2585,"primaryCompletion":2586,"completion":2586,"start":2587,"enrollment":2588,"conditions":2589,"interventions":2590},"NCT00150579","Efficacy and Safety of SPD465 in Adults With ADHD",[51],"2005-06-14","2005-01-27",240,[445],[2572],{"trials":2592,"activeCount":60},[],{"trials":2594,"activeCount":60},[],{"intervention":2596,"totalTrials":115,"cells":2597},"Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2604,"PHASE4":2615,"NA":2617},{"trials":2599,"activeCount":60},[],{"trials":2601,"activeCount":60},[],{"trials":2603,"activeCount":60},[],{"trials":2605,"activeCount":60},[2606],{"nctId":2607,"briefTitle":2608,"status":68,"phases":2609,"primaryCompletion":2610,"completion":2610,"start":2611,"enrollment":2612,"conditions":2613,"interventions":2614},"NCT00152022","Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.",[51],"2005-11-04","2005-04-25",412,[445],[2596],{"trials":2616,"activeCount":60},[],{"trials":2618,"activeCount":60},[],{"intervention":2152,"totalTrials":115,"cells":2620},{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2627,"PHASE4":2633,"NA":2635},{"trials":2622,"activeCount":60},[],{"trials":2624,"activeCount":60},[],{"trials":2626,"activeCount":60},[],{"trials":2628,"activeCount":60},[2629],{"nctId":2145,"briefTitle":2146,"status":68,"phases":2630,"primaryCompletion":2148,"completion":2148,"start":2149,"enrollment":174,"conditions":2631,"interventions":2632},[51],[2142],[2125,2152],{"trials":2634,"activeCount":60},[],{"trials":2636,"activeCount":60},[],{"intervention":2638,"totalTrials":115,"cells":2639},"DX-2930 - 300mg\u002F2wk",{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2646,"PHASE4":2659,"NA":2661},{"trials":2641,"activeCount":60},[],{"trials":2643,"activeCount":60},[],{"trials":2645,"activeCount":60},[],{"trials":2647,"activeCount":60},[2648],{"nctId":2649,"briefTitle":2650,"status":68,"phases":2651,"primaryCompletion":2652,"completion":2652,"start":2653,"enrollment":2654,"conditions":2655,"interventions":2656},"NCT02586805","Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE",[51],"2017-04-13","2016-03-03",125,[16],[2638,2657,2658],"DX-2930 - 300mg\u002F4wk","DX-2930 - 150mg\u002F4wk",{"trials":2660,"activeCount":60},[],{"trials":2662,"activeCount":60},[],{"intervention":2657,"totalTrials":115,"cells":2664},{"EARLY_PHASE1":2665,"PHASE1":2667,"PHASE2":2669,"PHASE3":2671,"PHASE4":2677,"NA":2679},{"trials":2666,"activeCount":60},[],{"trials":2668,"activeCount":60},[],{"trials":2670,"activeCount":60},[],{"trials":2672,"activeCount":60},[2673],{"nctId":2649,"briefTitle":2650,"status":68,"phases":2674,"primaryCompletion":2652,"completion":2652,"start":2653,"enrollment":2654,"conditions":2675,"interventions":2676},[51],[16],[2638,2657,2658],{"trials":2678,"activeCount":60},[],{"trials":2680,"activeCount":60},[],{"intervention":2658,"totalTrials":115,"cells":2682},{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2689,"PHASE4":2695,"NA":2697},{"trials":2684,"activeCount":60},[],{"trials":2686,"activeCount":60},[],{"trials":2688,"activeCount":60},[],{"trials":2690,"activeCount":60},[2691],{"nctId":2649,"briefTitle":2650,"status":68,"phases":2692,"primaryCompletion":2652,"completion":2652,"start":2653,"enrollment":2654,"conditions":2693,"interventions":2694},[51],[16],[2638,2657,2658],{"trials":2696,"activeCount":60},[],{"trials":2698,"activeCount":60},[],{"intervention":2700,"totalTrials":115,"cells":2701},"Budesonide oral suspension",{"EARLY_PHASE1":2702,"PHASE1":2704,"PHASE2":2706,"PHASE3":2708,"PHASE4":2719,"NA":2721},{"trials":2703,"activeCount":60},[],{"trials":2705,"activeCount":60},[],{"trials":2707,"activeCount":60},[],{"trials":2709,"activeCount":60},[2710],{"nctId":2711,"briefTitle":2712,"status":79,"phases":2713,"primaryCompletion":2714,"completion":2714,"start":2715,"enrollment":2716,"conditions":2717,"interventions":2718},"NCT03245840","Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)",[51],"2022-04-26","2017-10-05",133,[2065],[2700],{"trials":2720,"activeCount":60},[],{"trials":2722,"activeCount":60},[],{"intervention":2724,"totalTrials":115,"cells":2725},"Fosrenol",{"EARLY_PHASE1":2726,"PHASE1":2728,"PHASE2":2730,"PHASE3":2732,"PHASE4":2744,"NA":2746},{"trials":2727,"activeCount":60},[],{"trials":2729,"activeCount":60},[],{"trials":2731,"activeCount":60},[],{"trials":2733,"activeCount":60},[2734],{"nctId":2735,"briefTitle":2736,"status":68,"phases":2737,"primaryCompletion":2738,"completion":2738,"start":2739,"enrollment":1386,"conditions":2740,"interventions":2742},"NCT00441545","Head to Head Study Against Sevelamer Hydrochloride",[51],"2008-07-31","2007-01-05",[2741],"Chronic Kidney Disease, Stage 5",[2724,2743],"Sevelamer hydrochloride",{"trials":2745,"activeCount":60},[],{"trials":2747,"activeCount":60},[],{"intervention":2743,"totalTrials":115,"cells":2749},{"EARLY_PHASE1":2750,"PHASE1":2752,"PHASE2":2754,"PHASE3":2756,"PHASE4":2762,"NA":2764},{"trials":2751,"activeCount":60},[],{"trials":2753,"activeCount":60},[],{"trials":2755,"activeCount":60},[],{"trials":2757,"activeCount":60},[2758],{"nctId":2735,"briefTitle":2736,"status":68,"phases":2759,"primaryCompletion":2738,"completion":2738,"start":2739,"enrollment":1386,"conditions":2760,"interventions":2761},[51],[2741],[2724,2743],{"trials":2763,"activeCount":60},[],{"trials":2765,"activeCount":60},[],{"intervention":1240,"totalTrials":115,"cells":2767},{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2772,"PHASE3":2774,"PHASE4":2780,"NA":2782},{"trials":2769,"activeCount":60},[],{"trials":2771,"activeCount":60},[],{"trials":2773,"activeCount":60},[],{"trials":2775,"activeCount":60},[2776],{"nctId":1230,"briefTitle":1231,"status":68,"phases":2777,"primaryCompletion":1233,"completion":1233,"start":1234,"enrollment":1235,"conditions":2778,"interventions":2779},[51],[1173],[1152,1238,1239,1240,1241],{"trials":2781,"activeCount":60},[],{"trials":2783,"activeCount":60},[],{"intervention":1241,"totalTrials":115,"cells":2785},{"EARLY_PHASE1":2786,"PHASE1":2788,"PHASE2":2790,"PHASE3":2792,"PHASE4":2798,"NA":2800},{"trials":2787,"activeCount":60},[],{"trials":2789,"activeCount":60},[],{"trials":2791,"activeCount":60},[],{"trials":2793,"activeCount":60},[2794],{"nctId":1230,"briefTitle":1231,"status":68,"phases":2795,"primaryCompletion":1233,"completion":1233,"start":1234,"enrollment":1235,"conditions":2796,"interventions":2797},[51],[1173],[1152,1238,1239,1240,1241],{"trials":2799,"activeCount":60},[],{"trials":2801,"activeCount":60},[],{"intervention":2304,"totalTrials":115,"cells":2803},{"EARLY_PHASE1":2804,"PHASE1":2806,"PHASE2":2808,"PHASE3":2810,"PHASE4":2816,"NA":2818},{"trials":2805,"activeCount":60},[],{"trials":2807,"activeCount":60},[],{"trials":2809,"activeCount":60},[],{"trials":2811,"activeCount":60},[2812],{"nctId":2296,"briefTitle":2297,"status":79,"phases":2813,"primaryCompletion":2299,"completion":2299,"start":2300,"enrollment":1424,"conditions":2814,"interventions":2815},[51],[2302],[2285,2304],{"trials":2817,"activeCount":60},[],{"trials":2819,"activeCount":60},[],{"intervention":2821,"totalTrials":115,"cells":2822},"MMX Mesalamine\u002FMesalazine",{"EARLY_PHASE1":2823,"PHASE1":2825,"PHASE2":2827,"PHASE3":2829,"PHASE4":2840,"NA":2842},{"trials":2824,"activeCount":60},[],{"trials":2826,"activeCount":60},[],{"trials":2828,"activeCount":60},[],{"trials":2830,"activeCount":60},[2831],{"nctId":2832,"briefTitle":2833,"status":68,"phases":2834,"primaryCompletion":2835,"completion":2835,"start":2836,"enrollment":2837,"conditions":2838,"interventions":2839},"NCT02093663","Safety and Efficacy of MMX Mesalamine\u002FMesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis",[51],"2018-11-28","2014-12-12",107,[27],[2821,2821],{"trials":2841,"activeCount":60},[],{"trials":2843,"activeCount":60},[],{"intervention":2845,"totalTrials":115,"cells":2846},"TED",{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2851,"PHASE3":2853,"PHASE4":2864,"NA":2866},{"trials":2848,"activeCount":60},[],{"trials":2850,"activeCount":60},[],{"trials":2852,"activeCount":60},[],{"trials":2854,"activeCount":60},[2855],{"nctId":2856,"briefTitle":2857,"status":68,"phases":2858,"primaryCompletion":2859,"completion":2859,"start":2860,"enrollment":2861,"conditions":2862,"interventions":2863},"NCT02954458","Long-term Safety and Efficacy Study of Teduglutide in Pediatric Participants With Short Bowel Syndrome (SBS)",[51],"2020-11-05","2017-01-09",61,[22],[2845],{"trials":2865,"activeCount":60},[],{"trials":2867,"activeCount":60},[],{"intervention":2869,"totalTrials":115,"cells":2870},"LDX 30 mg",{"EARLY_PHASE1":2871,"PHASE1":2873,"PHASE2":2875,"PHASE3":2877,"PHASE4":2889,"NA":2891},{"trials":2872,"activeCount":60},[],{"trials":2874,"activeCount":60},[],{"trials":2876,"activeCount":60},[],{"trials":2878,"activeCount":60},[2879],{"nctId":2880,"briefTitle":2881,"status":68,"phases":2882,"primaryCompletion":2883,"completion":2883,"start":2884,"enrollment":290,"conditions":2885,"interventions":2886},"NCT00735371","Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[51],"2009-04-06","2008-10-08",[25],[2869,2887,2888],"LDX 50 mg","LDX 70 mg",{"trials":2890,"activeCount":60},[],{"trials":2892,"activeCount":60},[],{"intervention":2887,"totalTrials":115,"cells":2894},{"EARLY_PHASE1":2895,"PHASE1":2897,"PHASE2":2899,"PHASE3":2901,"PHASE4":2907,"NA":2909},{"trials":2896,"activeCount":60},[],{"trials":2898,"activeCount":60},[],{"trials":2900,"activeCount":60},[],{"trials":2902,"activeCount":60},[2903],{"nctId":2880,"briefTitle":2881,"status":68,"phases":2904,"primaryCompletion":2883,"completion":2883,"start":2884,"enrollment":290,"conditions":2905,"interventions":2906},[51],[25],[2869,2887,2888],{"trials":2908,"activeCount":60},[],{"trials":2910,"activeCount":60},[],{"intervention":2888,"totalTrials":115,"cells":2912},{"EARLY_PHASE1":2913,"PHASE1":2915,"PHASE2":2917,"PHASE3":2919,"PHASE4":2925,"NA":2927},{"trials":2914,"activeCount":60},[],{"trials":2916,"activeCount":60},[],{"trials":2918,"activeCount":60},[],{"trials":2920,"activeCount":60},[2921],{"nctId":2880,"briefTitle":2881,"status":68,"phases":2922,"primaryCompletion":2883,"completion":2883,"start":2884,"enrollment":290,"conditions":2923,"interventions":2924},[51],[25],[2869,2887,2888],{"trials":2926,"activeCount":60},[],{"trials":2928,"activeCount":60},[],{"intervention":2930,"totalTrials":115,"cells":2931},"SPD489 (Lisdexamfetamine dimesylate) + Antidepressant",{"EARLY_PHASE1":2932,"PHASE1":2934,"PHASE2":2936,"PHASE3":2938,"PHASE4":2949,"NA":2951},{"trials":2933,"activeCount":60},[],{"trials":2935,"activeCount":60},[],{"trials":2937,"activeCount":60},[],{"trials":2939,"activeCount":60},[2940],{"nctId":2941,"briefTitle":2942,"status":79,"phases":2943,"primaryCompletion":2944,"completion":2944,"start":2945,"enrollment":2946,"conditions":2947,"interventions":2948},"NCT01436175","SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study",[51],"2014-03-27","2012-02-27",1570,[332],[2930],{"trials":2950,"activeCount":60},[],{"trials":2952,"activeCount":60},[],{"intervention":2371,"totalTrials":115,"cells":2954},{"EARLY_PHASE1":2955,"PHASE1":2957,"PHASE2":2959,"PHASE3":2961,"PHASE4":2967,"NA":2969},{"trials":2956,"activeCount":60},[],{"trials":2958,"activeCount":60},[],{"trials":2960,"activeCount":60},[],{"trials":2962,"activeCount":60},[2963],{"nctId":2364,"briefTitle":2365,"status":68,"phases":2964,"primaryCompletion":2367,"completion":2367,"start":2368,"enrollment":1319,"conditions":2965,"interventions":2966},[51],[22],[2353,2371],{"trials":2968,"activeCount":60},[],{"trials":2970,"activeCount":60},[],{"intervention":1284,"totalTrials":115,"cells":2972},{"EARLY_PHASE1":2973,"PHASE1":2975,"PHASE2":2977,"PHASE3":2979,"PHASE4":2985,"NA":2987},{"trials":2974,"activeCount":60},[],{"trials":2976,"activeCount":60},[],{"trials":2978,"activeCount":60},[],{"trials":2980,"activeCount":60},[2981],{"nctId":1276,"briefTitle":1277,"status":68,"phases":2982,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":2983,"interventions":2984},[51],[886],[1256,1284,1285,1286],{"trials":2986,"activeCount":60},[],{"trials":2988,"activeCount":60},[],{"intervention":1285,"totalTrials":115,"cells":2990},{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":2995,"PHASE3":2997,"PHASE4":3003,"NA":3005},{"trials":2992,"activeCount":60},[],{"trials":2994,"activeCount":60},[],{"trials":2996,"activeCount":60},[],{"trials":2998,"activeCount":60},[2999],{"nctId":1276,"briefTitle":1277,"status":68,"phases":3000,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":3001,"interventions":3002},[51],[886],[1256,1284,1285,1286],{"trials":3004,"activeCount":60},[],{"trials":3006,"activeCount":60},[],{"intervention":1286,"totalTrials":115,"cells":3008},{"EARLY_PHASE1":3009,"PHASE1":3011,"PHASE2":3013,"PHASE3":3015,"PHASE4":3021,"NA":3023},{"trials":3010,"activeCount":60},[],{"trials":3012,"activeCount":60},[],{"trials":3014,"activeCount":60},[],{"trials":3016,"activeCount":60},[3017],{"nctId":1276,"briefTitle":1277,"status":68,"phases":3018,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":3019,"interventions":3020},[51],[886],[1256,1284,1285,1286],{"trials":3022,"activeCount":60},[],{"trials":3024,"activeCount":60},[],{"intervention":3026,"totalTrials":115,"cells":3027},"Iduronate-2-sulfatase enzyme replacement therapy",{"EARLY_PHASE1":3028,"PHASE1":3030,"PHASE2":3032,"PHASE3":3034,"PHASE4":3046,"NA":3048},{"trials":3029,"activeCount":60},[],{"trials":3031,"activeCount":60},[],{"trials":3033,"activeCount":60},[],{"trials":3035,"activeCount":60},[3036],{"nctId":3037,"briefTitle":3038,"status":68,"phases":3039,"primaryCompletion":3040,"completion":3040,"start":3041,"enrollment":2521,"conditions":3042,"interventions":3044},"NCT00069641","Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)",[50,51],"2005-03-16","2003-09-18",[3043],"Mucopolysaccharidosis II",[3026,3045],"iduronate-2-sulfatase enzyme replacement therapy",{"trials":3047,"activeCount":60},[],{"trials":3049,"activeCount":60},[],{"intervention":3051,"totalTrials":115,"cells":3052},"Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.",{"EARLY_PHASE1":3053,"PHASE1":3055,"PHASE2":3057,"PHASE3":3059,"PHASE4":3070,"NA":3072},{"trials":3054,"activeCount":60},[],{"trials":3056,"activeCount":60},[],{"trials":3058,"activeCount":60},[],{"trials":3060,"activeCount":60},[3061],{"nctId":3062,"briefTitle":3063,"status":68,"phases":3064,"primaryCompletion":3065,"completion":3065,"start":3066,"enrollment":3067,"conditions":3068,"interventions":3069},"NCT00152035","Safety of SPD465 in Treating Adults With ADHD.",[51],"2006-11-07","2005-03-10",505,[445],[3051],{"trials":3071,"activeCount":60},[],{"trials":3073,"activeCount":60},[],{"intervention":3075,"totalTrials":115,"cells":3076},"Delayed and extended release mesalazine",{"EARLY_PHASE1":3077,"PHASE1":3079,"PHASE2":3081,"PHASE3":3083,"PHASE4":3094,"NA":3096},{"trials":3078,"activeCount":60},[],{"trials":3080,"activeCount":60},[],{"trials":3082,"activeCount":60},[],{"trials":3084,"activeCount":60},[3085],{"nctId":3086,"briefTitle":3087,"status":68,"phases":3088,"primaryCompletion":3089,"completion":3089,"start":3090,"enrollment":3091,"conditions":3092,"interventions":3093},"NCT00503243","Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g\u002FDay) vs SPD476 Given as a Single Dose (4.8 g\u002FDay) in Subjects With Acute Mild to Moderate Ulcerative Colitis",[51],"2005-01-17","2003-09-30",280,[1903],[3075],{"trials":3095,"activeCount":60},[],{"trials":3097,"activeCount":60},[],{"intervention":3099,"totalTrials":115,"cells":3100},"imiglucerase",{"EARLY_PHASE1":3101,"PHASE1":3103,"PHASE2":3105,"PHASE3":3107,"PHASE4":3118,"NA":3120},{"trials":3102,"activeCount":60},[],{"trials":3104,"activeCount":60},[],{"trials":3106,"activeCount":60},[],{"trials":3108,"activeCount":60},[3109],{"nctId":3110,"briefTitle":3111,"status":68,"phases":3112,"primaryCompletion":3113,"completion":3113,"start":3114,"enrollment":1469,"conditions":3115,"interventions":3116},"NCT00553631","Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease",[51],"2009-05-05","2008-01-29",[2565],[3117,3099],"velaglucerase alfa",{"trials":3119,"activeCount":60},[],{"trials":3121,"activeCount":60},[],{"intervention":3123,"totalTrials":115,"cells":3124},"VPRIV®",{"EARLY_PHASE1":3125,"PHASE1":3127,"PHASE2":3129,"PHASE3":3131,"PHASE4":3141,"NA":3143},{"trials":3126,"activeCount":60},[],{"trials":3128,"activeCount":60},[],{"trials":3130,"activeCount":60},[],{"trials":3132,"activeCount":60},[3133],{"nctId":3134,"briefTitle":3135,"status":68,"phases":3136,"primaryCompletion":3137,"completion":3137,"start":3138,"enrollment":1031,"conditions":3139,"interventions":3140},"NCT00635427","An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease",[51],"2012-12-28","2008-03-13",[2565],[3123],{"trials":3142,"activeCount":60},[],{"trials":3144,"activeCount":60},[],{"intervention":3146,"totalTrials":115,"cells":3147},"SPD476, MMX™ mesalazine, 1.2g extended release",{"EARLY_PHASE1":3148,"PHASE1":3150,"PHASE2":3152,"PHASE3":3154,"PHASE4":3166,"NA":3168},{"trials":3149,"activeCount":60},[],{"trials":3151,"activeCount":60},[],{"trials":3153,"activeCount":60},[],{"trials":3155,"activeCount":60},[3156],{"nctId":3157,"briefTitle":1907,"status":68,"phases":3158,"primaryCompletion":3159,"completion":3159,"start":3160,"enrollment":3161,"conditions":3162,"interventions":3163},"NCT00545103",[51],"2011-11-28","2007-12-06",592,[1913],[3146,3164,3165],"SPD476, MMX™ mesalazine, 2.4g extended release","SPD476, MMX™ mesalazine, 4.8g extended release",{"trials":3167,"activeCount":60},[],{"trials":3169,"activeCount":60},[],{"intervention":3164,"totalTrials":115,"cells":3171},{"EARLY_PHASE1":3172,"PHASE1":3174,"PHASE2":3176,"PHASE3":3178,"PHASE4":3184,"NA":3186},{"trials":3173,"activeCount":60},[],{"trials":3175,"activeCount":60},[],{"trials":3177,"activeCount":60},[],{"trials":3179,"activeCount":60},[3180],{"nctId":3157,"briefTitle":1907,"status":68,"phases":3181,"primaryCompletion":3159,"completion":3159,"start":3160,"enrollment":3161,"conditions":3182,"interventions":3183},[51],[1913],[3146,3164,3165],{"trials":3185,"activeCount":60},[],{"trials":3187,"activeCount":60},[],{"intervention":3165,"totalTrials":115,"cells":3189},{"EARLY_PHASE1":3190,"PHASE1":3192,"PHASE2":3194,"PHASE3":3196,"PHASE4":3202,"NA":3204},{"trials":3191,"activeCount":60},[],{"trials":3193,"activeCount":60},[],{"trials":3195,"activeCount":60},[],{"trials":3197,"activeCount":60},[3198],{"nctId":3157,"briefTitle":1907,"status":68,"phases":3199,"primaryCompletion":3159,"completion":3159,"start":3160,"enrollment":3161,"conditions":3200,"interventions":3201},[51],[1913],[3146,3164,3165],{"trials":3203,"activeCount":60},[],{"trials":3205,"activeCount":60},[],{"intervention":3207,"totalTrials":115,"cells":3208},"hydrocortisone (modified release), oral tablet 20 and 5 mg",{"EARLY_PHASE1":3209,"PHASE1":3211,"PHASE2":3213,"PHASE3":3215,"PHASE4":3228,"NA":3230},{"trials":3210,"activeCount":60},[],{"trials":3212,"activeCount":60},[],{"trials":3214,"activeCount":60},[],{"trials":3216,"activeCount":60},[3217],{"nctId":3218,"briefTitle":3219,"status":68,"phases":3220,"primaryCompletion":3221,"completion":3222,"start":3223,"enrollment":1022,"conditions":3224,"interventions":3226},"NCT00915343","Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency",[50,51],"2008-07-28","2009-01-28","2007-08-21",[3225],"Adrenal Insufficiency",[3207,3227],"Hydrocortisone, oral tablet, 10 mg",{"trials":3229,"activeCount":60},[],{"trials":3231,"activeCount":60},[],{"intervention":3227,"totalTrials":115,"cells":3233},{"EARLY_PHASE1":3234,"PHASE1":3236,"PHASE2":3238,"PHASE3":3240,"PHASE4":3246,"NA":3248},{"trials":3235,"activeCount":60},[],{"trials":3237,"activeCount":60},[],{"trials":3239,"activeCount":60},[],{"trials":3241,"activeCount":60},[3242],{"nctId":3218,"briefTitle":3219,"status":68,"phases":3243,"primaryCompletion":3221,"completion":3222,"start":3223,"enrollment":1022,"conditions":3244,"interventions":3245},[50,51],[3225],[3207,3227],{"trials":3247,"activeCount":60},[],{"trials":3249,"activeCount":60},[],{"intervention":2381,"totalTrials":115,"cells":3251},{"EARLY_PHASE1":3252,"PHASE1":3254,"PHASE2":3256,"PHASE3":3258,"PHASE4":3264,"NA":3266},{"trials":3253,"activeCount":60},[],{"trials":3255,"activeCount":60},[],{"trials":3257,"activeCount":60},[],{"trials":3259,"activeCount":60},[3260],{"nctId":2373,"briefTitle":2374,"status":68,"phases":3261,"primaryCompletion":2376,"completion":2376,"start":1722,"enrollment":2377,"conditions":3262,"interventions":3263},[51],[22],[2380,2381],{"trials":3265,"activeCount":60},[],{"trials":3267,"activeCount":60},[],{"intervention":3269,"totalTrials":115,"cells":3270},"Phosphate Buffer Saline (PBS),",{"EARLY_PHASE1":3271,"PHASE1":3273,"PHASE2":3275,"PHASE3":3277,"PHASE4":3286,"NA":3288},{"trials":3272,"activeCount":60},[],{"trials":3274,"activeCount":60},[],{"trials":3276,"activeCount":60},[],{"trials":3278,"activeCount":60},[3279],{"nctId":3280,"briefTitle":3281,"status":68,"phases":3282,"primaryCompletion":3283,"completion":1577,"start":3283,"enrollment":1723,"conditions":3284,"interventions":3285},"NCT00262080","Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)",[51],"2005-12-31",[16],[2524,3269],{"trials":3287,"activeCount":60},[],{"trials":3289,"activeCount":60},[],{"intervention":3291,"totalTrials":115,"cells":3292},"25 mg Ontamalimab",{"EARLY_PHASE1":3293,"PHASE1":3295,"PHASE2":3297,"PHASE3":3299,"PHASE4":3311,"NA":3313},{"trials":3294,"activeCount":60},[],{"trials":3296,"activeCount":60},[],{"trials":3298,"activeCount":60},[],{"trials":3300,"activeCount":60},[3301],{"nctId":3302,"briefTitle":3303,"status":68,"phases":3304,"primaryCompletion":3305,"completion":3305,"start":3306,"enrollment":3307,"conditions":3308,"interventions":3309},"NCT03283085","A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)",[51],"2023-12-13","2018-02-27",557,[1056,27],[3291,3310],"75 mg Ontamalimab",{"trials":3312,"activeCount":60},[],{"trials":3314,"activeCount":60},[],{"intervention":3310,"totalTrials":115,"cells":3316},{"EARLY_PHASE1":3317,"PHASE1":3319,"PHASE2":3321,"PHASE3":3323,"PHASE4":3329,"NA":3331},{"trials":3318,"activeCount":60},[],{"trials":3320,"activeCount":60},[],{"trials":3322,"activeCount":60},[],{"trials":3324,"activeCount":60},[3325],{"nctId":3302,"briefTitle":3303,"status":68,"phases":3326,"primaryCompletion":3305,"completion":3305,"start":3306,"enrollment":3307,"conditions":3327,"interventions":3328},[51],[1056,27],[3291,3310],{"trials":3330,"activeCount":60},[],{"trials":3332,"activeCount":60},[],{"intervention":2499,"totalTrials":115,"cells":3334},{"EARLY_PHASE1":3335,"PHASE1":3337,"PHASE2":3339,"PHASE3":3341,"PHASE4":3347,"NA":3349},{"trials":3336,"activeCount":60},[],{"trials":3338,"activeCount":60},[],{"trials":3340,"activeCount":60},[],{"trials":3342,"activeCount":60},[3343],{"nctId":2492,"briefTitle":2493,"status":68,"phases":3344,"primaryCompletion":2485,"completion":2485,"start":2495,"enrollment":2496,"conditions":3345,"interventions":3346},[51],[27],[2473,2499],{"trials":3348,"activeCount":60},[],{"trials":3350,"activeCount":60},[],{"intervention":2257,"totalTrials":115,"cells":3352},{"EARLY_PHASE1":3353,"PHASE1":3355,"PHASE2":3357,"PHASE3":3359,"PHASE4":3365,"NA":3367},{"trials":3354,"activeCount":60},[],{"trials":3356,"activeCount":60},[],{"trials":3358,"activeCount":60},[],{"trials":3360,"activeCount":60},[3361],{"nctId":2249,"briefTitle":2250,"status":68,"phases":3362,"primaryCompletion":2252,"completion":2252,"start":2253,"enrollment":2254,"conditions":3363,"interventions":3364},[51],[25],[2229,2257],{"trials":3366,"activeCount":60},[],{"trials":3368,"activeCount":60},[],{"intervention":3370,"totalTrials":115,"cells":3371},"SPD503-AM",{"EARLY_PHASE1":3372,"PHASE1":3374,"PHASE2":3376,"PHASE3":3378,"PHASE4":3390,"NA":3392},{"trials":3373,"activeCount":60},[],{"trials":3375,"activeCount":60},[],{"trials":3377,"activeCount":60},[],{"trials":3379,"activeCount":60},[3380],{"nctId":3381,"briefTitle":3382,"status":68,"phases":3383,"primaryCompletion":3384,"completion":3384,"start":3385,"enrollment":3386,"conditions":3387,"interventions":3388},"NCT00734578","Efficacy and Safety of SPD503 in Combination With Psychostimulants",[51],"2009-12-10","2008-09-02",461,[213],[3370,3389],"SPD503-PM",{"trials":3391,"activeCount":60},[],{"trials":3393,"activeCount":60},[],{"intervention":3389,"totalTrials":115,"cells":3395},{"EARLY_PHASE1":3396,"PHASE1":3398,"PHASE2":3400,"PHASE3":3402,"PHASE4":3408,"NA":3410},{"trials":3397,"activeCount":60},[],{"trials":3399,"activeCount":60},[],{"trials":3401,"activeCount":60},[],{"trials":3403,"activeCount":60},[3404],{"nctId":3381,"briefTitle":3382,"status":68,"phases":3405,"primaryCompletion":3384,"completion":3384,"start":3385,"enrollment":3386,"conditions":3406,"interventions":3407},[51],[213],[3370,3389],{"trials":3409,"activeCount":60},[],{"trials":3411,"activeCount":60},[],{"intervention":3413,"totalTrials":115,"cells":3414},"CINRYZE 500 U",{"EARLY_PHASE1":3415,"PHASE1":3417,"PHASE2":3419,"PHASE3":3421,"PHASE4":3432,"NA":3434},{"trials":3416,"activeCount":60},[],{"trials":3418,"activeCount":60},[],{"trials":3420,"activeCount":60},[],{"trials":3422,"activeCount":60},[3423],{"nctId":3424,"briefTitle":3425,"status":68,"phases":3426,"primaryCompletion":3427,"completion":3427,"start":3428,"enrollment":1257,"conditions":3429,"interventions":3430},"NCT02865720","Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)",[51],"2017-06-23","2016-09-08",[16],[3413,3431],"CINRYZE 1000 U",{"trials":3433,"activeCount":60},[],{"trials":3435,"activeCount":60},[],{"intervention":3431,"totalTrials":115,"cells":3437},{"EARLY_PHASE1":3438,"PHASE1":3440,"PHASE2":3442,"PHASE3":3444,"PHASE4":3450,"NA":3452},{"trials":3439,"activeCount":60},[],{"trials":3441,"activeCount":60},[],{"trials":3443,"activeCount":60},[],{"trials":3445,"activeCount":60},[3446],{"nctId":3424,"briefTitle":3425,"status":68,"phases":3447,"primaryCompletion":3427,"completion":3427,"start":3428,"enrollment":1257,"conditions":3448,"interventions":3449},[51],[16],[3413,3431],{"trials":3451,"activeCount":60},[],{"trials":3453,"activeCount":60},[],{"intervention":3455,"totalTrials":115,"cells":3456},"PTH\u002FCalcium",{"EARLY_PHASE1":3457,"PHASE1":3459,"PHASE2":3461,"PHASE3":3463,"PHASE4":3474,"NA":3476},{"trials":3458,"activeCount":60},[],{"trials":3460,"activeCount":60},[],{"trials":3462,"activeCount":60},[],{"trials":3464,"activeCount":60},[3465],{"nctId":3466,"briefTitle":3467,"status":68,"phases":3468,"primaryCompletion":3469,"completion":3469,"start":3470,"enrollment":504,"conditions":3471,"interventions":3472},"NCT00172172","Calcium Supplementation in Postmenopausal Women",[51],"2005-03-11","2004-01-10",[1693],[3455,3473],"PTH\u002Fplacebo",{"trials":3475,"activeCount":60},[],{"trials":3477,"activeCount":60},[],{"intervention":3473,"totalTrials":115,"cells":3479},{"EARLY_PHASE1":3480,"PHASE1":3482,"PHASE2":3484,"PHASE3":3486,"PHASE4":3492,"NA":3494},{"trials":3481,"activeCount":60},[],{"trials":3483,"activeCount":60},[],{"trials":3485,"activeCount":60},[],{"trials":3487,"activeCount":60},[3488],{"nctId":3466,"briefTitle":3467,"status":68,"phases":3489,"primaryCompletion":3469,"completion":3469,"start":3470,"enrollment":504,"conditions":3490,"interventions":3491},[51],[1693],[3455,3473],{"trials":3493,"activeCount":60},[],{"trials":3495,"activeCount":60},[],{"intervention":3497,"totalTrials":115,"cells":3498},"C1 esterase inhibitor [human] liquid",{"EARLY_PHASE1":3499,"PHASE1":3501,"PHASE2":3503,"PHASE3":3505,"PHASE4":3516,"NA":3518},{"trials":3500,"activeCount":60},[],{"trials":3502,"activeCount":60},[],{"trials":3504,"activeCount":60},[],{"trials":3506,"activeCount":60},[3507],{"nctId":3508,"briefTitle":3509,"status":68,"phases":3510,"primaryCompletion":3511,"completion":3511,"start":3512,"enrollment":3513,"conditions":3514,"interventions":3515},"NCT02584959","Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema",[51],"2017-07-24","2015-11-01",75,[16],[3497],{"trials":3517,"activeCount":60},[],{"trials":3519,"activeCount":60},[],{"intervention":3521,"totalTrials":115,"cells":3522},"SPD489 low dose range",{"EARLY_PHASE1":3523,"PHASE1":3525,"PHASE2":3527,"PHASE3":3529,"PHASE4":3538,"NA":3540},{"trials":3524,"activeCount":60},[],{"trials":3526,"activeCount":60},[],{"trials":3528,"activeCount":60},[],{"trials":3530,"activeCount":60},[3531],{"nctId":3532,"briefTitle":3533,"status":79,"phases":3534,"primaryCompletion":366,"completion":366,"start":367,"enrollment":115,"conditions":3535,"interventions":3536},"NCT01760889","SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia",[51],[310],[3521,3537],"SPD489 high dose range",{"trials":3539,"activeCount":60},[],{"trials":3541,"activeCount":60},[],{"intervention":3537,"totalTrials":115,"cells":3543},{"EARLY_PHASE1":3544,"PHASE1":3546,"PHASE2":3548,"PHASE3":3550,"PHASE4":3556,"NA":3558},{"trials":3545,"activeCount":60},[],{"trials":3547,"activeCount":60},[],{"trials":3549,"activeCount":60},[],{"trials":3551,"activeCount":60},[3552],{"nctId":3532,"briefTitle":3533,"status":79,"phases":3553,"primaryCompletion":366,"completion":366,"start":367,"enrollment":115,"conditions":3554,"interventions":3555},[51],[310],[3521,3537],{"trials":3557,"activeCount":60},[],{"trials":3559,"activeCount":60},[],{"intervention":2347,"totalTrials":115,"cells":3561},{"EARLY_PHASE1":3562,"PHASE1":3564,"PHASE2":3566,"PHASE3":3568,"PHASE4":3574,"NA":3576},{"trials":3563,"activeCount":60},[],{"trials":3565,"activeCount":60},[],{"trials":3567,"activeCount":60},[],{"trials":3569,"activeCount":60},[3570],{"nctId":2338,"briefTitle":2339,"status":68,"phases":3571,"primaryCompletion":2341,"completion":2341,"start":2342,"enrollment":2343,"conditions":3572,"interventions":3573},[50,51],[35],[2346,2347],{"trials":3575,"activeCount":60},[],{"trials":3577,"activeCount":60},[],{"intervention":3579,"totalTrials":115,"cells":3580},"FST201",{"EARLY_PHASE1":3581,"PHASE1":3583,"PHASE2":3585,"PHASE3":3587,"PHASE4":3598,"NA":3600},{"trials":3582,"activeCount":60},[],{"trials":3584,"activeCount":60},[],{"trials":3586,"activeCount":60},[],{"trials":3588,"activeCount":60},[3589],{"nctId":3590,"briefTitle":3591,"status":68,"phases":3592,"primaryCompletion":3593,"completion":3593,"start":884,"enrollment":3594,"conditions":3595,"interventions":3596},"NCT00961675","FST-201 in the Treatment of Acute Otitis Externa",[51],"2010-06-30",70,[2310],[3579,3597],"Ciprodex",{"trials":3599,"activeCount":60},[],{"trials":3601,"activeCount":60},[],{"intervention":3597,"totalTrials":115,"cells":3603},{"EARLY_PHASE1":3604,"PHASE1":3606,"PHASE2":3608,"PHASE3":3610,"PHASE4":3616,"NA":3618},{"trials":3605,"activeCount":60},[],{"trials":3607,"activeCount":60},[],{"trials":3609,"activeCount":60},[],{"trials":3611,"activeCount":60},[3612],{"nctId":3590,"briefTitle":3591,"status":68,"phases":3613,"primaryCompletion":3593,"completion":3593,"start":884,"enrollment":3594,"conditions":3614,"interventions":3615},[51],[2310],[3579,3597],{"trials":3617,"activeCount":60},[],{"trials":3619,"activeCount":60},[],{"intervention":3621,"totalTrials":115,"cells":3622},"ABH001",{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3627,"PHASE3":3629,"PHASE4":3640,"NA":3642},{"trials":3624,"activeCount":60},[],{"trials":3626,"activeCount":60},[],{"trials":3628,"activeCount":60},[],{"trials":3630,"activeCount":60},[3631],{"nctId":3632,"briefTitle":3633,"status":79,"phases":3634,"primaryCompletion":3635,"completion":3635,"start":3636,"enrollment":115,"conditions":3637,"interventions":3639},"NCT01749306","A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing",[51],"2013-11","2012-12",[3638],"Epidermolysis Bullosa",[3621],{"trials":3641,"activeCount":60},[],{"trials":3643,"activeCount":60},[],{"intervention":2312,"totalTrials":115,"cells":3645},{"EARLY_PHASE1":3646,"PHASE1":3648,"PHASE2":3650,"PHASE3":3652,"PHASE4":3658,"NA":3660},{"trials":3647,"activeCount":60},[],{"trials":3649,"activeCount":60},[],{"trials":3651,"activeCount":60},[],{"trials":3653,"activeCount":60},[3654],{"nctId":2306,"briefTitle":2307,"status":79,"phases":3655,"primaryCompletion":2299,"completion":2299,"start":2300,"enrollment":56,"conditions":3656,"interventions":3657},[51],[2310],[2285,2312],{"trials":3659,"activeCount":60},[],{"trials":3661,"activeCount":60},[],{"intervention":3663,"totalTrials":115,"cells":3664},"Cinryze®",{"EARLY_PHASE1":3665,"PHASE1":3667,"PHASE2":3669,"PHASE3":3671,"PHASE4":3682,"NA":3684},{"trials":3666,"activeCount":60},[],{"trials":3668,"activeCount":60},[],{"trials":3670,"activeCount":60},[],{"trials":3672,"activeCount":60},[3673],{"nctId":3674,"briefTitle":3675,"status":79,"phases":3676,"primaryCompletion":3677,"completion":3677,"start":3678,"enrollment":608,"conditions":3679,"interventions":3681},"NCT02547220","A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant",[51],"2019-05-31","2016-05-20",[3680],"Acute Antibody-Mediated Rejection (AMR)",[3663],{"trials":3683,"activeCount":60},[],{"trials":3685,"activeCount":60},[],{"intervention":3687,"totalTrials":115,"cells":3688},"LDX",{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3693,"PHASE3":3695,"PHASE4":3706,"NA":3708},{"trials":3690,"activeCount":60},[],{"trials":3692,"activeCount":60},[],{"trials":3694,"activeCount":60},[],{"trials":3696,"activeCount":60},[3697],{"nctId":3698,"briefTitle":3699,"status":68,"phases":3700,"primaryCompletion":3701,"completion":3701,"start":3702,"enrollment":3703,"conditions":3704,"interventions":3705},"NCT00697515","Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)",[51],"2008-12-20","2008-07-18",142,[213],[3687],{"trials":3707,"activeCount":60},[],{"trials":3709,"activeCount":60},[],{"intervention":3711,"totalTrials":115,"cells":3712},"SPD489 Low-Dose",{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3717,"PHASE3":3719,"PHASE4":3730,"NA":3732},{"trials":3714,"activeCount":60},[],{"trials":3716,"activeCount":60},[],{"trials":3718,"activeCount":60},[],{"trials":3720,"activeCount":60},[3721],{"nctId":3722,"briefTitle":3723,"status":391,"phases":3724,"primaryCompletion":3725,"completion":3725,"start":1328,"enrollment":60,"conditions":3726,"interventions":3728},"NCT01234298","SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia",[51],"2014-02-24",[3727],"Negative Symptoms of Schizophrenia",[3711,3729],"SPD489 High-Dose",{"trials":3731,"activeCount":60},[],{"trials":3733,"activeCount":60},[],{"intervention":3729,"totalTrials":115,"cells":3735},{"EARLY_PHASE1":3736,"PHASE1":3738,"PHASE2":3740,"PHASE3":3742,"PHASE4":3748,"NA":3750},{"trials":3737,"activeCount":60},[],{"trials":3739,"activeCount":60},[],{"trials":3741,"activeCount":60},[],{"trials":3743,"activeCount":60},[3744],{"nctId":3722,"briefTitle":3723,"status":391,"phases":3745,"primaryCompletion":3725,"completion":3725,"start":1328,"enrollment":60,"conditions":3746,"interventions":3747},[51],[3727],[3711,3729],{"trials":3749,"activeCount":60},[],{"trials":3751,"activeCount":60},[],{"intervention":3753,"totalTrials":115,"cells":3754},"SPD489 40mg",{"EARLY_PHASE1":3755,"PHASE1":3757,"PHASE2":3759,"PHASE3":3761,"PHASE4":3772,"NA":3774},{"trials":3756,"activeCount":60},[],{"trials":3758,"activeCount":60},[],{"trials":3760,"activeCount":60},[],{"trials":3762,"activeCount":60},[3763],{"nctId":3764,"briefTitle":3765,"status":79,"phases":3766,"primaryCompletion":366,"completion":366,"start":3767,"enrollment":9,"conditions":3768,"interventions":3769},"NCT01738698","Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia",[51],"2012-11-01",[310],[3753,3770,3771],"SPD489 100mg","SPD489 160mg",{"trials":3773,"activeCount":60},[],{"trials":3775,"activeCount":60},[],{"intervention":3770,"totalTrials":115,"cells":3777},{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3784,"PHASE4":3790,"NA":3792},{"trials":3779,"activeCount":60},[],{"trials":3781,"activeCount":60},[],{"trials":3783,"activeCount":60},[],{"trials":3785,"activeCount":60},[3786],{"nctId":3764,"briefTitle":3765,"status":79,"phases":3787,"primaryCompletion":366,"completion":366,"start":3767,"enrollment":9,"conditions":3788,"interventions":3789},[51],[310],[3753,3770,3771],{"trials":3791,"activeCount":60},[],{"trials":3793,"activeCount":60},[],{"intervention":3771,"totalTrials":115,"cells":3795},{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3802,"PHASE4":3808,"NA":3810},{"trials":3797,"activeCount":60},[],{"trials":3799,"activeCount":60},[],{"trials":3801,"activeCount":60},[],{"trials":3803,"activeCount":60},[3804],{"nctId":3764,"briefTitle":3765,"status":79,"phases":3805,"primaryCompletion":366,"completion":366,"start":3767,"enrollment":9,"conditions":3806,"interventions":3807},[51],[310],[3753,3770,3771],{"trials":3809,"activeCount":60},[],{"trials":3811,"activeCount":60},[],{"intervention":3813,"totalTrials":115,"cells":3814},"CINRYZE 500",{"EARLY_PHASE1":3815,"PHASE1":3817,"PHASE2":3819,"PHASE3":3821,"PHASE4":3832,"NA":3834},{"trials":3816,"activeCount":60},[],{"trials":3818,"activeCount":60},[],{"trials":3820,"activeCount":60},[],{"trials":3822,"activeCount":60},[3823],{"nctId":3824,"briefTitle":3825,"status":68,"phases":3826,"primaryCompletion":3827,"completion":3827,"start":3828,"enrollment":31,"conditions":3829,"interventions":3830},"NCT02052141","Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema",[51],"2017-05-04","2014-03-20",[16],[3813,3831],"CINRYZE 1000",{"trials":3833,"activeCount":60},[],{"trials":3835,"activeCount":60},[],{"intervention":3831,"totalTrials":115,"cells":3837},{"EARLY_PHASE1":3838,"PHASE1":3840,"PHASE2":3842,"PHASE3":3844,"PHASE4":3850,"NA":3852},{"trials":3839,"activeCount":60},[],{"trials":3841,"activeCount":60},[],{"trials":3843,"activeCount":60},[],{"trials":3845,"activeCount":60},[3846],{"nctId":3824,"briefTitle":3825,"status":68,"phases":3847,"primaryCompletion":3827,"completion":3827,"start":3828,"enrollment":31,"conditions":3848,"interventions":3849},[51],[16],[3813,3831],{"trials":3851,"activeCount":60},[],{"trials":3853,"activeCount":60},[],{"intervention":3855,"totalTrials":115,"cells":3856},"Teduglutide 0.05mg\u002Fkg",{"EARLY_PHASE1":3857,"PHASE1":3859,"PHASE2":3861,"PHASE3":3863,"PHASE4":3875,"NA":3877},{"trials":3858,"activeCount":60},[],{"trials":3860,"activeCount":60},[],{"trials":3862,"activeCount":60},[],{"trials":3864,"activeCount":60},[3865],{"nctId":3866,"briefTitle":3867,"status":68,"phases":3868,"primaryCompletion":3869,"completion":3869,"start":3870,"enrollment":3871,"conditions":3872,"interventions":3873},"NCT02682381","Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition",[51],"2017-08-18","2016-06-23",59,[22],[3855,3874],"Teduglutide 0.025 mg\u002Fkg",{"trials":3876,"activeCount":60},[],{"trials":3878,"activeCount":60},[],{"intervention":3874,"totalTrials":115,"cells":3880},{"EARLY_PHASE1":3881,"PHASE1":3883,"PHASE2":3885,"PHASE3":3887,"PHASE4":3893,"NA":3895},{"trials":3882,"activeCount":60},[],{"trials":3884,"activeCount":60},[],{"trials":3886,"activeCount":60},[],{"trials":3888,"activeCount":60},[3889],{"nctId":3866,"briefTitle":3867,"status":68,"phases":3890,"primaryCompletion":3869,"completion":3869,"start":3870,"enrollment":3871,"conditions":3891,"interventions":3892},[51],[22],[3855,3874],{"trials":3894,"activeCount":60},[],{"trials":3896,"activeCount":60},[],{"intervention":3898,"totalTrials":115,"cells":3899},"Extended-release Guanfacine HCl",{"EARLY_PHASE1":3900,"PHASE1":3902,"PHASE2":3904,"PHASE3":3906,"PHASE4":3916,"NA":3918},{"trials":3901,"activeCount":60},[],{"trials":3903,"activeCount":60},[],{"trials":3905,"activeCount":60},[],{"trials":3907,"activeCount":60},[3908],{"nctId":3909,"briefTitle":3910,"status":68,"phases":3911,"primaryCompletion":3912,"completion":3912,"start":3913,"enrollment":481,"conditions":3914,"interventions":3915},"NCT01500694","Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe",[51],"2015-09-15","2012-03-20",[25],[3898],{"trials":3917,"activeCount":60},[],{"trials":3919,"activeCount":60},[],{"intervention":528,"totalTrials":115,"cells":3921},{"EARLY_PHASE1":3922,"PHASE1":3924,"PHASE2":3926,"PHASE3":3928,"PHASE4":3934,"NA":3936},{"trials":3923,"activeCount":60},[],{"trials":3925,"activeCount":60},[],{"trials":3927,"activeCount":60},[],{"trials":3929,"activeCount":60},[3930],{"nctId":520,"briefTitle":521,"status":68,"phases":3931,"primaryCompletion":523,"completion":523,"start":524,"enrollment":481,"conditions":3932,"interventions":3933},[51],[526],[488,528],{"trials":3935,"activeCount":60},[],{"trials":3937,"activeCount":60},[],{"intervention":3939,"totalTrials":9,"cells":3940},"SPD602",{"EARLY_PHASE1":3941,"PHASE1":3943,"PHASE2":3945,"PHASE3":3989,"PHASE4":3991,"NA":3993},{"trials":3942,"activeCount":60},[],{"trials":3944,"activeCount":60},[],{"trials":3946,"activeCount":60},[3947,3956,3966,3980],{"nctId":3948,"briefTitle":3949,"status":79,"phases":3950,"primaryCompletion":3951,"completion":3951,"start":3952,"enrollment":1329,"conditions":3953,"interventions":3955},"NCT01604941","Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy",[50],"2014-04-18","2012-09-14",[3954],"Iron Overload Due to Repeated Red Blood Cell Transfusions",[3939],{"nctId":3957,"briefTitle":3958,"status":68,"phases":3959,"primaryCompletion":3960,"completion":3960,"start":3961,"enrollment":1850,"conditions":3962,"interventions":3965},"NCT01186419","Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload",[50],"2013-01-08","2010-08-13",[3963,3964],"Transfusional Iron Overload","Beta-thalassemia",[3939],{"nctId":3967,"briefTitle":3968,"status":391,"phases":3969,"primaryCompletion":3970,"completion":3970,"start":3971,"enrollment":60,"conditions":3972,"interventions":3978},"NCT01927913","Treatment of Iron Overload Requiring Chelation Therapy",[50],"2015-10-30","2014-11-20",[3963,3973,3974,3964,3975,3976,3977],"Iron Overload","Iron Chelation","Transfusional Hemosiderosis","Iron Metabolism Disorders","Metabolic Diseases",[3939,3979],"Deferasirox",{"nctId":3981,"briefTitle":3982,"status":79,"phases":3983,"primaryCompletion":3984,"completion":3984,"start":3985,"enrollment":165,"conditions":3986,"interventions":3988},"NCT01363908","Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload",[50],"2014-05-13","2011-08-10",[3963,3987],"Beta-Thalassemia",[3939],{"trials":3990,"activeCount":60},[],{"trials":3992,"activeCount":60},[],{"trials":3994,"activeCount":60},[],{"intervention":3996,"totalTrials":12,"cells":3997},"FST-100",{"EARLY_PHASE1":3998,"PHASE1":4000,"PHASE2":4002,"PHASE3":4025,"PHASE4":4027,"NA":4029},{"trials":3999,"activeCount":60},[],{"trials":4001,"activeCount":60},[],{"trials":4003,"activeCount":60},[4004,4015],{"nctId":4005,"briefTitle":4006,"status":68,"phases":4007,"primaryCompletion":4008,"completion":4008,"start":4009,"enrollment":4010,"conditions":4011,"interventions":4013},"NCT01470664","FST-100 in the Treatment of Acute Adenoviral Conjunctivitis",[50],"2014-05-23","2012-12-17",176,[4012],"Acute Adenoviral Conjunctivitis",[3996,3996,4014],"FST-100 Vehicle",{"nctId":4016,"briefTitle":4017,"status":68,"phases":4018,"primaryCompletion":4019,"completion":4019,"start":4020,"enrollment":4021,"conditions":4022,"interventions":4024},"NCT01461954","FST-100 in the Treatment of Acute Viral Conjunctivitis",[50],"2014-03-10","2013-05-17",132,[4023],"Acute Viral Conjunctivitis",[3996,4014],{"trials":4026,"activeCount":60},[],{"trials":4028,"activeCount":60},[],{"trials":4030,"activeCount":60},[],{"intervention":4014,"totalTrials":12,"cells":4032},{"EARLY_PHASE1":4033,"PHASE1":4035,"PHASE2":4037,"PHASE3":4047,"PHASE4":4049,"NA":4051},{"trials":4034,"activeCount":60},[],{"trials":4036,"activeCount":60},[],{"trials":4038,"activeCount":60},[4039,4043],{"nctId":4005,"briefTitle":4006,"status":68,"phases":4040,"primaryCompletion":4008,"completion":4008,"start":4009,"enrollment":4010,"conditions":4041,"interventions":4042},[50],[4012],[3996,3996,4014],{"nctId":4016,"briefTitle":4017,"status":68,"phases":4044,"primaryCompletion":4019,"completion":4019,"start":4020,"enrollment":4021,"conditions":4045,"interventions":4046},[50],[4023],[3996,4014],{"trials":4048,"activeCount":60},[],{"trials":4050,"activeCount":60},[],{"trials":4052,"activeCount":60},[],{"intervention":4054,"totalTrials":12,"cells":4055},"Recombinant human Arylsulfatase A",{"EARLY_PHASE1":4056,"PHASE1":4058,"PHASE2":4060,"PHASE3":4079,"PHASE4":4081,"NA":4083},{"trials":4057,"activeCount":60},[],{"trials":4059,"activeCount":60},[],{"trials":4061,"activeCount":60},[4062,4070],{"nctId":4063,"briefTitle":4064,"status":68,"phases":4065,"primaryCompletion":1126,"completion":1126,"start":4066,"enrollment":28,"conditions":4067,"interventions":4069},"NCT00633139","Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)",[49,50],"2007-01-22",[4068],"Late Infantile Metachromatic Leukodystrophy",[4054],{"nctId":4071,"briefTitle":4072,"status":68,"phases":4073,"primaryCompletion":4074,"completion":4074,"start":4075,"enrollment":155,"conditions":4076,"interventions":4077},"NCT01510028","Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)",[49,50],"2017-01-20","2012-02-02",[133],[4078],"Recombinant human arylsulfatase A",{"trials":4080,"activeCount":60},[],{"trials":4082,"activeCount":60},[],{"trials":4084,"activeCount":60},[],{"intervention":4086,"totalTrials":12,"cells":4087},"SSP-004184AQ",{"EARLY_PHASE1":4088,"PHASE1":4090,"PHASE2":4100,"PHASE3":4110,"PHASE4":4112,"NA":4114},{"trials":4089,"activeCount":60},[],{"trials":4091,"activeCount":60},[4092],{"nctId":4093,"briefTitle":4094,"status":68,"phases":4095,"primaryCompletion":357,"completion":357,"start":4096,"enrollment":625,"conditions":4097,"interventions":4098},"NCT01905540","A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)",[49],"2013-08-05",[19],[4086,4099],"SSP-004184SS",{"trials":4101,"activeCount":60},[4102],{"nctId":4103,"briefTitle":4104,"status":79,"phases":4105,"primaryCompletion":4106,"completion":4106,"start":4107,"enrollment":165,"conditions":4108,"interventions":4109},"NCT01671111","Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)",[50],"2014-04-24","2012-08-14",[3954],[4086],{"trials":4111,"activeCount":60},[],{"trials":4113,"activeCount":60},[],{"trials":4115,"activeCount":60},[],{"intervention":4117,"totalTrials":12,"cells":4118},"PF-00547659 SC",{"EARLY_PHASE1":4119,"PHASE1":4121,"PHASE2":4123,"PHASE3":4144,"PHASE4":4146,"NA":4148},{"trials":4120,"activeCount":60},[],{"trials":4122,"activeCount":60},[],{"trials":4124,"activeCount":60},[4125,4134],{"nctId":4126,"briefTitle":4127,"status":68,"phases":4128,"primaryCompletion":4129,"completion":4130,"start":546,"enrollment":4131,"conditions":4132,"interventions":4133},"NCT01276509","Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease",[50],"2014-02-07","2015-10-09",265,[1056],[4117,4117,4117,4117],{"nctId":4135,"briefTitle":4136,"status":68,"phases":4137,"primaryCompletion":4138,"completion":4139,"start":4140,"enrollment":4141,"conditions":4142,"interventions":4143},"NCT01620255","A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis",[50],"2014-09-22","2016-02-04","2012-11-02",357,[27],[4117,4117,4117,4117],{"trials":4145,"activeCount":60},[],{"trials":4147,"activeCount":60},[],{"trials":4149,"activeCount":60},[],{"intervention":4151,"totalTrials":12,"cells":4152},"CINRYZE with rHuPH20",{"EARLY_PHASE1":4153,"PHASE1":4155,"PHASE2":4157,"PHASE3":4175,"PHASE4":4177,"NA":4179},{"trials":4154,"activeCount":60},[],{"trials":4156,"activeCount":60},[],{"trials":4158,"activeCount":60},[4159,4168],{"nctId":4160,"briefTitle":4161,"status":68,"phases":4162,"primaryCompletion":4163,"completion":4163,"start":4164,"enrollment":4165,"conditions":4166,"interventions":4167},"NCT01756157","Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks",[50],"2013-09-13","2013-02-04",47,[16],[4151],{"nctId":4169,"briefTitle":4170,"status":68,"phases":4171,"primaryCompletion":3159,"completion":3159,"start":4172,"enrollment":31,"conditions":4173,"interventions":4174},"NCT01426763","A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase",[50],"2011-09-12",[886],[4151],{"trials":4176,"activeCount":60},[],{"trials":4178,"activeCount":60},[],{"trials":4180,"activeCount":60},[],{"intervention":4182,"totalTrials":12,"cells":4183},"CINRYZE",{"EARLY_PHASE1":4184,"PHASE1":4186,"PHASE2":4188,"PHASE3":4205,"PHASE4":4207,"NA":4209},{"trials":4185,"activeCount":60},[],{"trials":4187,"activeCount":60},[],{"trials":4189,"activeCount":60},[4190,4197],{"nctId":4191,"briefTitle":4192,"status":68,"phases":4193,"primaryCompletion":280,"completion":280,"start":4194,"enrollment":1066,"conditions":4195,"interventions":4196},"NCT01095510","CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12",[50],"2010-06-02",[16],[4182],{"nctId":4198,"briefTitle":4199,"status":68,"phases":4200,"primaryCompletion":4201,"completion":4201,"start":4202,"enrollment":17,"conditions":4203,"interventions":4204},"NCT01095497","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration",[50],"2010-12-16","2010-06-07",[886],[4182],{"trials":4206,"activeCount":60},[],{"trials":4208,"activeCount":60},[],{"trials":4210,"activeCount":60},[],{"intervention":4212,"totalTrials":12,"cells":4213},"SRM003",{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4218,"PHASE3":4238,"PHASE4":4240,"NA":4242},{"trials":4215,"activeCount":60},[],{"trials":4217,"activeCount":60},[],{"trials":4219,"activeCount":60},[4220,4229],{"nctId":4221,"briefTitle":4222,"status":68,"phases":4223,"primaryCompletion":4224,"completion":4224,"start":4225,"enrollment":1022,"conditions":4226,"interventions":4228},"NCT01806545","An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access",[50],"2014-10-27","2013-03-26",[4227],"Arteriovenous Fistula",[4212],{"nctId":4230,"briefTitle":4231,"status":79,"phases":4232,"primaryCompletion":4233,"completion":4233,"start":4234,"enrollment":1329,"conditions":4235,"interventions":4237},"NCT01806584","An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access",[50],"2014-10-23","2013-03-28",[4236],"Arteriovenous Graft",[4212],{"trials":4239,"activeCount":60},[],{"trials":4241,"activeCount":60},[],{"trials":4243,"activeCount":60},[],{"intervention":1695,"totalTrials":115,"cells":4245},{"EARLY_PHASE1":4246,"PHASE1":4248,"PHASE2":4250,"PHASE3":4256,"PHASE4":4258,"NA":4260},{"trials":4247,"activeCount":60},[],{"trials":4249,"activeCount":60},[],{"trials":4251,"activeCount":60},[4252],{"nctId":1687,"briefTitle":1688,"status":68,"phases":4253,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1415,"conditions":4254,"interventions":4255},[50],[1693],[1695,1696,1678],{"trials":4257,"activeCount":60},[],{"trials":4259,"activeCount":60},[],{"trials":4261,"activeCount":60},[],{"intervention":1696,"totalTrials":115,"cells":4263},{"EARLY_PHASE1":4264,"PHASE1":4266,"PHASE2":4268,"PHASE3":4274,"PHASE4":4276,"NA":4278},{"trials":4265,"activeCount":60},[],{"trials":4267,"activeCount":60},[],{"trials":4269,"activeCount":60},[4270],{"nctId":1687,"briefTitle":1688,"status":68,"phases":4271,"primaryCompletion":1690,"completion":1690,"start":1691,"enrollment":1415,"conditions":4272,"interventions":4273},[50],[1693],[1695,1696,1678],{"trials":4275,"activeCount":60},[],{"trials":4277,"activeCount":60},[],{"trials":4279,"activeCount":60},[],{"intervention":4281,"totalTrials":115,"cells":4282},"HGT-1110",{"EARLY_PHASE1":4283,"PHASE1":4285,"PHASE2":4287,"PHASE3":4297,"PHASE4":4299,"NA":4301},{"trials":4284,"activeCount":60},[],{"trials":4286,"activeCount":60},[],{"trials":4288,"activeCount":60},[4289],{"nctId":4290,"briefTitle":4291,"status":68,"phases":4292,"primaryCompletion":4293,"completion":4293,"start":4294,"enrollment":155,"conditions":4295,"interventions":4296},"NCT01887938","An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy",[49,50],"2026-02-13","2013-05-23",[133],[4281],{"trials":4298,"activeCount":60},[],{"trials":4300,"activeCount":60},[],{"trials":4302,"activeCount":60},[],{"intervention":4304,"totalTrials":115,"cells":4305},"HGT-1410",{"EARLY_PHASE1":4306,"PHASE1":4308,"PHASE2":4310,"PHASE3":4321,"PHASE4":4323,"NA":4325},{"trials":4307,"activeCount":60},[],{"trials":4309,"activeCount":60},[],{"trials":4311,"activeCount":60},[4312],{"nctId":4313,"briefTitle":4314,"status":79,"phases":4315,"primaryCompletion":4316,"completion":4316,"start":259,"enrollment":83,"conditions":4317,"interventions":4320},"NCT02350816","An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.",[50],"2019-04-12",[4318,4319],"Sanfilippo Syndrome","Mucopolysaccharidosis (MPS)",[4304],{"trials":4322,"activeCount":60},[],{"trials":4324,"activeCount":60},[],{"trials":4326,"activeCount":60},[],{"intervention":4328,"totalTrials":115,"cells":4329},"HGT-1111",{"EARLY_PHASE1":4330,"PHASE1":4332,"PHASE2":4334,"PHASE3":4343,"PHASE4":4345,"NA":4347},{"trials":4331,"activeCount":60},[],{"trials":4333,"activeCount":60},[],{"trials":4335,"activeCount":60},[4336],{"nctId":4337,"briefTitle":4338,"status":79,"phases":4339,"primaryCompletion":623,"completion":623,"start":4340,"enrollment":1093,"conditions":4341,"interventions":4342},"NCT00681811","Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD",[50],"2008-02-20",[4068],[4328],{"trials":4344,"activeCount":60},[],{"trials":4346,"activeCount":60},[],{"trials":4348,"activeCount":60},[],{"intervention":2021,"totalTrials":115,"cells":4350},{"EARLY_PHASE1":4351,"PHASE1":4353,"PHASE2":4355,"PHASE3":4361,"PHASE4":4363,"NA":4365},{"trials":4352,"activeCount":60},[],{"trials":4354,"activeCount":60},[],{"trials":4356,"activeCount":60},[4357],{"nctId":2013,"briefTitle":2014,"status":68,"phases":4358,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":4359,"interventions":4360},[50],[332],[2021,2022,2023,2024,2004],{"trials":4362,"activeCount":60},[],{"trials":4364,"activeCount":60},[],{"trials":4366,"activeCount":60},[],{"intervention":2022,"totalTrials":115,"cells":4368},{"EARLY_PHASE1":4369,"PHASE1":4371,"PHASE2":4373,"PHASE3":4379,"PHASE4":4381,"NA":4383},{"trials":4370,"activeCount":60},[],{"trials":4372,"activeCount":60},[],{"trials":4374,"activeCount":60},[4375],{"nctId":2013,"briefTitle":2014,"status":68,"phases":4376,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":4377,"interventions":4378},[50],[332],[2021,2022,2023,2024,2004],{"trials":4380,"activeCount":60},[],{"trials":4382,"activeCount":60},[],{"trials":4384,"activeCount":60},[],{"intervention":2023,"totalTrials":115,"cells":4386},{"EARLY_PHASE1":4387,"PHASE1":4389,"PHASE2":4391,"PHASE3":4397,"PHASE4":4399,"NA":4401},{"trials":4388,"activeCount":60},[],{"trials":4390,"activeCount":60},[],{"trials":4392,"activeCount":60},[4393],{"nctId":2013,"briefTitle":2014,"status":68,"phases":4394,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":4395,"interventions":4396},[50],[332],[2021,2022,2023,2024,2004],{"trials":4398,"activeCount":60},[],{"trials":4400,"activeCount":60},[],{"trials":4402,"activeCount":60},[],{"intervention":2024,"totalTrials":115,"cells":4404},{"EARLY_PHASE1":4405,"PHASE1":4407,"PHASE2":4409,"PHASE3":4415,"PHASE4":4417,"NA":4419},{"trials":4406,"activeCount":60},[],{"trials":4408,"activeCount":60},[],{"trials":4410,"activeCount":60},[4411],{"nctId":2013,"briefTitle":2014,"status":68,"phases":4412,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":2018,"conditions":4413,"interventions":4414},[50],[332],[2021,2022,2023,2024,2004],{"trials":4416,"activeCount":60},[],{"trials":4418,"activeCount":60},[],{"trials":4420,"activeCount":60},[],{"intervention":4422,"totalTrials":115,"cells":4423},"SSP-002358 (0.1 mg) + PPI",{"EARLY_PHASE1":4424,"PHASE1":4426,"PHASE2":4428,"PHASE3":4441,"PHASE4":4443,"NA":4445},{"trials":4425,"activeCount":60},[],{"trials":4427,"activeCount":60},[],{"trials":4429,"activeCount":60},[4430],{"nctId":4431,"briefTitle":4432,"status":68,"phases":4433,"primaryCompletion":4434,"completion":4434,"start":2945,"enrollment":4435,"conditions":4436,"interventions":4438},"NCT01472939","Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)",[50],"2013-05-14",480,[4437],"Gastroesophageal Reflux Disease",[4422,4439,4440],"SSP-002358 (0.5 mg) + PPI","SSP-002358 (2.0 mg) + PPI",{"trials":4442,"activeCount":60},[],{"trials":4444,"activeCount":60},[],{"trials":4446,"activeCount":60},[],{"intervention":4439,"totalTrials":115,"cells":4448},{"EARLY_PHASE1":4449,"PHASE1":4451,"PHASE2":4453,"PHASE3":4459,"PHASE4":4461,"NA":4463},{"trials":4450,"activeCount":60},[],{"trials":4452,"activeCount":60},[],{"trials":4454,"activeCount":60},[4455],{"nctId":4431,"briefTitle":4432,"status":68,"phases":4456,"primaryCompletion":4434,"completion":4434,"start":2945,"enrollment":4435,"conditions":4457,"interventions":4458},[50],[4437],[4422,4439,4440],{"trials":4460,"activeCount":60},[],{"trials":4462,"activeCount":60},[],{"trials":4464,"activeCount":60},[],{"intervention":4440,"totalTrials":115,"cells":4466},{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4471,"PHASE3":4477,"PHASE4":4479,"NA":4481},{"trials":4468,"activeCount":60},[],{"trials":4470,"activeCount":60},[],{"trials":4472,"activeCount":60},[4473],{"nctId":4431,"briefTitle":4432,"status":68,"phases":4474,"primaryCompletion":4434,"completion":4434,"start":2945,"enrollment":4435,"conditions":4475,"interventions":4476},[50],[4437],[4422,4439,4440],{"trials":4478,"activeCount":60},[],{"trials":4480,"activeCount":60},[],{"trials":4482,"activeCount":60},[],{"intervention":4484,"totalTrials":115,"cells":4485},"Methylphenidate + SPD503",{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4490,"PHASE3":4501,"PHASE4":4503,"NA":4505},{"trials":4487,"activeCount":60},[],{"trials":4489,"activeCount":60},[],{"trials":4491,"activeCount":60},[4492],{"nctId":4493,"briefTitle":4494,"status":68,"phases":4495,"primaryCompletion":4496,"completion":4496,"start":4497,"enrollment":3513,"conditions":4498,"interventions":4499},"NCT00151996","Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[50],"2004-12-27","2004-08-16",[445],[4484,4500],"Amphetamine + SPD503",{"trials":4502,"activeCount":60},[],{"trials":4504,"activeCount":60},[],{"trials":4506,"activeCount":60},[],{"intervention":4500,"totalTrials":115,"cells":4508},{"EARLY_PHASE1":4509,"PHASE1":4511,"PHASE2":4513,"PHASE3":4519,"PHASE4":4521,"NA":4523},{"trials":4510,"activeCount":60},[],{"trials":4512,"activeCount":60},[],{"trials":4514,"activeCount":60},[4515],{"nctId":4493,"briefTitle":4494,"status":68,"phases":4516,"primaryCompletion":4496,"completion":4496,"start":4497,"enrollment":3513,"conditions":4517,"interventions":4518},[50],[445],[4484,4500],{"trials":4520,"activeCount":60},[],{"trials":4522,"activeCount":60},[],{"trials":4524,"activeCount":60},[],{"intervention":4526,"totalTrials":115,"cells":4527},"Idursulfase IT",{"EARLY_PHASE1":4528,"PHASE1":4530,"PHASE2":4532,"PHASE3":4543,"PHASE4":4545,"NA":4547},{"trials":4529,"activeCount":60},[],{"trials":4531,"activeCount":60},[],{"trials":4533,"activeCount":60},[4534],{"nctId":4535,"briefTitle":4536,"status":68,"phases":4537,"primaryCompletion":4538,"completion":4538,"start":4539,"enrollment":4540,"conditions":4541,"interventions":4542},"NCT00920647","A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®",[49,50],"2012-10-29","2009-11-18",16,[35],[4526,4526,4526],{"trials":4544,"activeCount":60},[],{"trials":4546,"activeCount":60},[],{"trials":4548,"activeCount":60},[],{"intervention":4550,"totalTrials":115,"cells":4551},"FST-100 Ophthalmic Suspension",{"EARLY_PHASE1":4552,"PHASE1":4554,"PHASE2":4556,"PHASE3":4565,"PHASE4":4567,"NA":4569},{"trials":4553,"activeCount":60},[],{"trials":4555,"activeCount":60},[],{"trials":4557,"activeCount":60},[4558],{"nctId":4559,"briefTitle":4560,"status":79,"phases":4561,"primaryCompletion":3593,"completion":3593,"start":4562,"enrollment":165,"conditions":4563,"interventions":4564},"NCT00941486","FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis",[50],"2009-06-30",[4012],[4550],{"trials":4566,"activeCount":60},[],{"trials":4568,"activeCount":60},[],{"trials":4570,"activeCount":60},[],{"intervention":4572,"totalTrials":115,"cells":4573},"Recombinant human heparan N-sulfatase",{"EARLY_PHASE1":4574,"PHASE1":4576,"PHASE2":4578,"PHASE3":4588,"PHASE4":4590,"NA":4592},{"trials":4575,"activeCount":60},[],{"trials":4577,"activeCount":60},[],{"trials":4579,"activeCount":60},[4580],{"nctId":4581,"briefTitle":4582,"status":68,"phases":4583,"primaryCompletion":4584,"completion":4584,"start":4585,"enrollment":31,"conditions":4586,"interventions":4587},"NCT01155778","Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients",[49,50],"2012-09-01","2010-06-01",[4319],[4572],{"trials":4589,"activeCount":60},[],{"trials":4591,"activeCount":60},[],{"trials":4593,"activeCount":60},[],{"intervention":4595,"totalTrials":115,"cells":4596},"ecallantide 60 mg",{"EARLY_PHASE1":4597,"PHASE1":4599,"PHASE2":4601,"PHASE3":4614,"PHASE4":4616,"NA":4618},{"trials":4598,"activeCount":60},[],{"trials":4600,"activeCount":60},[],{"trials":4602,"activeCount":60},[4603],{"nctId":4604,"briefTitle":4605,"status":79,"phases":4606,"primaryCompletion":91,"completion":91,"start":4607,"enrollment":4608,"conditions":4609,"interventions":4611},"NCT01343823","Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema",[50],"2011-06-01",79,[4610],"ACE Inhibitor Induced Angioedema",[4595,4612,4613],"ecallantide 30 mg","ecallantide 10 mg",{"trials":4615,"activeCount":60},[],{"trials":4617,"activeCount":60},[],{"trials":4619,"activeCount":60},[],{"intervention":4612,"totalTrials":115,"cells":4621},{"EARLY_PHASE1":4622,"PHASE1":4624,"PHASE2":4626,"PHASE3":4632,"PHASE4":4634,"NA":4636},{"trials":4623,"activeCount":60},[],{"trials":4625,"activeCount":60},[],{"trials":4627,"activeCount":60},[4628],{"nctId":4604,"briefTitle":4605,"status":79,"phases":4629,"primaryCompletion":91,"completion":91,"start":4607,"enrollment":4608,"conditions":4630,"interventions":4631},[50],[4610],[4595,4612,4613],{"trials":4633,"activeCount":60},[],{"trials":4635,"activeCount":60},[],{"trials":4637,"activeCount":60},[],{"intervention":4613,"totalTrials":115,"cells":4639},{"EARLY_PHASE1":4640,"PHASE1":4642,"PHASE2":4644,"PHASE3":4650,"PHASE4":4652,"NA":4654},{"trials":4641,"activeCount":60},[],{"trials":4643,"activeCount":60},[],{"trials":4645,"activeCount":60},[4646],{"nctId":4604,"briefTitle":4605,"status":79,"phases":4647,"primaryCompletion":91,"completion":91,"start":4607,"enrollment":4608,"conditions":4648,"interventions":4649},[50],[4610],[4595,4612,4613],{"trials":4651,"activeCount":60},[],{"trials":4653,"activeCount":60},[],{"trials":4655,"activeCount":60},[],{"intervention":4657,"totalTrials":115,"cells":4658},"Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate",{"EARLY_PHASE1":4659,"PHASE1":4661,"PHASE2":4663,"PHASE3":4674,"PHASE4":4676,"NA":4678},{"trials":4660,"activeCount":60},[],{"trials":4662,"activeCount":60},[],{"trials":4664,"activeCount":60},[4665],{"nctId":4666,"briefTitle":4667,"status":68,"phases":4668,"primaryCompletion":4669,"completion":4669,"start":4670,"enrollment":4671,"conditions":4672,"interventions":4673},"NCT00202605","Safety and Efficacy of SPD465 in Adults With ADHD",[50],"2006-01-06","2005-09-29",72,[445],[4657],{"trials":4675,"activeCount":60},[],{"trials":4677,"activeCount":60},[],{"trials":4679,"activeCount":60},[],{"intervention":4681,"totalTrials":115,"cells":4682},"PVS-10200",{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4687,"PHASE3":4699,"PHASE4":4701,"NA":4703},{"trials":4684,"activeCount":60},[],{"trials":4686,"activeCount":60},[],{"trials":4688,"activeCount":60},[4689],{"nctId":4690,"briefTitle":4691,"status":68,"phases":4692,"primaryCompletion":4693,"completion":4694,"start":4695,"enrollment":909,"conditions":4696,"interventions":4698},"NCT01099215","Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH)",[49,50],"2012-06-30","2012-10-31","2010-04-30",[4697],"Peripheral Artery Disease",[4681],{"trials":4700,"activeCount":60},[],{"trials":4702,"activeCount":60},[],{"trials":4704,"activeCount":60},[],{"intervention":4706,"totalTrials":115,"cells":4707},"Recombinant human heparan N-sulfatase [rhHNS]",{"EARLY_PHASE1":4708,"PHASE1":4710,"PHASE2":4712,"PHASE3":4722,"PHASE4":4724,"NA":4726},{"trials":4709,"activeCount":60},[],{"trials":4711,"activeCount":60},[],{"trials":4713,"activeCount":60},[4714],{"nctId":4715,"briefTitle":4716,"status":68,"phases":4717,"primaryCompletion":4718,"completion":4718,"start":4719,"enrollment":909,"conditions":4720,"interventions":4721},"NCT02060526","Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease",[50],"2016-06-01","2014-02-26",[4318],[4706],{"trials":4723,"activeCount":60},[],{"trials":4725,"activeCount":60},[],{"trials":4727,"activeCount":60},[],{"intervention":4729,"totalTrials":115,"cells":4730},"SPD557",{"EARLY_PHASE1":4731,"PHASE1":4733,"PHASE2":4735,"PHASE3":4745,"PHASE4":4747,"NA":4749},{"trials":4732,"activeCount":60},[],{"trials":4734,"activeCount":60},[],{"trials":4736,"activeCount":60},[4737],{"nctId":4738,"briefTitle":4739,"status":79,"phases":4740,"primaryCompletion":4741,"completion":4741,"start":4742,"enrollment":1054,"conditions":4743,"interventions":4744},"NCT01370863","An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients",[50],"2012-05-29","2010-12-02",[4437],[4729],{"trials":4746,"activeCount":60},[],{"trials":4748,"activeCount":60},[],{"trials":4750,"activeCount":60},[],{"intervention":4752,"totalTrials":115,"cells":4753},"NPSP795",{"EARLY_PHASE1":4754,"PHASE1":4756,"PHASE2":4758,"PHASE3":4769,"PHASE4":4771,"NA":4773},{"trials":4755,"activeCount":60},[],{"trials":4757,"activeCount":60},[],{"trials":4759,"activeCount":60},[4760],{"nctId":4761,"briefTitle":4762,"status":68,"phases":4763,"primaryCompletion":4764,"completion":4764,"start":4765,"enrollment":1144,"conditions":4766,"interventions":4768},"NCT02204579","A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations",[50],"2015-05-04","2014-07-18",[4767],"Autosomal Dominant Hypocalcemia (ADH)",[4752],{"trials":4770,"activeCount":60},[],{"trials":4772,"activeCount":60},[],{"trials":4774,"activeCount":60},[],{"intervention":4776,"totalTrials":115,"cells":4777},"SHP655",{"EARLY_PHASE1":4778,"PHASE1":4780,"PHASE2":4782,"PHASE3":4793,"PHASE4":4795,"NA":4797},{"trials":4779,"activeCount":60},[],{"trials":4781,"activeCount":60},[],{"trials":4783,"activeCount":60},[4784],{"nctId":4785,"briefTitle":4786,"status":68,"phases":4787,"primaryCompletion":4788,"completion":4788,"start":4789,"enrollment":625,"conditions":4790,"interventions":4792},"NCT03922308","Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)",[50],"2021-08-05","2019-10-09",[4791],"Acquired Thrombotic Thrombocytopenic Purpura (aTTP)",[4776],{"trials":4794,"activeCount":60},[],{"trials":4796,"activeCount":60},[],{"trials":4798,"activeCount":60},[],{"intervention":4800,"totalTrials":115,"cells":4801},"VP20621",{"EARLY_PHASE1":4802,"PHASE1":4804,"PHASE2":4806,"PHASE3":4818,"PHASE4":4820,"NA":4822},{"trials":4803,"activeCount":60},[],{"trials":4805,"activeCount":60},[],{"trials":4807,"activeCount":60},[4808],{"nctId":4809,"briefTitle":4810,"status":68,"phases":4811,"primaryCompletion":4812,"completion":4812,"start":4813,"enrollment":4814,"conditions":4815,"interventions":4817},"NCT01259726","Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection",[50],"2013-06-11","2011-06-27",173,[4816],"Clostridium Difficile Infection",[4800,4800,4800],{"trials":4819,"activeCount":60},[],{"trials":4821,"activeCount":60},[],{"trials":4823,"activeCount":60},[],{"intervention":4825,"totalTrials":115,"cells":4826},"75mg SHP647",{"EARLY_PHASE1":4827,"PHASE1":4829,"PHASE2":4831,"PHASE3":4843,"PHASE4":4845,"NA":4847},{"trials":4828,"activeCount":60},[],{"trials":4830,"activeCount":60},[],{"trials":4832,"activeCount":60},[4833],{"nctId":4834,"briefTitle":4835,"status":68,"phases":4836,"primaryCompletion":4837,"completion":4837,"start":4838,"enrollment":4839,"conditions":4840,"interventions":4841},"NCT01771809","Long-Term Safety Of PF-00547659 In Ulcerative Colitis",[50],"2017-12-13","2013-03-18",330,[27],[4825,4842],"225mg SHP647",{"trials":4844,"activeCount":60},[],{"trials":4846,"activeCount":60},[],{"trials":4848,"activeCount":60},[],{"intervention":4842,"totalTrials":115,"cells":4850},{"EARLY_PHASE1":4851,"PHASE1":4853,"PHASE2":4855,"PHASE3":4861,"PHASE4":4863,"NA":4865},{"trials":4852,"activeCount":60},[],{"trials":4854,"activeCount":60},[],{"trials":4856,"activeCount":60},[4857],{"nctId":4834,"briefTitle":4835,"status":68,"phases":4858,"primaryCompletion":4837,"completion":4837,"start":4838,"enrollment":4839,"conditions":4859,"interventions":4860},[50],[27],[4825,4842],{"trials":4862,"activeCount":60},[],{"trials":4864,"activeCount":60},[],{"trials":4866,"activeCount":60},[],{"intervention":4868,"totalTrials":115,"cells":4869},"rhIGF-1\u002FrhIGFBP-3",{"EARLY_PHASE1":4870,"PHASE1":4872,"PHASE2":4874,"PHASE3":4886,"PHASE4":4888,"NA":4890},{"trials":4871,"activeCount":60},[],{"trials":4873,"activeCount":60},[],{"trials":4875,"activeCount":60},[4876],{"nctId":4877,"briefTitle":4878,"status":68,"phases":4879,"primaryCompletion":4880,"completion":4880,"start":4881,"enrollment":4882,"conditions":4883,"interventions":4885},"NCT02386839","Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)",[50],"2021-09-28","2015-03-26",76,[4884],"Retinopathy of Prematurity (ROP)",[4868],{"trials":4887,"activeCount":60},[],{"trials":4889,"activeCount":60},[],{"trials":4891,"activeCount":60},[],{"intervention":4893,"totalTrials":115,"cells":4894},"Calcium Carbonate",{"EARLY_PHASE1":4895,"PHASE1":4897,"PHASE2":4899,"PHASE3":4913,"PHASE4":4915,"NA":4917},{"trials":4896,"activeCount":60},[],{"trials":4898,"activeCount":60},[],{"trials":4900,"activeCount":60},[4901],{"nctId":4902,"briefTitle":4903,"status":68,"phases":4904,"primaryCompletion":4905,"completion":4905,"start":4906,"enrollment":4907,"conditions":4908,"interventions":4911},"NCT01696279","A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis",[50],"2018-11-16","2013-02-15",63,[4909,4910],"Chronic Kidney Disease","Hyperphosphatemia",[4912,4893],"Lanthanum Carbonate",{"trials":4914,"activeCount":60},[],{"trials":4916,"activeCount":60},[],{"trials":4918,"activeCount":60},[],{"intervention":4920,"totalTrials":115,"cells":4921},"DX-88",{"EARLY_PHASE1":4922,"PHASE1":4924,"PHASE2":4926,"PHASE3":4938,"PHASE4":4940,"NA":4942},{"trials":4923,"activeCount":60},[],{"trials":4925,"activeCount":60},[],{"trials":4927,"activeCount":60},[4928],{"nctId":4929,"briefTitle":4930,"status":68,"phases":4931,"primaryCompletion":4932,"completion":4933,"start":4934,"enrollment":4935,"conditions":4936,"interventions":4937},"NCT01826916","EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema",[50],"2005-12-01","2006-01-01","2003-11-01",77,[16],[4920],{"trials":4939,"activeCount":60},[],{"trials":4941,"activeCount":60},[],{"trials":4943,"activeCount":60},[],{"intervention":4945,"totalTrials":115,"cells":4946},"PF-00547659",{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4951,"PHASE3":4962,"PHASE4":4964,"NA":4966},{"trials":4948,"activeCount":60},[],{"trials":4950,"activeCount":60},[],{"trials":4952,"activeCount":60},[4953],{"nctId":4954,"briefTitle":4955,"status":68,"phases":4956,"primaryCompletion":4957,"completion":4957,"start":4958,"enrollment":4959,"conditions":4960,"interventions":4961},"NCT01298492","A Study To Monitor Long-Term Treatment With PF-00547659",[50],"2016-07-27","2011-07-01",268,[1056],[4945],{"trials":4963,"activeCount":60},[],{"trials":4965,"activeCount":60},[],{"trials":4967,"activeCount":60},[],{"intervention":3979,"totalTrials":115,"cells":4969},{"EARLY_PHASE1":4970,"PHASE1":4972,"PHASE2":4974,"PHASE3":4980,"PHASE4":4982,"NA":4984},{"trials":4971,"activeCount":60},[],{"trials":4973,"activeCount":60},[],{"trials":4975,"activeCount":60},[4976],{"nctId":3967,"briefTitle":3968,"status":391,"phases":4977,"primaryCompletion":3970,"completion":3970,"start":3971,"enrollment":60,"conditions":4978,"interventions":4979},[50],[3963,3973,3974,3964,3975,3976,3977],[3939,3979],{"trials":4981,"activeCount":60},[],{"trials":4983,"activeCount":60},[],{"trials":4985,"activeCount":60},[],{"intervention":4987,"totalTrials":115,"cells":4988},"rhIGF-I\u002FrhIGFBP-3",{"EARLY_PHASE1":4989,"PHASE1":4991,"PHASE2":4993,"PHASE3":5004,"PHASE4":5006,"NA":5008},{"trials":4990,"activeCount":60},[],{"trials":4992,"activeCount":60},[],{"trials":4994,"activeCount":60},[4995],{"nctId":4996,"briefTitle":4997,"status":68,"phases":4998,"primaryCompletion":4999,"completion":4999,"start":5000,"enrollment":5001,"conditions":5002,"interventions":5003},"NCT01096784","IGF-1\u002FIGFBP3 Prevention of Retinopathy of Prematurity",[50],"2016-03-30","2010-06-18",121,[4884],[4987],{"trials":5005,"activeCount":60},[],{"trials":5007,"activeCount":60},[],{"trials":5009,"activeCount":60},[],{"intervention":5011,"totalTrials":115,"cells":5012},"ALX-0600",{"EARLY_PHASE1":5013,"PHASE1":5015,"PHASE2":5017,"PHASE3":5032,"PHASE4":5034,"NA":5036},{"trials":5014,"activeCount":60},[],{"trials":5016,"activeCount":60},[],{"trials":5018,"activeCount":60},[5019],{"nctId":5020,"briefTitle":5021,"status":68,"phases":5022,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":5025,"conditions":5026,"interventions":5027},"NCT00072839","Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease",[50],"2005-07-28","2003-11-12",100,[1056],[5011,5028,5029,5030,5031],"teduglutide 0.05","teduglutide 0.2 mg","Teduglutide 0.05 dose","teduglutide 0.1 mg dose",{"trials":5033,"activeCount":60},[],{"trials":5035,"activeCount":60},[],{"trials":5037,"activeCount":60},[],{"intervention":5028,"totalTrials":115,"cells":5039},{"EARLY_PHASE1":5040,"PHASE1":5042,"PHASE2":5044,"PHASE3":5050,"PHASE4":5052,"NA":5054},{"trials":5041,"activeCount":60},[],{"trials":5043,"activeCount":60},[],{"trials":5045,"activeCount":60},[5046],{"nctId":5020,"briefTitle":5021,"status":68,"phases":5047,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":5025,"conditions":5048,"interventions":5049},[50],[1056],[5011,5028,5029,5030,5031],{"trials":5051,"activeCount":60},[],{"trials":5053,"activeCount":60},[],{"trials":5055,"activeCount":60},[],{"intervention":5029,"totalTrials":115,"cells":5057},{"EARLY_PHASE1":5058,"PHASE1":5060,"PHASE2":5062,"PHASE3":5068,"PHASE4":5070,"NA":5072},{"trials":5059,"activeCount":60},[],{"trials":5061,"activeCount":60},[],{"trials":5063,"activeCount":60},[5064],{"nctId":5020,"briefTitle":5021,"status":68,"phases":5065,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":5025,"conditions":5066,"interventions":5067},[50],[1056],[5011,5028,5029,5030,5031],{"trials":5069,"activeCount":60},[],{"trials":5071,"activeCount":60},[],{"trials":5073,"activeCount":60},[],{"intervention":5030,"totalTrials":115,"cells":5075},{"EARLY_PHASE1":5076,"PHASE1":5078,"PHASE2":5080,"PHASE3":5086,"PHASE4":5088,"NA":5090},{"trials":5077,"activeCount":60},[],{"trials":5079,"activeCount":60},[],{"trials":5081,"activeCount":60},[5082],{"nctId":5020,"briefTitle":5021,"status":68,"phases":5083,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":5025,"conditions":5084,"interventions":5085},[50],[1056],[5011,5028,5029,5030,5031],{"trials":5087,"activeCount":60},[],{"trials":5089,"activeCount":60},[],{"trials":5091,"activeCount":60},[],{"intervention":5031,"totalTrials":115,"cells":5093},{"EARLY_PHASE1":5094,"PHASE1":5096,"PHASE2":5098,"PHASE3":5104,"PHASE4":5106,"NA":5108},{"trials":5095,"activeCount":60},[],{"trials":5097,"activeCount":60},[],{"trials":5099,"activeCount":60},[5100],{"nctId":5020,"briefTitle":5021,"status":68,"phases":5101,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":5025,"conditions":5102,"interventions":5103},[50],[1056],[5011,5028,5029,5030,5031],{"trials":5105,"activeCount":60},[],{"trials":5107,"activeCount":60},[],{"trials":5109,"activeCount":60},[],{"intervention":5111,"totalTrials":115,"cells":5112},"budesonide",{"EARLY_PHASE1":5113,"PHASE1":5115,"PHASE2":5117,"PHASE3":5128,"PHASE4":5130,"NA":5132},{"trials":5114,"activeCount":60},[],{"trials":5116,"activeCount":60},[],{"trials":5118,"activeCount":60},[5119],{"nctId":5120,"briefTitle":5121,"status":68,"phases":5122,"primaryCompletion":5123,"completion":5123,"start":5124,"enrollment":5125,"conditions":5126,"interventions":5127},"NCT00762073","Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis",[50],"2010-04-02","2009-01-08",82,[2065],[5111],{"trials":5129,"activeCount":60},[],{"trials":5131,"activeCount":60},[],{"trials":5133,"activeCount":60},[],{"intervention":2425,"totalTrials":115,"cells":5135},{"EARLY_PHASE1":5136,"PHASE1":5138,"PHASE2":5140,"PHASE3":5146,"PHASE4":5148,"NA":5150},{"trials":5137,"activeCount":60},[],{"trials":5139,"activeCount":60},[],{"trials":5141,"activeCount":60},[5142],{"nctId":2418,"briefTitle":2419,"status":68,"phases":5143,"primaryCompletion":2421,"completion":2421,"start":2422,"enrollment":1127,"conditions":5144,"interventions":5145},[50],[252],[2409,2425],{"trials":5147,"activeCount":60},[],{"trials":5149,"activeCount":60},[],{"trials":5151,"activeCount":60},[],{"intervention":5153,"totalTrials":115,"cells":5154},"SPD489 20 mg",{"EARLY_PHASE1":5155,"PHASE1":5157,"PHASE2":5159,"PHASE3":5174,"PHASE4":5176,"NA":5178},{"trials":5156,"activeCount":60},[],{"trials":5158,"activeCount":60},[],{"trials":5160,"activeCount":60},[5161],{"nctId":5162,"briefTitle":5163,"status":68,"phases":5164,"primaryCompletion":5165,"completion":5165,"start":5166,"enrollment":5167,"conditions":5168,"interventions":5170},"NCT01096680","Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss",[50],"2010-07-18","2010-04-05",135,[5169],"Sleep Deprivation",[5153,5171,5172,5173],"SPD489 50 mg","SPD489 70 mg","Armodafinil",{"trials":5175,"activeCount":60},[],{"trials":5177,"activeCount":60},[],{"trials":5179,"activeCount":60},[],{"intervention":5171,"totalTrials":115,"cells":5181},{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5186,"PHASE3":5192,"PHASE4":5194,"NA":5196},{"trials":5183,"activeCount":60},[],{"trials":5185,"activeCount":60},[],{"trials":5187,"activeCount":60},[5188],{"nctId":5162,"briefTitle":5163,"status":68,"phases":5189,"primaryCompletion":5165,"completion":5165,"start":5166,"enrollment":5167,"conditions":5190,"interventions":5191},[50],[5169],[5153,5171,5172,5173],{"trials":5193,"activeCount":60},[],{"trials":5195,"activeCount":60},[],{"trials":5197,"activeCount":60},[],{"intervention":5172,"totalTrials":115,"cells":5199},{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5210,"PHASE4":5212,"NA":5214},{"trials":5201,"activeCount":60},[],{"trials":5203,"activeCount":60},[],{"trials":5205,"activeCount":60},[5206],{"nctId":5162,"briefTitle":5163,"status":68,"phases":5207,"primaryCompletion":5165,"completion":5165,"start":5166,"enrollment":5167,"conditions":5208,"interventions":5209},[50],[5169],[5153,5171,5172,5173],{"trials":5211,"activeCount":60},[],{"trials":5213,"activeCount":60},[],{"trials":5215,"activeCount":60},[],{"intervention":5173,"totalTrials":115,"cells":5217},{"EARLY_PHASE1":5218,"PHASE1":5220,"PHASE2":5222,"PHASE3":5228,"PHASE4":5230,"NA":5232},{"trials":5219,"activeCount":60},[],{"trials":5221,"activeCount":60},[],{"trials":5223,"activeCount":60},[5224],{"nctId":5162,"briefTitle":5163,"status":68,"phases":5225,"primaryCompletion":5165,"completion":5165,"start":5166,"enrollment":5167,"conditions":5226,"interventions":5227},[50],[5169],[5153,5171,5172,5173],{"trials":5229,"activeCount":60},[],{"trials":5231,"activeCount":60},[],{"trials":5233,"activeCount":60},[],{"intervention":5235,"totalTrials":115,"cells":5236},"C1 Esterase Inhibitor",{"EARLY_PHASE1":5237,"PHASE1":5239,"PHASE2":5241,"PHASE3":5253,"PHASE4":5255,"NA":5257},{"trials":5238,"activeCount":60},[],{"trials":5240,"activeCount":60},[],{"trials":5242,"activeCount":60},[5243],{"nctId":5244,"briefTitle":5245,"status":68,"phases":5246,"primaryCompletion":5247,"completion":5248,"start":5249,"enrollment":184,"conditions":5250,"interventions":5252},"NCT01147302","A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection",[50],"2013-04-19","2013-06-28","2011-08-24",[5251],"Graft Rejection",[5235],{"trials":5254,"activeCount":60},[],{"trials":5256,"activeCount":60},[],{"trials":5258,"activeCount":60},[],{"intervention":5260,"totalTrials":115,"cells":5261},"NPS 1776",{"EARLY_PHASE1":5262,"PHASE1":5264,"PHASE2":5266,"PHASE3":5279,"PHASE4":5281,"NA":5283},{"trials":5263,"activeCount":60},[],{"trials":5265,"activeCount":60},[],{"trials":5267,"activeCount":60},[5268],{"nctId":5269,"briefTitle":5270,"status":68,"phases":5271,"primaryCompletion":5272,"completion":5273,"start":5274,"enrollment":5275,"conditions":5276,"interventions":5278},"NCT00172094","Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches",[50],"2004-06-30","2004-07-31","2003-12-31",189,[5277],"Migraine Headache",[5260,5260],{"trials":5280,"activeCount":60},[],{"trials":5282,"activeCount":60},[],{"trials":5284,"activeCount":60},[],{"intervention":5286,"totalTrials":115,"cells":5287},"rhHNS-10 mg",{"EARLY_PHASE1":5288,"PHASE1":5290,"PHASE2":5292,"PHASE3":5303,"PHASE4":5305,"NA":5307},{"trials":5289,"activeCount":60},[],{"trials":5291,"activeCount":60},[],{"trials":5293,"activeCount":60},[5294],{"nctId":5295,"briefTitle":5296,"status":79,"phases":5297,"primaryCompletion":4316,"completion":4316,"start":5298,"enrollment":31,"conditions":5299,"interventions":5300},"NCT01299727","Extension of Study HGT-SAN-055 Evaluating Administration of rhHNS in Patients With Sanfilippo Syndrome Type A (MPS IIIA)",[49,50],"2011-03-01",[4318],[5286,5301,5302],"rhHNS-45 mg","rhHNS-90 mg",{"trials":5304,"activeCount":60},[],{"trials":5306,"activeCount":60},[],{"trials":5308,"activeCount":60},[],{"intervention":5301,"totalTrials":115,"cells":5310},{"EARLY_PHASE1":5311,"PHASE1":5313,"PHASE2":5315,"PHASE3":5321,"PHASE4":5323,"NA":5325},{"trials":5312,"activeCount":60},[],{"trials":5314,"activeCount":60},[],{"trials":5316,"activeCount":60},[5317],{"nctId":5295,"briefTitle":5296,"status":79,"phases":5318,"primaryCompletion":4316,"completion":4316,"start":5298,"enrollment":31,"conditions":5319,"interventions":5320},[49,50],[4318],[5286,5301,5302],{"trials":5322,"activeCount":60},[],{"trials":5324,"activeCount":60},[],{"trials":5326,"activeCount":60},[],{"intervention":5302,"totalTrials":115,"cells":5328},{"EARLY_PHASE1":5329,"PHASE1":5331,"PHASE2":5333,"PHASE3":5339,"PHASE4":5341,"NA":5343},{"trials":5330,"activeCount":60},[],{"trials":5332,"activeCount":60},[],{"trials":5334,"activeCount":60},[5335],{"nctId":5295,"briefTitle":5296,"status":79,"phases":5336,"primaryCompletion":4316,"completion":4316,"start":5298,"enrollment":31,"conditions":5337,"interventions":5338},[49,50],[4318],[5286,5301,5302],{"trials":5340,"activeCount":60},[],{"trials":5342,"activeCount":60},[],{"trials":5344,"activeCount":60},[],{"intervention":5346,"totalTrials":115,"cells":5347},"troxacitabine",{"EARLY_PHASE1":5348,"PHASE1":5350,"PHASE2":5352,"PHASE3":5363,"PHASE4":5365,"NA":5367},{"trials":5349,"activeCount":60},[],{"trials":5351,"activeCount":60},[],{"trials":5353,"activeCount":60},[5354],{"nctId":5355,"briefTitle":5356,"status":68,"phases":5357,"primaryCompletion":5358,"completion":5358,"start":5359,"enrollment":308,"conditions":5360,"interventions":5362},"NCT00012259","Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia",[50],"2002-03-27","2000-12-11",[5361],"Leukemia",[5346],{"trials":5364,"activeCount":60},[],{"trials":5366,"activeCount":60},[],{"trials":5368,"activeCount":60},[],{"intervention":4099,"totalTrials":9,"cells":5370},{"EARLY_PHASE1":5371,"PHASE1":5373,"PHASE2":5405,"PHASE3":5407,"PHASE4":5409,"NA":5411},{"trials":5372,"activeCount":60},[],{"trials":5374,"activeCount":60},[5375,5384,5388,5397],{"nctId":5376,"briefTitle":5377,"status":68,"phases":5378,"primaryCompletion":5379,"completion":5379,"start":5380,"enrollment":165,"conditions":5381,"interventions":5382},"NCT01979185","Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects",[49],"2013-12-13","2013-11-18",[19],[5383,4099],"Simvastatin",{"nctId":4093,"briefTitle":4094,"status":68,"phases":5385,"primaryCompletion":357,"completion":357,"start":4096,"enrollment":625,"conditions":5386,"interventions":5387},[49],[19],[4086,4099],{"nctId":5389,"briefTitle":5390,"status":68,"phases":5391,"primaryCompletion":5392,"completion":5392,"start":5393,"enrollment":165,"conditions":5394,"interventions":5395},"NCT01989169","Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects",[49],"2014-01-06","2013-11-26",[19],[5396,4099],"Midazolam",{"nctId":5398,"briefTitle":5399,"status":68,"phases":5400,"primaryCompletion":5401,"completion":5401,"start":5402,"enrollment":1066,"conditions":5403,"interventions":5404},"NCT01905553","The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects",[49],"2013-09-24","2013-08-27",[19],[4099],{"trials":5406,"activeCount":60},[],{"trials":5408,"activeCount":60},[],{"trials":5410,"activeCount":60},[],{"trials":5412,"activeCount":60},[],{"intervention":5414,"totalTrials":12,"cells":5415},"Moxifloxacin",{"EARLY_PHASE1":5416,"PHASE1":5418,"PHASE2":5440,"PHASE3":5442,"PHASE4":5444,"NA":5446},{"trials":5417,"activeCount":60},[],{"trials":5419,"activeCount":60},[5420,5430],{"nctId":5421,"briefTitle":5422,"status":68,"phases":5423,"primaryCompletion":5424,"completion":5424,"start":5425,"enrollment":1519,"conditions":5426,"interventions":5427},"NCT01552928","Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers",[49],"2012-07-25","2012-03-29",[19],[5428,5429,5414],"Anagrelide 0.5 mg","Anagrelide 2.5 mg",{"nctId":5431,"briefTitle":5432,"status":68,"phases":5433,"primaryCompletion":5434,"completion":5434,"start":5435,"enrollment":1374,"conditions":5436,"interventions":5437},"NCT00672984","Guanfacine Immediate-release Electrocardiogram Results (QTc) Study",[49],"2008-08-07","2008-04-18",[30],[5438,5439],"immediate release guanfacine hydrochloride","moxifloxacin",{"trials":5441,"activeCount":60},[],{"trials":5443,"activeCount":60},[],{"trials":5445,"activeCount":60},[],{"trials":5447,"activeCount":60},[],{"intervention":5449,"totalTrials":12,"cells":5450},"SSP-004184",{"EARLY_PHASE1":5451,"PHASE1":5453,"PHASE2":5471,"PHASE3":5473,"PHASE4":5475,"NA":5477},{"trials":5452,"activeCount":60},[],{"trials":5454,"activeCount":60},[5455,5464],{"nctId":5456,"briefTitle":5457,"status":68,"phases":5458,"primaryCompletion":5459,"completion":5459,"start":4538,"enrollment":5460,"conditions":5461,"interventions":5463},"NCT01716455","Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function",[49],"2013-03-10",66,[5462],"Impaired Renal Function",[5449],{"nctId":5465,"briefTitle":5466,"status":68,"phases":5467,"primaryCompletion":366,"completion":366,"start":5468,"enrollment":94,"conditions":5469,"interventions":5470},"NCT01732263","Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function",[49],"2012-11-09",[1043,19],[5449],{"trials":5472,"activeCount":60},[],{"trials":5474,"activeCount":60},[],{"trials":5476,"activeCount":60},[],{"trials":5478,"activeCount":60},[],{"intervention":5383,"totalTrials":115,"cells":5480},{"EARLY_PHASE1":5481,"PHASE1":5483,"PHASE2":5489,"PHASE3":5491,"PHASE4":5493,"NA":5495},{"trials":5482,"activeCount":60},[],{"trials":5484,"activeCount":60},[5485],{"nctId":5376,"briefTitle":5377,"status":68,"phases":5486,"primaryCompletion":5379,"completion":5379,"start":5380,"enrollment":165,"conditions":5487,"interventions":5488},[49],[19],[5383,4099],{"trials":5490,"activeCount":60},[],{"trials":5492,"activeCount":60},[],{"trials":5494,"activeCount":60},[],{"trials":5496,"activeCount":60},[],{"intervention":5498,"totalTrials":115,"cells":5499},"Ciprofloxacin XR + MMX Placebo",{"EARLY_PHASE1":5500,"PHASE1":5502,"PHASE2":5513,"PHASE3":5515,"PHASE4":5517,"NA":5519},{"trials":5501,"activeCount":60},[],{"trials":5503,"activeCount":60},[5504],{"nctId":5505,"briefTitle":5506,"status":68,"phases":5507,"primaryCompletion":5508,"completion":5508,"start":5509,"enrollment":165,"conditions":5510,"interventions":5511},"NCT01402947","Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine\u002FMesalamine",[49],"2011-08-30","2011-07-25",[19],[5498,5512],"MMX Mesalazine\u002Fmesalamine + Ciprofloxacin XR",{"trials":5514,"activeCount":60},[],{"trials":5516,"activeCount":60},[],{"trials":5518,"activeCount":60},[],{"trials":5520,"activeCount":60},[],{"intervention":5512,"totalTrials":115,"cells":5522},{"EARLY_PHASE1":5523,"PHASE1":5525,"PHASE2":5531,"PHASE3":5533,"PHASE4":5535,"NA":5537},{"trials":5524,"activeCount":60},[],{"trials":5526,"activeCount":60},[5527],{"nctId":5505,"briefTitle":5506,"status":68,"phases":5528,"primaryCompletion":5508,"completion":5508,"start":5509,"enrollment":165,"conditions":5529,"interventions":5530},[49],[19],[5498,5512],{"trials":5532,"activeCount":60},[],{"trials":5534,"activeCount":60},[],{"trials":5536,"activeCount":60},[],{"trials":5538,"activeCount":60},[],{"intervention":2105,"totalTrials":115,"cells":5540},{"EARLY_PHASE1":5541,"PHASE1":5543,"PHASE2":5549,"PHASE3":5551,"PHASE4":5553,"NA":5555},{"trials":5542,"activeCount":60},[],{"trials":5544,"activeCount":60},[5545],{"nctId":2098,"briefTitle":2099,"status":68,"phases":5546,"primaryCompletion":2101,"completion":2101,"start":2102,"enrollment":20,"conditions":5547,"interventions":5548},[49],[30],[2091,2105],{"trials":5550,"activeCount":60},[],{"trials":5552,"activeCount":60},[],{"trials":5554,"activeCount":60},[],{"trials":5556,"activeCount":60},[],{"intervention":5558,"totalTrials":115,"cells":5559},"Lanthanum carbonate Granule Formulation",{"EARLY_PHASE1":5560,"PHASE1":5562,"PHASE2":5573,"PHASE3":5575,"PHASE4":5577,"NA":5579},{"trials":5561,"activeCount":60},[],{"trials":5563,"activeCount":60},[5564],{"nctId":5565,"briefTitle":5566,"status":68,"phases":5567,"primaryCompletion":5568,"completion":5568,"start":3222,"enrollment":4671,"conditions":5569,"interventions":5571},"NCT00880750","Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults",[49],"2009-06-22",[5570],"End Stage Renal Disease",[5558,5572],"Lanthanum carbonate Chewable",{"trials":5574,"activeCount":60},[],{"trials":5576,"activeCount":60},[],{"trials":5578,"activeCount":60},[],{"trials":5580,"activeCount":60},[],{"intervention":5572,"totalTrials":115,"cells":5582},{"EARLY_PHASE1":5583,"PHASE1":5585,"PHASE2":5591,"PHASE3":5593,"PHASE4":5595,"NA":5597},{"trials":5584,"activeCount":60},[],{"trials":5586,"activeCount":60},[5587],{"nctId":5565,"briefTitle":5566,"status":68,"phases":5588,"primaryCompletion":5568,"completion":5568,"start":3222,"enrollment":4671,"conditions":5589,"interventions":5590},[49],[5570],[5558,5572],{"trials":5592,"activeCount":60},[],{"trials":5594,"activeCount":60},[],{"trials":5596,"activeCount":60},[],{"trials":5598,"activeCount":60},[],{"intervention":5428,"totalTrials":115,"cells":5600},{"EARLY_PHASE1":5601,"PHASE1":5603,"PHASE2":5609,"PHASE3":5611,"PHASE4":5613,"NA":5615},{"trials":5602,"activeCount":60},[],{"trials":5604,"activeCount":60},[5605],{"nctId":5421,"briefTitle":5422,"status":68,"phases":5606,"primaryCompletion":5424,"completion":5424,"start":5425,"enrollment":1519,"conditions":5607,"interventions":5608},[49],[19],[5428,5429,5414],{"trials":5610,"activeCount":60},[],{"trials":5612,"activeCount":60},[],{"trials":5614,"activeCount":60},[],{"trials":5616,"activeCount":60},[],{"intervention":5429,"totalTrials":115,"cells":5618},{"EARLY_PHASE1":5619,"PHASE1":5621,"PHASE2":5627,"PHASE3":5629,"PHASE4":5631,"NA":5633},{"trials":5620,"activeCount":60},[],{"trials":5622,"activeCount":60},[5623],{"nctId":5421,"briefTitle":5422,"status":68,"phases":5624,"primaryCompletion":5424,"completion":5424,"start":5425,"enrollment":1519,"conditions":5625,"interventions":5626},[49],[19],[5428,5429,5414],{"trials":5628,"activeCount":60},[],{"trials":5630,"activeCount":60},[],{"trials":5632,"activeCount":60},[],{"trials":5634,"activeCount":60},[],{"intervention":5396,"totalTrials":115,"cells":5636},{"EARLY_PHASE1":5637,"PHASE1":5639,"PHASE2":5645,"PHASE3":5647,"PHASE4":5649,"NA":5651},{"trials":5638,"activeCount":60},[],{"trials":5640,"activeCount":60},[5641],{"nctId":5389,"briefTitle":5390,"status":68,"phases":5642,"primaryCompletion":5392,"completion":5392,"start":5393,"enrollment":165,"conditions":5643,"interventions":5644},[49],[19],[5396,4099],{"trials":5646,"activeCount":60},[],{"trials":5648,"activeCount":60},[],{"trials":5650,"activeCount":60},[],{"trials":5652,"activeCount":60},[],{"intervention":5654,"totalTrials":115,"cells":5655},"sulfamethoxazole + MMX placebo",{"EARLY_PHASE1":5656,"PHASE1":5658,"PHASE2":5669,"PHASE3":5671,"PHASE4":5673,"NA":5675},{"trials":5657,"activeCount":60},[],{"trials":5659,"activeCount":60},[5660],{"nctId":5661,"briefTitle":5662,"status":68,"phases":5663,"primaryCompletion":5664,"completion":5664,"start":5665,"enrollment":94,"conditions":5666,"interventions":5667},"NCT01469637","Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine\u002FMesalamine",[49],"2011-12-20","2011-11-07",[19],[5654,5668],"Sulfamethoxazole + MMX Mesalazine\u002Fmesalamine",{"trials":5670,"activeCount":60},[],{"trials":5672,"activeCount":60},[],{"trials":5674,"activeCount":60},[],{"trials":5676,"activeCount":60},[],{"intervention":5668,"totalTrials":115,"cells":5678},{"EARLY_PHASE1":5679,"PHASE1":5681,"PHASE2":5687,"PHASE3":5689,"PHASE4":5691,"NA":5693},{"trials":5680,"activeCount":60},[],{"trials":5682,"activeCount":60},[5683],{"nctId":5661,"briefTitle":5662,"status":68,"phases":5684,"primaryCompletion":5664,"completion":5664,"start":5665,"enrollment":94,"conditions":5685,"interventions":5686},[49],[19],[5654,5668],{"trials":5688,"activeCount":60},[],{"trials":5690,"activeCount":60},[],{"trials":5692,"activeCount":60},[],{"trials":5694,"activeCount":60},[],{"intervention":5696,"totalTrials":115,"cells":5697},"rhASA - Dose Level 1",{"EARLY_PHASE1":5698,"PHASE1":5700,"PHASE2":5711,"PHASE3":5713,"PHASE4":5715,"NA":5717},{"trials":5699,"activeCount":60},[],{"trials":5701,"activeCount":60},[5702],{"nctId":5703,"briefTitle":5704,"status":68,"phases":5705,"primaryCompletion":5706,"completion":5706,"start":4066,"enrollment":28,"conditions":5707,"interventions":5708},"NCT00418561","Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)",[49],"2008-03-27",[133],[5696,5709,5710],"rhASA - Dose Level 2","rhASA - Dose Level 3",{"trials":5712,"activeCount":60},[],{"trials":5714,"activeCount":60},[],{"trials":5716,"activeCount":60},[],{"trials":5718,"activeCount":60},[],{"intervention":5709,"totalTrials":115,"cells":5720},{"EARLY_PHASE1":5721,"PHASE1":5723,"PHASE2":5729,"PHASE3":5731,"PHASE4":5733,"NA":5735},{"trials":5722,"activeCount":60},[],{"trials":5724,"activeCount":60},[5725],{"nctId":5703,"briefTitle":5704,"status":68,"phases":5726,"primaryCompletion":5706,"completion":5706,"start":4066,"enrollment":28,"conditions":5727,"interventions":5728},[49],[133],[5696,5709,5710],{"trials":5730,"activeCount":60},[],{"trials":5732,"activeCount":60},[],{"trials":5734,"activeCount":60},[],{"trials":5736,"activeCount":60},[],{"intervention":5710,"totalTrials":115,"cells":5738},{"EARLY_PHASE1":5739,"PHASE1":5741,"PHASE2":5747,"PHASE3":5749,"PHASE4":5751,"NA":5753},{"trials":5740,"activeCount":60},[],{"trials":5742,"activeCount":60},[5743],{"nctId":5703,"briefTitle":5704,"status":68,"phases":5744,"primaryCompletion":5706,"completion":5706,"start":4066,"enrollment":28,"conditions":5745,"interventions":5746},[49],[133],[5696,5709,5710],{"trials":5748,"activeCount":60},[],{"trials":5750,"activeCount":60},[],{"trials":5752,"activeCount":60},[],{"trials":5754,"activeCount":60},[],{"intervention":5756,"totalTrials":115,"cells":5757},"Amoxicillin + MMX placebo",{"EARLY_PHASE1":5758,"PHASE1":5760,"PHASE2":5772,"PHASE3":5774,"PHASE4":5776,"NA":5778},{"trials":5759,"activeCount":60},[],{"trials":5761,"activeCount":60},[5762],{"nctId":5763,"briefTitle":5764,"status":68,"phases":5765,"primaryCompletion":5766,"completion":5766,"start":5767,"enrollment":5768,"conditions":5769,"interventions":5770},"NCT01442688","Amoxicillin Drug Interaction Study With MMX® Mesalazine\u002FMesalamine",[49],"2011-11-20","2011-10-07",62,[19],[5756,5771],"Amoxicillin + MMX mesalazine\u002Fmesalamine",{"trials":5773,"activeCount":60},[],{"trials":5775,"activeCount":60},[],{"trials":5777,"activeCount":60},[],{"trials":5779,"activeCount":60},[],{"intervention":5771,"totalTrials":115,"cells":5781},{"EARLY_PHASE1":5782,"PHASE1":5784,"PHASE2":5790,"PHASE3":5792,"PHASE4":5794,"NA":5796},{"trials":5783,"activeCount":60},[],{"trials":5785,"activeCount":60},[5786],{"nctId":5763,"briefTitle":5764,"status":68,"phases":5787,"primaryCompletion":5766,"completion":5766,"start":5767,"enrollment":5768,"conditions":5788,"interventions":5789},[49],[19],[5756,5771],{"trials":5791,"activeCount":60},[],{"trials":5793,"activeCount":60},[],{"trials":5795,"activeCount":60},[],{"trials":5797,"activeCount":60},[],{"intervention":158,"totalTrials":115,"cells":5799},{"EARLY_PHASE1":5800,"PHASE1":5802,"PHASE2":5808,"PHASE3":5810,"PHASE4":5812,"NA":5814},{"trials":5801,"activeCount":60},[],{"trials":5803,"activeCount":60},[5804],{"nctId":150,"briefTitle":151,"status":68,"phases":5805,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":5806,"interventions":5807},[49],[30],[142,158],{"trials":5809,"activeCount":60},[],{"trials":5811,"activeCount":60},[],{"trials":5813,"activeCount":60},[],{"trials":5815,"activeCount":60},[],{"intervention":5817,"totalTrials":115,"cells":5818},"Radiolabeled Prucalopride Succinate",{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5830,"PHASE3":5832,"PHASE4":5834,"NA":5836},{"trials":5820,"activeCount":60},[],{"trials":5822,"activeCount":60},[5823],{"nctId":5824,"briefTitle":5825,"status":68,"phases":5826,"primaryCompletion":5827,"completion":5827,"start":4838,"enrollment":1424,"conditions":5828,"interventions":5829},"NCT01807000","Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers",[49],"2013-04-28",[19],[5817],{"trials":5831,"activeCount":60},[],{"trials":5833,"activeCount":60},[],{"trials":5835,"activeCount":60},[],{"trials":5837,"activeCount":60},[],{"intervention":5839,"totalTrials":115,"cells":5840},"Sevelamer",{"EARLY_PHASE1":5841,"PHASE1":5843,"PHASE2":5854,"PHASE3":5856,"PHASE4":5858,"NA":5860},{"trials":5842,"activeCount":60},[],{"trials":5844,"activeCount":60},[5845],{"nctId":5846,"briefTitle":5847,"status":68,"phases":5848,"primaryCompletion":5849,"completion":5849,"start":5850,"enrollment":308,"conditions":5851,"interventions":5853},"NCT00875017","Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers",[49],"2009-06-16","2009-04-20",[5852],"Kidney Failure, Chronic",[4912,5839],{"trials":5855,"activeCount":60},[],{"trials":5857,"activeCount":60},[],{"trials":5859,"activeCount":60},[],{"trials":5861,"activeCount":60},[],{"intervention":2243,"totalTrials":115,"cells":5863},{"EARLY_PHASE1":5864,"PHASE1":5866,"PHASE2":5872,"PHASE3":5874,"PHASE4":5876,"NA":5878},{"trials":5865,"activeCount":60},[],{"trials":5867,"activeCount":60},[5868],{"nctId":2236,"briefTitle":2237,"status":68,"phases":5869,"primaryCompletion":2239,"completion":2239,"start":2240,"enrollment":1579,"conditions":5870,"interventions":5871},[49],[25],[2229,2243],{"trials":5873,"activeCount":60},[],{"trials":5875,"activeCount":60},[],{"trials":5877,"activeCount":60},[],{"trials":5879,"activeCount":60},[],{"intervention":5881,"totalTrials":115,"cells":5882},"Mesalamine",{"EARLY_PHASE1":5883,"PHASE1":5885,"PHASE2":5895,"PHASE3":5897,"PHASE4":5899,"NA":5901},{"trials":5884,"activeCount":60},[],{"trials":5886,"activeCount":60},[5887],{"nctId":5888,"briefTitle":5889,"status":68,"phases":5890,"primaryCompletion":5891,"completion":5891,"start":5892,"enrollment":184,"conditions":5893,"interventions":5894},"NCT02125292","Taste Assessment Study of SHP429 in Healthy Adult Subjects",[49],"2014-06-19","2014-06-02",[19],[5881],{"trials":5896,"activeCount":60},[],{"trials":5898,"activeCount":60},[],{"trials":5900,"activeCount":60},[],{"trials":5902,"activeCount":60},[],{"intervention":5904,"totalTrials":115,"cells":5905},"SHP681",{"EARLY_PHASE1":5906,"PHASE1":5908,"PHASE2":5918,"PHASE3":5920,"PHASE4":5922,"NA":5924},{"trials":5907,"activeCount":60},[],{"trials":5909,"activeCount":60},[5910],{"nctId":5911,"briefTitle":5912,"status":68,"phases":5913,"primaryCompletion":1181,"completion":1181,"start":5914,"enrollment":5915,"conditions":5916,"interventions":5917},"NCT03859323","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants",[49],"2019-03-26",104,[30],[5904],{"trials":5919,"activeCount":60},[],{"trials":5921,"activeCount":60},[],{"trials":5923,"activeCount":60},[],{"trials":5925,"activeCount":60},[],{"intervention":5927,"totalTrials":115,"cells":5928},"TAK-755",{"EARLY_PHASE1":5929,"PHASE1":5931,"PHASE2":5943,"PHASE3":5945,"PHASE4":5947,"NA":5949},{"trials":5930,"activeCount":60},[],{"trials":5932,"activeCount":60},[5933],{"nctId":5934,"briefTitle":5935,"status":68,"phases":5936,"primaryCompletion":5937,"completion":5937,"start":5938,"enrollment":5939,"conditions":5940,"interventions":5942},"NCT03997760","A Study of SHP655 (rADAMTS13) in Sickle Cell Disease",[49],"2022-10-26","2019-10-21",19,[5941],"Sickle Cell Disease",[5927],{"trials":5944,"activeCount":60},[],{"trials":5946,"activeCount":60},[],{"trials":5948,"activeCount":60},[],{"trials":5950,"activeCount":60},[],{"intervention":5952,"totalTrials":115,"cells":5953},"VP 20629",{"EARLY_PHASE1":5954,"PHASE1":5956,"PHASE2":5967,"PHASE3":5969,"PHASE4":5971,"NA":5973},{"trials":5955,"activeCount":60},[],{"trials":5957,"activeCount":60},[5958],{"nctId":5959,"briefTitle":5960,"status":68,"phases":5961,"primaryCompletion":1772,"completion":1772,"start":5962,"enrollment":5963,"conditions":5964,"interventions":5966},"NCT01898884","Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia",[49],"2013-08-13",46,[5965],"Friedreich's Ataxia",[5952],{"trials":5968,"activeCount":60},[],{"trials":5970,"activeCount":60},[],{"trials":5972,"activeCount":60},[],{"trials":5974,"activeCount":60},[],{"intervention":5976,"totalTrials":115,"cells":5977},"Radiolabeled SPD557",{"EARLY_PHASE1":5978,"PHASE1":5980,"PHASE2":5990,"PHASE3":5992,"PHASE4":5994,"NA":5996},{"trials":5979,"activeCount":60},[],{"trials":5981,"activeCount":60},[5982],{"nctId":5983,"briefTitle":5984,"status":68,"phases":5985,"primaryCompletion":5986,"completion":5986,"start":5987,"enrollment":1424,"conditions":5988,"interventions":5989},"NCT01786876","Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers",[49],"2013-04-12","2013-03-07",[30],[5976],{"trials":5991,"activeCount":60},[],{"trials":5993,"activeCount":60},[],{"trials":5995,"activeCount":60},[],{"trials":5997,"activeCount":60},[],{"intervention":5999,"totalTrials":115,"cells":6000},"Recombinant human C1 esterase inhibitor",{"EARLY_PHASE1":6001,"PHASE1":6003,"PHASE2":6015,"PHASE3":6017,"PHASE4":6019,"NA":6021},{"trials":6002,"activeCount":60},[],{"trials":6004,"activeCount":60},[6005],{"nctId":6006,"briefTitle":6007,"status":68,"phases":6008,"primaryCompletion":6009,"completion":6009,"start":6010,"enrollment":6011,"conditions":6012,"interventions":6013},"NCT02663687","Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects",[49],"2016-12-05","2016-02-19",48,[16],[5999,6014],"SHP623",{"trials":6016,"activeCount":60},[],{"trials":6018,"activeCount":60},[],{"trials":6020,"activeCount":60},[],{"trials":6022,"activeCount":60},[],{"intervention":6014,"totalTrials":115,"cells":6024},{"EARLY_PHASE1":6025,"PHASE1":6027,"PHASE2":6033,"PHASE3":6035,"PHASE4":6037,"NA":6039},{"trials":6026,"activeCount":60},[],{"trials":6028,"activeCount":60},[6029],{"nctId":6006,"briefTitle":6007,"status":68,"phases":6030,"primaryCompletion":6009,"completion":6009,"start":6010,"enrollment":6011,"conditions":6031,"interventions":6032},[49],[16],[5999,6014],{"trials":6034,"activeCount":60},[],{"trials":6036,"activeCount":60},[],{"trials":6038,"activeCount":60},[],{"trials":6040,"activeCount":60},[],{"intervention":6042,"totalTrials":115,"cells":6043},"Radiolabeled SPD602",{"EARLY_PHASE1":6044,"PHASE1":6046,"PHASE2":6055,"PHASE3":6057,"PHASE4":6059,"NA":6061},{"trials":6045,"activeCount":60},[],{"trials":6047,"activeCount":60},[6048],{"nctId":6049,"briefTitle":6050,"status":68,"phases":6051,"primaryCompletion":6052,"completion":6052,"start":452,"enrollment":1424,"conditions":6053,"interventions":6054},"NCT01824446","AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184",[49],"2013-05-29",[19],[6042],{"trials":6056,"activeCount":60},[],{"trials":6058,"activeCount":60},[],{"trials":6060,"activeCount":60},[],{"trials":6062,"activeCount":60},[],{"intervention":1175,"totalTrials":115,"cells":6064},{"EARLY_PHASE1":6065,"PHASE1":6067,"PHASE2":6073,"PHASE3":6075,"PHASE4":6077,"NA":6079},{"trials":6066,"activeCount":60},[],{"trials":6068,"activeCount":60},[6069],{"nctId":1167,"briefTitle":1168,"status":68,"phases":6070,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":184,"conditions":6071,"interventions":6072},[49],[1173],[1175,1152,1176],{"trials":6074,"activeCount":60},[],{"trials":6076,"activeCount":60},[],{"trials":6078,"activeCount":60},[],{"trials":6080,"activeCount":60},[],{"intervention":1176,"totalTrials":115,"cells":6082},{"EARLY_PHASE1":6083,"PHASE1":6085,"PHASE2":6091,"PHASE3":6093,"PHASE4":6095,"NA":6097},{"trials":6084,"activeCount":60},[],{"trials":6086,"activeCount":60},[6087],{"nctId":1167,"briefTitle":1168,"status":68,"phases":6088,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":184,"conditions":6089,"interventions":6090},[49],[1173],[1175,1152,1176],{"trials":6092,"activeCount":60},[],{"trials":6094,"activeCount":60},[],{"trials":6096,"activeCount":60},[],{"trials":6098,"activeCount":60},[],{"intervention":177,"totalTrials":115,"cells":6100},{"EARLY_PHASE1":6101,"PHASE1":6103,"PHASE2":6109,"PHASE3":6111,"PHASE4":6113,"NA":6115},{"trials":6102,"activeCount":60},[],{"trials":6104,"activeCount":60},[6105],{"nctId":169,"briefTitle":170,"status":79,"phases":6106,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":6107,"interventions":6108},[49],[19],[142,177],{"trials":6110,"activeCount":60},[],{"trials":6112,"activeCount":60},[],{"trials":6114,"activeCount":60},[],{"trials":6116,"activeCount":60},[],{"intervention":6118,"totalTrials":115,"cells":6119},"LDX + Venlafaxine XR",{"EARLY_PHASE1":6120,"PHASE1":6122,"PHASE2":6134,"PHASE3":6136,"PHASE4":6138,"NA":6140},{"trials":6121,"activeCount":60},[],{"trials":6123,"activeCount":60},[6124],{"nctId":6125,"briefTitle":6126,"status":68,"phases":6127,"primaryCompletion":6128,"completion":453,"start":6129,"enrollment":6130,"conditions":6131,"interventions":6132},"NCT01235338","Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers",[49],"2010-12-30","2010-10-28",80,[19],[6118,6133],"Venlafaxine XR + LDX",{"trials":6135,"activeCount":60},[],{"trials":6137,"activeCount":60},[],{"trials":6139,"activeCount":60},[],{"trials":6141,"activeCount":60},[],{"intervention":6133,"totalTrials":115,"cells":6143},{"EARLY_PHASE1":6144,"PHASE1":6146,"PHASE2":6152,"PHASE3":6154,"PHASE4":6156,"NA":6158},{"trials":6145,"activeCount":60},[],{"trials":6147,"activeCount":60},[6148],{"nctId":6125,"briefTitle":6126,"status":68,"phases":6149,"primaryCompletion":6128,"completion":453,"start":6129,"enrollment":6130,"conditions":6150,"interventions":6151},[49],[19],[6118,6133],{"trials":6153,"activeCount":60},[],{"trials":6155,"activeCount":60},[],{"trials":6157,"activeCount":60},[],{"trials":6159,"activeCount":60},[],{"intervention":1361,"totalTrials":115,"cells":6161},{"EARLY_PHASE1":6162,"PHASE1":6164,"PHASE2":6170,"PHASE3":6172,"PHASE4":6174,"NA":6176},{"trials":6163,"activeCount":60},[],{"trials":6165,"activeCount":60},[6166],{"nctId":1353,"briefTitle":1354,"status":68,"phases":6167,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":1358,"conditions":6168,"interventions":6169},[49],[19],[710,1361,1362],{"trials":6171,"activeCount":60},[],{"trials":6173,"activeCount":60},[],{"trials":6175,"activeCount":60},[],{"trials":6177,"activeCount":60},[],{"intervention":1362,"totalTrials":115,"cells":6179},{"EARLY_PHASE1":6180,"PHASE1":6182,"PHASE2":6188,"PHASE3":6190,"PHASE4":6192,"NA":6194},{"trials":6181,"activeCount":60},[],{"trials":6183,"activeCount":60},[6184],{"nctId":1353,"briefTitle":1354,"status":68,"phases":6185,"primaryCompletion":1356,"completion":1356,"start":1357,"enrollment":1358,"conditions":6186,"interventions":6187},[49],[19],[710,1361,1362],{"trials":6189,"activeCount":60},[],{"trials":6191,"activeCount":60},[],{"trials":6193,"activeCount":60},[],{"trials":6195,"activeCount":60},[],{"intervention":712,"totalTrials":115,"cells":6197},{"EARLY_PHASE1":6198,"PHASE1":6200,"PHASE2":6206,"PHASE3":6208,"PHASE4":6210,"NA":6212},{"trials":6199,"activeCount":60},[],{"trials":6201,"activeCount":60},[6202],{"nctId":702,"briefTitle":703,"status":68,"phases":6203,"primaryCompletion":705,"completion":705,"start":706,"enrollment":707,"conditions":6204,"interventions":6205},[49],[19],[710,711,712],{"trials":6207,"activeCount":60},[],{"trials":6209,"activeCount":60},[],{"trials":6211,"activeCount":60},[],{"trials":6213,"activeCount":60},[],{"intervention":1035,"totalTrials":115,"cells":6215},{"EARLY_PHASE1":6216,"PHASE1":6218,"PHASE2":6224,"PHASE3":6226,"PHASE4":6228,"NA":6230},{"trials":6217,"activeCount":60},[],{"trials":6219,"activeCount":60},[6220],{"nctId":1026,"briefTitle":1027,"status":68,"phases":6221,"primaryCompletion":1029,"completion":1029,"start":1030,"enrollment":1031,"conditions":6222,"interventions":6223},[49],[1033],[1015,1015,1035],{"trials":6225,"activeCount":60},[],{"trials":6227,"activeCount":60},[],{"trials":6229,"activeCount":60},[],{"trials":6231,"activeCount":60},[],{"intervention":5438,"totalTrials":115,"cells":6233},{"EARLY_PHASE1":6234,"PHASE1":6236,"PHASE2":6242,"PHASE3":6244,"PHASE4":6246,"NA":6248},{"trials":6235,"activeCount":60},[],{"trials":6237,"activeCount":60},[6238],{"nctId":5431,"briefTitle":5432,"status":68,"phases":6239,"primaryCompletion":5434,"completion":5434,"start":5435,"enrollment":1374,"conditions":6240,"interventions":6241},[49],[30],[5438,5439],{"trials":6243,"activeCount":60},[],{"trials":6245,"activeCount":60},[],{"trials":6247,"activeCount":60},[],{"trials":6249,"activeCount":60},[],{"intervention":628,"totalTrials":115,"cells":6251},{"EARLY_PHASE1":6252,"PHASE1":6254,"PHASE2":6260,"PHASE3":6262,"PHASE4":6264,"NA":6266},{"trials":6253,"activeCount":60},[],{"trials":6255,"activeCount":60},[6256],{"nctId":620,"briefTitle":621,"status":68,"phases":6257,"primaryCompletion":623,"completion":623,"start":624,"enrollment":625,"conditions":6258,"interventions":6259},[49],[213],[628,629],{"trials":6261,"activeCount":60},[],{"trials":6263,"activeCount":60},[],{"trials":6265,"activeCount":60},[],{"trials":6267,"activeCount":60},[],{"intervention":188,"totalTrials":115,"cells":6269},{"EARLY_PHASE1":6270,"PHASE1":6272,"PHASE2":6278,"PHASE3":6280,"PHASE4":6282,"NA":6284},{"trials":6271,"activeCount":60},[],{"trials":6273,"activeCount":60},[6274],{"nctId":179,"briefTitle":180,"status":68,"phases":6275,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":6276,"interventions":6277},[49],[186],[142,188,189],{"trials":6279,"activeCount":60},[],{"trials":6281,"activeCount":60},[],{"trials":6283,"activeCount":60},[],{"trials":6285,"activeCount":60},[],{"intervention":189,"totalTrials":115,"cells":6287},{"EARLY_PHASE1":6288,"PHASE1":6290,"PHASE2":6296,"PHASE3":6298,"PHASE4":6300,"NA":6302},{"trials":6289,"activeCount":60},[],{"trials":6291,"activeCount":60},[6292],{"nctId":179,"briefTitle":180,"status":68,"phases":6293,"primaryCompletion":182,"completion":182,"start":183,"enrollment":184,"conditions":6294,"interventions":6295},[49],[186],[142,188,189],{"trials":6297,"activeCount":60},[],{"trials":6299,"activeCount":60},[],{"trials":6301,"activeCount":60},[],{"trials":6303,"activeCount":60},[],{"intervention":6305,"totalTrials":115,"cells":6306},"SHP639",{"EARLY_PHASE1":6307,"PHASE1":6309,"PHASE2":6320,"PHASE3":6322,"PHASE4":6324,"NA":6326},{"trials":6308,"activeCount":60},[],{"trials":6310,"activeCount":60},[6311],{"nctId":6312,"briefTitle":6313,"status":68,"phases":6314,"primaryCompletion":1631,"completion":1631,"start":6315,"enrollment":4907,"conditions":6316,"interventions":6319},"NCT03131167","Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma",[49],"2017-05-10",[6317,6318],"Primary Open-angle Glaucoma (POAG)","Ocular Hypertension",[6305],{"trials":6321,"activeCount":60},[],{"trials":6323,"activeCount":60},[],{"trials":6325,"activeCount":60},[],{"trials":6327,"activeCount":60},[],{"intervention":6329,"totalTrials":115,"cells":6330},"SSP-002358",{"EARLY_PHASE1":6331,"PHASE1":6333,"PHASE2":6343,"PHASE3":6345,"PHASE4":6347,"NA":6349},{"trials":6332,"activeCount":60},[],{"trials":6334,"activeCount":60},[6335],{"nctId":6336,"briefTitle":6337,"status":68,"phases":6338,"primaryCompletion":1857,"completion":1857,"start":6339,"enrollment":707,"conditions":6340,"interventions":6341},"NCT01415349","SSP-002358 Drug Interaction Study With Omeprazole",[49],"2011-08-11",[19],[6329,6342],"SSP-002358 + omeprazole",{"trials":6344,"activeCount":60},[],{"trials":6346,"activeCount":60},[],{"trials":6348,"activeCount":60},[],{"trials":6350,"activeCount":60},[],{"intervention":6342,"totalTrials":115,"cells":6352},{"EARLY_PHASE1":6353,"PHASE1":6355,"PHASE2":6361,"PHASE3":6363,"PHASE4":6365,"NA":6367},{"trials":6354,"activeCount":60},[],{"trials":6356,"activeCount":60},[6357],{"nctId":6336,"briefTitle":6337,"status":68,"phases":6358,"primaryCompletion":1857,"completion":1857,"start":6339,"enrollment":707,"conditions":6359,"interventions":6360},[49],[19],[6329,6342],{"trials":6362,"activeCount":60},[],{"trials":6364,"activeCount":60},[],{"trials":6366,"activeCount":60},[],{"trials":6368,"activeCount":60},[],{"intervention":6370,"totalTrials":115,"cells":6371},"Metronidazole + MMX Mesalazine\u002Fmesalamine placebo",{"EARLY_PHASE1":6372,"PHASE1":6374,"PHASE2":6385,"PHASE3":6387,"PHASE4":6389,"NA":6391},{"trials":6373,"activeCount":60},[],{"trials":6375,"activeCount":60},[6376],{"nctId":6377,"briefTitle":6378,"status":68,"phases":6379,"primaryCompletion":6380,"completion":6380,"start":6381,"enrollment":165,"conditions":6382,"interventions":6383},"NCT01418365","Metronidazole Drug Interaction Study With MMX® Mesalazine\u002FMesalamine",[49],"2011-10-05","2011-08-22",[19],[6370,6384],"Metronidazole + MMX Mesalazine\u002Fmesalamine",{"trials":6386,"activeCount":60},[],{"trials":6388,"activeCount":60},[],{"trials":6390,"activeCount":60},[],{"trials":6392,"activeCount":60},[],{"intervention":6384,"totalTrials":115,"cells":6394},{"EARLY_PHASE1":6395,"PHASE1":6397,"PHASE2":6403,"PHASE3":6405,"PHASE4":6407,"NA":6409},{"trials":6396,"activeCount":60},[],{"trials":6398,"activeCount":60},[6399],{"nctId":6377,"briefTitle":6378,"status":68,"phases":6400,"primaryCompletion":6380,"completion":6380,"start":6381,"enrollment":165,"conditions":6401,"interventions":6402},[49],[19],[6370,6384],{"trials":6404,"activeCount":60},[],{"trials":6406,"activeCount":60},[],{"trials":6408,"activeCount":60},[],{"trials":6410,"activeCount":60},[],{"intervention":6412,"totalTrials":115,"cells":6413},"Calcitriol",{"EARLY_PHASE1":6414,"PHASE1":6416,"PHASE2":6427,"PHASE3":6429,"PHASE4":6431,"NA":6433},{"trials":6415,"activeCount":60},[],{"trials":6417,"activeCount":60},[6418],{"nctId":6419,"briefTitle":6420,"status":68,"phases":6421,"primaryCompletion":2300,"completion":2300,"start":6422,"enrollment":2116,"conditions":6423,"interventions":6424},"NCT00925704","The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers",[49],"2009-06-01",[19],[6412,6425,6426],"Lanthanum carbonate + Calcitriol","Sevelamer carbonate + Calcitriol",{"trials":6428,"activeCount":60},[],{"trials":6430,"activeCount":60},[],{"trials":6432,"activeCount":60},[],{"trials":6434,"activeCount":60},[],{"intervention":6425,"totalTrials":115,"cells":6436},{"EARLY_PHASE1":6437,"PHASE1":6439,"PHASE2":6445,"PHASE3":6447,"PHASE4":6449,"NA":6451},{"trials":6438,"activeCount":60},[],{"trials":6440,"activeCount":60},[6441],{"nctId":6419,"briefTitle":6420,"status":68,"phases":6442,"primaryCompletion":2300,"completion":2300,"start":6422,"enrollment":2116,"conditions":6443,"interventions":6444},[49],[19],[6412,6425,6426],{"trials":6446,"activeCount":60},[],{"trials":6448,"activeCount":60},[],{"trials":6450,"activeCount":60},[],{"trials":6452,"activeCount":60},[],{"intervention":6426,"totalTrials":115,"cells":6454},{"EARLY_PHASE1":6455,"PHASE1":6457,"PHASE2":6463,"PHASE3":6465,"PHASE4":6467,"NA":6469},{"trials":6456,"activeCount":60},[],{"trials":6458,"activeCount":60},[6459],{"nctId":6419,"briefTitle":6420,"status":68,"phases":6460,"primaryCompletion":2300,"completion":2300,"start":6422,"enrollment":2116,"conditions":6461,"interventions":6462},[49],[19],[6412,6425,6426],{"trials":6464,"activeCount":60},[],{"trials":6466,"activeCount":60},[],{"trials":6468,"activeCount":60},[],{"trials":6470,"activeCount":60},[],{"intervention":6472,"totalTrials":115,"cells":6473},"Deferitazole",{"EARLY_PHASE1":6474,"PHASE1":6476,"PHASE2":6486,"PHASE3":6488,"PHASE4":6490,"NA":6492},{"trials":6475,"activeCount":60},[],{"trials":6477,"activeCount":60},[6478],{"nctId":6479,"briefTitle":6480,"status":391,"phases":6481,"primaryCompletion":6482,"completion":6482,"start":6483,"enrollment":60,"conditions":6484,"interventions":6485},"NCT02065401","Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)",[49],"2014-03-19","2014-02-28",[19],[6472,6472,6472],{"trials":6487,"activeCount":60},[],{"trials":6489,"activeCount":60},[],{"trials":6491,"activeCount":60},[],{"trials":6493,"activeCount":60},[],{"intervention":6495,"totalTrials":115,"cells":6496},"25mcg rhPTH",{"EARLY_PHASE1":6497,"PHASE1":6499,"PHASE2":6511,"PHASE3":6513,"PHASE4":6515,"NA":6517},{"trials":6498,"activeCount":60},[],{"trials":6500,"activeCount":60},[6501],{"nctId":6502,"briefTitle":6503,"status":68,"phases":6504,"primaryCompletion":6505,"completion":6505,"start":6506,"enrollment":1469,"conditions":6507,"interventions":6508},"NCT02781844","Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism",[49],"2019-03-08","2017-04-03",[567],[6495,6509,6510],"50mcg rhPTH","100mcg rhPTH",{"trials":6512,"activeCount":60},[],{"trials":6514,"activeCount":60},[],{"trials":6516,"activeCount":60},[],{"trials":6518,"activeCount":60},[],{"intervention":6509,"totalTrials":115,"cells":6520},{"EARLY_PHASE1":6521,"PHASE1":6523,"PHASE2":6529,"PHASE3":6531,"PHASE4":6533,"NA":6535},{"trials":6522,"activeCount":60},[],{"trials":6524,"activeCount":60},[6525],{"nctId":6502,"briefTitle":6503,"status":68,"phases":6526,"primaryCompletion":6505,"completion":6505,"start":6506,"enrollment":1469,"conditions":6527,"interventions":6528},[49],[567],[6495,6509,6510],{"trials":6530,"activeCount":60},[],{"trials":6532,"activeCount":60},[],{"trials":6534,"activeCount":60},[],{"trials":6536,"activeCount":60},[],{"intervention":6510,"totalTrials":115,"cells":6538},{"EARLY_PHASE1":6539,"PHASE1":6541,"PHASE2":6547,"PHASE3":6549,"PHASE4":6551,"NA":6553},{"trials":6540,"activeCount":60},[],{"trials":6542,"activeCount":60},[6543],{"nctId":6502,"briefTitle":6503,"status":68,"phases":6544,"primaryCompletion":6505,"completion":6505,"start":6506,"enrollment":1469,"conditions":6545,"interventions":6546},[49],[567],[6495,6509,6510],{"trials":6548,"activeCount":60},[],{"trials":6550,"activeCount":60},[],{"trials":6552,"activeCount":60},[],{"trials":6554,"activeCount":60},[],{"intervention":6556,"totalTrials":115,"cells":6557},"SHP643",{"EARLY_PHASE1":6558,"PHASE1":6560,"PHASE2":6571,"PHASE3":6573,"PHASE4":6575,"NA":6577},{"trials":6559,"activeCount":60},[],{"trials":6561,"activeCount":60},[6562],{"nctId":6563,"briefTitle":6564,"status":68,"phases":6565,"primaryCompletion":6566,"completion":6566,"start":6567,"enrollment":6568,"conditions":6569,"interventions":6570},"NCT03918239","A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.",[49],"2019-11-13","2019-05-14",190,[30],[6556],{"trials":6572,"activeCount":60},[],{"trials":6574,"activeCount":60},[],{"trials":6576,"activeCount":60},[],{"trials":6578,"activeCount":60},[],{"intervention":6580,"totalTrials":115,"cells":6581},"lumbar puncture",{"EARLY_PHASE1":6582,"PHASE1":6584,"PHASE2":6600,"PHASE3":6602,"PHASE4":6604,"NA":6606},{"trials":6583,"activeCount":60},[],{"trials":6585,"activeCount":60},[6586],{"nctId":6587,"briefTitle":6588,"status":68,"phases":6589,"primaryCompletion":6590,"completion":6591,"start":6592,"enrollment":6593,"conditions":6594,"interventions":6599},"NCT01387594","Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs",[49],"2014-03-31","2015-11-26","2012-05-03",49,[1056,6595,6596,6597,6598,27],"Ileitis","Ileo-colonic and Colonic Crohn's Disease","Granulomatous Colitis","Regional Enteritis",[6580],{"trials":6601,"activeCount":60},[],{"trials":6603,"activeCount":60},[],{"trials":6605,"activeCount":60},[],{"trials":6607,"activeCount":60},[],{"intervention":6609,"totalTrials":31,"cells":6610},"Lanthanum carbonate",{"EARLY_PHASE1":6611,"PHASE1":6613,"PHASE2":6619,"PHASE3":6642,"PHASE4":6678,"NA":6697},{"trials":6612,"activeCount":60},[],{"trials":6614,"activeCount":60},[6615],{"nctId":5846,"briefTitle":5847,"status":68,"phases":6616,"primaryCompletion":5849,"completion":5849,"start":5850,"enrollment":308,"conditions":6617,"interventions":6618},[49],[5852],[4912,5839],{"trials":6620,"activeCount":60},[6621,6630,6638],{"nctId":6622,"briefTitle":6623,"status":68,"phases":6624,"primaryCompletion":6625,"completion":6625,"start":6626,"enrollment":1319,"conditions":6627,"interventions":6629},"NCT00234702","Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease",[50],"2007-06-01","2006-01-11",[6628],"Kidney Diseases",[6609],{"nctId":6631,"briefTitle":6632,"status":68,"phases":6633,"primaryCompletion":6634,"completion":6634,"start":6635,"enrollment":103,"conditions":6636,"interventions":6637},"NCT01128179","Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD",[50],"2012-04-16","2010-12-06",[4909],[6609],{"nctId":4902,"briefTitle":4903,"status":68,"phases":6639,"primaryCompletion":4905,"completion":4905,"start":4906,"enrollment":4907,"conditions":6640,"interventions":6641},[50],[4909,4910],[4912,4893],{"trials":6643,"activeCount":60},[6644,6652,6660,6669],{"nctId":6645,"briefTitle":6646,"status":68,"phases":6647,"primaryCompletion":6648,"completion":6648,"start":6649,"enrollment":6011,"conditions":6650,"interventions":6651},"NCT00151918","Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease",[51],"2005-08-22","2005-01-07",[5852],[6609],{"nctId":6653,"briefTitle":6654,"status":68,"phases":6655,"primaryCompletion":6656,"completion":6656,"start":6657,"enrollment":599,"conditions":6658,"interventions":6659},"NCT00150540","A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.",[51],"2005-06-29","2002-10-14",[5852],[6609],{"nctId":6661,"briefTitle":6662,"status":68,"phases":6663,"primaryCompletion":6664,"completion":6664,"start":6665,"enrollment":6666,"conditions":6667,"interventions":6668},"NCT00151931","Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis",[51],"2006-01-12","2004-05-11",456,[5852],[6609],{"nctId":6670,"briefTitle":6671,"status":68,"phases":6672,"primaryCompletion":6673,"completion":6673,"start":6674,"enrollment":6675,"conditions":6676,"interventions":6677},"NCT00150566","Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood",[51],"2005-10-08","2004-02-09",460,[5852],[6609],{"trials":6679,"activeCount":60},[6680,6688],{"nctId":6681,"briefTitle":6682,"status":68,"phases":6683,"primaryCompletion":6684,"completion":6684,"start":1722,"enrollment":6685,"conditions":6686,"interventions":6687},"NCT00160121","Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease",[52],"2005-12-13",2500,[5852],[6609],{"nctId":6689,"briefTitle":6690,"status":79,"phases":6691,"primaryCompletion":6692,"completion":6692,"start":6693,"enrollment":6694,"conditions":6695,"interventions":6696},"NCT00452478","Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5",[52],"2007-12-10","2007-05-22",68,[6628],[6609],{"trials":6698,"activeCount":60},[6699,6707],{"nctId":6700,"briefTitle":6701,"status":68,"phases":6702,"primaryCompletion":6703,"completion":6703,"start":6704,"enrollment":1469,"conditions":6705,"interventions":6706},"NCT00557323","Long-term Effect of Lanthanum Carbonate on Bone",[],"2010-08-31","2007-03-15",[4910],[6609],{"nctId":6708,"briefTitle":6709,"status":68,"phases":6710,"primaryCompletion":6711,"completion":6711,"start":6712,"enrollment":5460,"conditions":6713,"interventions":6714},"NCT01130831","Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy",[],"2012-06-12","2010-04-26",[5570],[6609],{"intervention":3117,"totalTrials":1424,"cells":6716},{"EARLY_PHASE1":6717,"PHASE1":6719,"PHASE2":6721,"PHASE3":6731,"PHASE4":6753,"NA":6764},{"trials":6718,"activeCount":60},[],{"trials":6720,"activeCount":60},[],{"trials":6722,"activeCount":60},[6723],{"nctId":6724,"briefTitle":6725,"status":68,"phases":6726,"primaryCompletion":6727,"completion":6727,"start":3952,"enrollment":1144,"conditions":6728,"interventions":6730},"NCT01685216","Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease",[49,50],"2015-03-15",[6729],"Gaucher Disease, Type 3",[3117],{"trials":6732,"activeCount":60},[6733,6741,6745],{"nctId":6734,"briefTitle":6735,"status":68,"phases":6736,"primaryCompletion":6737,"completion":6737,"start":6738,"enrollment":1424,"conditions":6739,"interventions":6740},"NCT01614574","Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease",[51],"2013-05-25","2012-03-02",[2456],[3117],{"nctId":3110,"briefTitle":3111,"status":68,"phases":6742,"primaryCompletion":3113,"completion":3113,"start":3114,"enrollment":1469,"conditions":6743,"interventions":6744},[51],[2565],[3117,3099],{"nctId":6746,"briefTitle":6747,"status":68,"phases":6748,"primaryCompletion":6749,"completion":6749,"start":6750,"enrollment":56,"conditions":6751,"interventions":6752},"NCT01842841","Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease",[51],"2014-10-08","2013-03-13",[2456],[3117],{"trials":6754,"activeCount":60},[6755],{"nctId":6756,"briefTitle":6757,"status":68,"phases":6758,"primaryCompletion":1162,"completion":6759,"start":6760,"enrollment":909,"conditions":6761,"interventions":6762},"NCT02574286","Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease",[52],"2020-11-30","2016-06-29",[2456],[6763],"Velaglucerase alfa",{"trials":6765,"activeCount":60},[6766],{"nctId":6767,"briefTitle":6768,"status":6769,"phases":6770,"conditions":6771,"interventions":6772},"NCT00954460","Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease","APPROVED_FOR_MARKETING",[],[2565],[3117],{"intervention":2524,"totalTrials":56,"cells":6774},{"EARLY_PHASE1":6775,"PHASE1":6777,"PHASE2":6779,"PHASE3":6781,"PHASE4":6806,"NA":6808},{"trials":6776,"activeCount":60},[],{"trials":6778,"activeCount":60},[],{"trials":6780,"activeCount":60},[],{"trials":6782,"activeCount":60},[6783,6787,6795,6799],{"nctId":2516,"briefTitle":2517,"status":68,"phases":6784,"primaryCompletion":2519,"completion":2519,"start":2520,"enrollment":2521,"conditions":6785,"interventions":6786},[51],[16],[2524,2505],{"nctId":6788,"briefTitle":6789,"status":68,"phases":6790,"primaryCompletion":4585,"completion":6791,"start":2520,"enrollment":6792,"conditions":6793,"interventions":6794},"NCT00456508","Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)",[51],"2010-09-01",147,[16],[2524],{"nctId":3280,"briefTitle":3281,"status":68,"phases":6796,"primaryCompletion":3283,"completion":1577,"start":3283,"enrollment":1723,"conditions":6797,"interventions":6798},[51],[16],[2524,3269],{"nctId":6800,"briefTitle":6801,"status":391,"phases":6802,"primaryCompletion":6803,"start":91,"enrollment":60,"conditions":6804,"interventions":6805},"NCT01253382","Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema",[50,51],"2015-04-01",[16],[2524],{"trials":6807,"activeCount":60},[],{"trials":6809,"activeCount":60},[6810],{"nctId":6811,"briefTitle":6812,"status":68,"phases":6813,"primaryCompletion":6814,"completion":6815,"start":6816,"enrollment":6817,"conditions":6818,"interventions":6819},"NCT01059526","Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema",[],"2013-09-01","2014-06-01","2010-02-01",81,[16],[2524],{"intervention":6821,"totalTrials":9,"cells":6822},"agalsidase alfa",{"EARLY_PHASE1":6823,"PHASE1":6825,"PHASE2":6827,"PHASE3":6845,"PHASE4":6855,"NA":6857},{"trials":6824,"activeCount":60},[],{"trials":6826,"activeCount":60},[],{"trials":6828,"activeCount":60},[6829,6838],{"nctId":6830,"briefTitle":6831,"status":68,"phases":6832,"primaryCompletion":6833,"completion":6833,"start":6834,"enrollment":83,"conditions":6835,"interventions":6836},"NCT00084084","Replagal Enzyme Replacement Therapy for Children With Fabry Disease",[50],"2011-06-15","2004-06-10",[33],[6837],"Agalsidase alfa",{"nctId":6839,"briefTitle":6840,"status":68,"phases":6841,"primaryCompletion":3137,"completion":3137,"start":6842,"enrollment":83,"conditions":6843,"interventions":6844},"NCT01304277","This Study is Designed to Evaluate PD\u002FPK and Safety of Replagal Manufactured by Two Different Processes.",[50],"2011-11-17",[33],[6821],{"trials":6846,"activeCount":60},[6847],{"nctId":6848,"briefTitle":6849,"status":68,"phases":6850,"primaryCompletion":6851,"completion":6851,"start":3985,"enrollment":6852,"conditions":6853,"interventions":6854},"NCT01298141","A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease",[51],"2017-09-25",171,[33],[6821],{"trials":6856,"activeCount":60},[],{"trials":6858,"activeCount":60},[6859],{"nctId":6860,"briefTitle":6861,"status":6862,"phases":6863,"conditions":6864,"interventions":6865},"NCT01031173","Treatment Protocol of Replagal for Patients With Fabry Disease","NO_LONGER_AVAILABLE",[],[33],[6821],{"intervention":6867,"totalTrials":174,"cells":6868},"Idursulfase",{"EARLY_PHASE1":6869,"PHASE1":6871,"PHASE2":6873,"PHASE3":6875,"PHASE4":6885,"NA":6896},{"trials":6870,"activeCount":60},[],{"trials":6872,"activeCount":60},[],{"trials":6874,"activeCount":60},[],{"trials":6876,"activeCount":60},[6877],{"nctId":6878,"briefTitle":6879,"status":68,"phases":6880,"primaryCompletion":2453,"completion":2453,"start":2454,"enrollment":6881,"conditions":6882,"interventions":6884},"NCT00630747","Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase",[50,51],94,[35,6883],"Mucopolysaccharidosis II (MPS II)",[6867],{"trials":6886,"activeCount":60},[6887],{"nctId":6888,"briefTitle":6889,"status":68,"phases":6890,"primaryCompletion":6891,"completion":6891,"start":6892,"enrollment":625,"conditions":6893,"interventions":6895},"NCT00607386","Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy",[52],"2011-07-08","2007-12-31",[35,3043,6894],"MPS II",[6867],{"trials":6897,"activeCount":60},[6898],{"nctId":6899,"briefTitle":6900,"status":68,"phases":6901,"primaryCompletion":6902,"completion":6902,"start":6903,"enrollment":17,"conditions":6904,"interventions":6905},"NCT00882921","An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients",[],"2013-02-08","2008-10-14",[35],[6867],{"intervention":6907,"totalTrials":174,"cells":6908},"anagrelide hydrochloride",{"EARLY_PHASE1":6909,"PHASE1":6911,"PHASE2":6913,"PHASE3":6924,"PHASE4":6935,"NA":6937},{"trials":6910,"activeCount":60},[],{"trials":6912,"activeCount":60},[],{"trials":6914,"activeCount":60},[6915],{"nctId":6916,"briefTitle":6917,"status":68,"phases":6918,"primaryCompletion":6919,"completion":6919,"start":6920,"enrollment":155,"conditions":6921,"interventions":6923},"NCT00413634","The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)",[50],"2008-01-22","2006-11-13",[6922],"Essential Thrombocythaemia",[6907,6907],{"trials":6925,"activeCount":60},[6926],{"nctId":6927,"briefTitle":6928,"status":68,"phases":6929,"primaryCompletion":6930,"completion":6930,"start":2115,"enrollment":6931,"conditions":6932,"interventions":6933},"NCT01214915","Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia",[51],"2012-10-24",53,[2118],[6934],"Anagrelide Hydrochloride",{"trials":6936,"activeCount":60},[],{"trials":6938,"activeCount":60},[6939],{"nctId":6940,"briefTitle":6941,"status":68,"phases":6942,"primaryCompletion":6943,"completion":6943,"start":6944,"enrollment":4165,"conditions":6945,"interventions":6946},"NCT01352585","Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®",[],"2013-09-19","2011-07-19",[2118],[6947],"Anagrelide hydrochloride",{"intervention":6949,"totalTrials":174,"cells":6950},"Dynepo",{"EARLY_PHASE1":6951,"PHASE1":6953,"PHASE2":6955,"PHASE3":6957,"PHASE4":6969,"NA":6979},{"trials":6952,"activeCount":60},[],{"trials":6954,"activeCount":60},[],{"trials":6956,"activeCount":60},[],{"trials":6958,"activeCount":60},[6959],{"nctId":6960,"briefTitle":6961,"status":79,"phases":6962,"primaryCompletion":2738,"completion":2738,"start":6963,"enrollment":6964,"conditions":6965,"interventions":6968},"NCT00450333","Dynepo Infrequent Dosing Study",[51],"2006-10-30",407,[6966,6967],"Anemia","Kidney Failure",[6949,6949,6949,6949],{"trials":6970,"activeCount":60},[6971],{"nctId":6972,"briefTitle":6973,"status":79,"phases":6974,"primaryCompletion":2738,"completion":2738,"start":6975,"enrollment":6976,"conditions":6977,"interventions":6978},"NCT00514813","Dynepo Long-Term Safety Study",[52],"2007-06-06",152,[6966,5852],[6949],{"trials":6980,"activeCount":60},[6981],{"nctId":6982,"briefTitle":6983,"status":79,"phases":6984,"primaryCompletion":6985,"completion":6985,"start":6986,"enrollment":174,"conditions":6987,"interventions":6989},"NCT00664066","DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)",[],"2008-07-30","2008-04-25",[6966,6628,6988,5852],"Renal Failure, Chronic",[6990],"DYNEPO",{"intervention":6992,"totalTrials":115,"cells":6993},"Lanadelumab 150 mg",{"EARLY_PHASE1":6994,"PHASE1":6996,"PHASE2":6998,"PHASE3":7000,"PHASE4":7002,"NA":7004},{"trials":6995,"activeCount":60},[],{"trials":6997,"activeCount":60},[],{"trials":6999,"activeCount":60},[],{"trials":7001,"activeCount":60},[],{"trials":7003,"activeCount":60},[],{"trials":7005,"activeCount":60},[7006],{"nctId":7007,"briefTitle":7008,"status":6862,"phases":7009,"conditions":7010,"interventions":7011},"NCT04583007","Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults",[],[16,1321],[6992,7012],"Lanadelumab 300 mg",{"intervention":7012,"totalTrials":115,"cells":7014},{"EARLY_PHASE1":7015,"PHASE1":7017,"PHASE2":7019,"PHASE3":7021,"PHASE4":7023,"NA":7025},{"trials":7016,"activeCount":60},[],{"trials":7018,"activeCount":60},[],{"trials":7020,"activeCount":60},[],{"trials":7022,"activeCount":60},[],{"trials":7024,"activeCount":60},[],{"trials":7026,"activeCount":60},[7027],{"nctId":7007,"briefTitle":7008,"status":6862,"phases":7028,"conditions":7029,"interventions":7030},[],[16,1321],[6992,7012],{"intervention":7032,"totalTrials":115,"cells":7033},"Firazyr",{"EARLY_PHASE1":7034,"PHASE1":7036,"PHASE2":7038,"PHASE3":7040,"PHASE4":7042,"NA":7044},{"trials":7035,"activeCount":60},[],{"trials":7037,"activeCount":60},[],{"trials":7039,"activeCount":60},[],{"trials":7041,"activeCount":60},[],{"trials":7043,"activeCount":60},[],{"trials":7045,"activeCount":60},[7046],{"nctId":7047,"briefTitle":7048,"status":68,"phases":7049,"primaryCompletion":7050,"completion":7050,"start":7051,"enrollment":7052,"conditions":7053,"interventions":7054},"NCT04057131","FIRAZYR General Drug Use-Results Survey (Japan)",[],"2024-07-29","2018-11-20",179,[16],[7032]]